{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 3,
      "metadata": {
        "id": "0QTn7AYkpinv"
      },
      "outputs": [],
      "source": [
        "import numpy as np\n",
        "import matplotlib.pyplot as plt\n",
        "import pandas as pd\n",
        "# import seaborn as sns\n",
        "# from itertools import product\n",
        "import nltk\n",
        "from nltk.tokenize import word_tokenize, sent_tokenize\n",
        "import os\n",
        "from sklearn.feature_extraction.text import TfidfVectorizer\n",
        "from sklearn.metrics.pairwise import cosine_similarity"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/gdrive')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "9bIVWJ_GpkdZ",
        "outputId": "5632f7d3-07c3-47c1-bab9-69f7d1e65250"
      },
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Drive already mounted at /content/gdrive; to attempt to forcibly remount, call drive.mount(\"/content/gdrive\", force_remount=True).\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "GOOGLE_DRIVE_PATH_AFTER_MYDRIVE = os.path.join('/content/gdrive/MyDrive/Hackathon')\n",
        "GOOGLE_DRIVE_PATH = os.path.join('gdrive', 'MyDrive',GOOGLE_DRIVE_PATH_AFTER_MYDRIVE)\n",
        "print('List files: ', os.listdir(GOOGLE_DRIVE_PATH))\n",
        "data_file = os.path.join(GOOGLE_DRIVE_PATH,'clinical_dataset.csv')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Zcc8mTlVpmS0",
        "outputId": "ddfcb351-a080-4902-a96f-6a24a0c7db71"
      },
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "List files:  ['clinical_dataset.csv', 'Harmony_hack.ipynb']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df = pd.read_csv(data_file)"
      ],
      "metadata": {
        "id": "c31HWQM6pqd3"
      },
      "execution_count": 6,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df.columns"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "u-uaaAbMps34",
        "outputId": "9f5ff59f-e652-42fc-e831-aa08aa4d2927"
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['Unnamed: 0', 'id', 'nct_id', 'outcome_type', 'measure', 'time_frame',\n",
              "       'population', 'description'],\n",
              "      dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df.head(2)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 181
        },
        "id": "4mBBROLypu6S",
        "outputId": "55e7afa8-8723-431b-9481-892297e60443"
      },
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "   Unnamed: 0         id       nct_id outcome_type  \\\n",
              "0           0  272006148  NCT03556657      primary   \n",
              "1           1  273155865  NCT01812382    secondary   \n",
              "\n",
              "                                             measure  \\\n",
              "0  Change from baseline in Adult Sickle Cell Qual...   \n",
              "1  Safety and tolerability of the microdialysis t...   \n",
              "\n",
              "                                       time_frame  population  \\\n",
              "0  Pre-test at baseline and post-test at 10 weeks         NaN   \n",
              "1                                      Single day         NaN   \n",
              "\n",
              "                                         description  \n",
              "0  A patient-reported outcome measurement system ...  \n",
              "1  Laboratory parameters include: Hematology, Cli...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-877b1d99-67dc-40fc-93de-656a840baa3e\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Unnamed: 0</th>\n",
              "      <th>id</th>\n",
              "      <th>nct_id</th>\n",
              "      <th>outcome_type</th>\n",
              "      <th>measure</th>\n",
              "      <th>time_frame</th>\n",
              "      <th>population</th>\n",
              "      <th>description</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>0</td>\n",
              "      <td>272006148</td>\n",
              "      <td>NCT03556657</td>\n",
              "      <td>primary</td>\n",
              "      <td>Change from baseline in Adult Sickle Cell Qual...</td>\n",
              "      <td>Pre-test at baseline and post-test at 10 weeks</td>\n",
              "      <td>NaN</td>\n",
              "      <td>A patient-reported outcome measurement system ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>1</td>\n",
              "      <td>273155865</td>\n",
              "      <td>NCT01812382</td>\n",
              "      <td>secondary</td>\n",
              "      <td>Safety and tolerability of the microdialysis t...</td>\n",
              "      <td>Single day</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Laboratory parameters include: Hematology, Cli...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-877b1d99-67dc-40fc-93de-656a840baa3e')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-877b1d99-67dc-40fc-93de-656a840baa3e button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-877b1d99-67dc-40fc-93de-656a840baa3e');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-2daf5c10-5a90-4ce1-ac91-df6f627a4d08\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-2daf5c10-5a90-4ce1-ac91-df6f627a4d08')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-2daf5c10-5a90-4ce1-ac91-df6f627a4d08 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 10000,\n  \"fields\": [\n    {\n      \"column\": \"Unnamed: 0\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2886,\n        \"min\": 0,\n        \"max\": 9999,\n        \"num_unique_values\": 10000,\n        \"samples\": [\n          6252,\n          4684,\n          1731\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"id\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 841312,\n        \"min\": 271324431,\n        \"max\": 274249606,\n        \"num_unique_values\": 10000,\n        \"samples\": [\n          272741015,\n          273924278,\n          274202887\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"nct_id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 9754,\n        \"samples\": [\n          \"NCT01108445\",\n          \"NCT01951456\",\n          \"NCT02825251\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"outcome_type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"primary\",\n          \"secondary\",\n          \"other\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"measure\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 9578,\n        \"samples\": [\n          \"Change in symptom burden as measured by the Rivermead Post-Concussion Symptoms Questionnaire-3 (RPQ-3)\",\n          \"Part 1, MRT: Mean Residence Time of (14C)E7386\",\n          \"Weight Gain\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"time_frame\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6768,\n        \"samples\": [\n          \"From date of randomization until 1-2 months\",\n          \"4-8 weeks\",\n          \"7 months\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"population\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": null,\n        \"min\": null,\n        \"max\": null,\n        \"num_unique_values\": 0,\n        \"samples\": [],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"description\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 8027,\n        \"samples\": [],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 8
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df2 = df.copy()\n",
        "\n",
        "df2.drop(columns = ['id','population'])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 597
        },
        "id": "FCHM_GzspyFT",
        "outputId": "cbd9fc9f-5370-4061-ddaa-e1f2c71a707a"
      },
      "execution_count": 9,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "      Unnamed: 0       nct_id outcome_type  \\\n",
              "0              0  NCT03556657      primary   \n",
              "1              1  NCT01812382    secondary   \n",
              "2              2  NCT01751113      primary   \n",
              "3              3  NCT05834790      primary   \n",
              "4              4  NCT01813474    secondary   \n",
              "...          ...          ...          ...   \n",
              "9995        9995  NCT00579280    secondary   \n",
              "9996        9996  NCT02111005      primary   \n",
              "9997        9997  NCT05282628      primary   \n",
              "9998        9998  NCT02193178      primary   \n",
              "9999        9999  NCT04674085      primary   \n",
              "\n",
              "                                                measure  \\\n",
              "0     Change from baseline in Adult Sickle Cell Qual...   \n",
              "1     Safety and tolerability of the microdialysis t...   \n",
              "2     Area Under the Curve Calculated From 0 to 4 Ho...   \n",
              "3            Baseline oral healthcare-related knowledge   \n",
              "4                          Tmax Following Single Dosing   \n",
              "...                                                 ...   \n",
              "9995  Change From Baseline in Hamilton Anxiety Scale...   \n",
              "9996              P53 levels in gingival biopsy samples   \n",
              "9997                           Child Behavior Checklist   \n",
              "9998                       Lens Fit - Overall Stability   \n",
              "9999  Evaluates the effects of tofacitinib therapy b...   \n",
              "\n",
              "                                             time_frame  \\\n",
              "0        Pre-test at baseline and post-test at 10 weeks   \n",
              "1                                            Single day   \n",
              "2       Day 28 of each treatment period (up to 35 days)   \n",
              "3     This outcome will be measured before intervent...   \n",
              "4     Day 1: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6...   \n",
              "...                                                 ...   \n",
              "9995                                            8 weeks   \n",
              "9996  The measurement will be performed at T0 (basel...   \n",
              "9997                                             Week 1   \n",
              "9998  2 weeks prior to baseline, Baseline, 2 weeks p...   \n",
              "9999                                           6 months   \n",
              "\n",
              "                                            description  \n",
              "0     A patient-reported outcome measurement system ...  \n",
              "1     Laboratory parameters include: Hematology, Cli...  \n",
              "2     sGaw is a measure of airways conductance and i...  \n",
              "3     Fifteen statements will be used to measure par...  \n",
              "4                                                   NaN  \n",
              "...                                                 ...  \n",
              "9995  Hamilton Anxiety Scale (HAM-A) measures severi...  \n",
              "9996  This variable is going to be measured by an im...  \n",
              "9997                                     Child Behavior  \n",
              "9998  Lens Fit (stability) for habitual lenses asses...  \n",
              "9999  Laboratory parameters (C-reactive protein (CRP...  \n",
              "\n",
              "[10000 rows x 6 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-aeb17996-cb6b-4635-9278-f3884c8bddbf\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Unnamed: 0</th>\n",
              "      <th>nct_id</th>\n",
              "      <th>outcome_type</th>\n",
              "      <th>measure</th>\n",
              "      <th>time_frame</th>\n",
              "      <th>description</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>0</td>\n",
              "      <td>NCT03556657</td>\n",
              "      <td>primary</td>\n",
              "      <td>Change from baseline in Adult Sickle Cell Qual...</td>\n",
              "      <td>Pre-test at baseline and post-test at 10 weeks</td>\n",
              "      <td>A patient-reported outcome measurement system ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>1</td>\n",
              "      <td>NCT01812382</td>\n",
              "      <td>secondary</td>\n",
              "      <td>Safety and tolerability of the microdialysis t...</td>\n",
              "      <td>Single day</td>\n",
              "      <td>Laboratory parameters include: Hematology, Cli...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>2</td>\n",
              "      <td>NCT01751113</td>\n",
              "      <td>primary</td>\n",
              "      <td>Area Under the Curve Calculated From 0 to 4 Ho...</td>\n",
              "      <td>Day 28 of each treatment period (up to 35 days)</td>\n",
              "      <td>sGaw is a measure of airways conductance and i...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>3</td>\n",
              "      <td>NCT05834790</td>\n",
              "      <td>primary</td>\n",
              "      <td>Baseline oral healthcare-related knowledge</td>\n",
              "      <td>This outcome will be measured before intervent...</td>\n",
              "      <td>Fifteen statements will be used to measure par...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>4</td>\n",
              "      <td>NCT01813474</td>\n",
              "      <td>secondary</td>\n",
              "      <td>Tmax Following Single Dosing</td>\n",
              "      <td>Day 1: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6...</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9995</th>\n",
              "      <td>9995</td>\n",
              "      <td>NCT00579280</td>\n",
              "      <td>secondary</td>\n",
              "      <td>Change From Baseline in Hamilton Anxiety Scale...</td>\n",
              "      <td>8 weeks</td>\n",
              "      <td>Hamilton Anxiety Scale (HAM-A) measures severi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9996</th>\n",
              "      <td>9996</td>\n",
              "      <td>NCT02111005</td>\n",
              "      <td>primary</td>\n",
              "      <td>P53 levels in gingival biopsy samples</td>\n",
              "      <td>The measurement will be performed at T0 (basel...</td>\n",
              "      <td>This variable is going to be measured by an im...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9997</th>\n",
              "      <td>9997</td>\n",
              "      <td>NCT05282628</td>\n",
              "      <td>primary</td>\n",
              "      <td>Child Behavior Checklist</td>\n",
              "      <td>Week 1</td>\n",
              "      <td>Child Behavior</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9998</th>\n",
              "      <td>9998</td>\n",
              "      <td>NCT02193178</td>\n",
              "      <td>primary</td>\n",
              "      <td>Lens Fit - Overall Stability</td>\n",
              "      <td>2 weeks prior to baseline, Baseline, 2 weeks p...</td>\n",
              "      <td>Lens Fit (stability) for habitual lenses asses...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9999</th>\n",
              "      <td>9999</td>\n",
              "      <td>NCT04674085</td>\n",
              "      <td>primary</td>\n",
              "      <td>Evaluates the effects of tofacitinib therapy b...</td>\n",
              "      <td>6 months</td>\n",
              "      <td>Laboratory parameters (C-reactive protein (CRP...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>10000 rows × 6 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-aeb17996-cb6b-4635-9278-f3884c8bddbf')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-aeb17996-cb6b-4635-9278-f3884c8bddbf button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-aeb17996-cb6b-4635-9278-f3884c8bddbf');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-b5734174-1af5-4891-b61f-65ca63b81572\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-b5734174-1af5-4891-b61f-65ca63b81572')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-b5734174-1af5-4891-b61f-65ca63b81572 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"df2\",\n  \"rows\": 10000,\n  \"fields\": [\n    {\n      \"column\": \"Unnamed: 0\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2886,\n        \"min\": 0,\n        \"max\": 9999,\n        \"num_unique_values\": 10000,\n        \"samples\": [\n          6252,\n          4684,\n          1731\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"nct_id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 9754,\n        \"samples\": [\n          \"NCT01108445\",\n          \"NCT01951456\",\n          \"NCT02825251\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"outcome_type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"primary\",\n          \"secondary\",\n          \"other\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"measure\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 9578,\n        \"samples\": [\n          \"Change in symptom burden as measured by the Rivermead Post-Concussion Symptoms Questionnaire-3 (RPQ-3)\",\n          \"Part 1, MRT: Mean Residence Time of (14C)E7386\",\n          \"Weight Gain\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"time_frame\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6768,\n        \"samples\": [\n          \"From date of randomization until 1-2 months\",\n          \"4-8 weeks\",\n          \"7 months\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"description\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 8027,\n        \"samples\": [\n          \"Assessment from the patient only through data collection from the Medical Outcome Study Short Form (SF-36) instrument. This 36 item questionnaire has a minimum score of 36 with a maximum score of 180; a higher score generally correlates to poorer health.\",\n          \"Safety\",\n          \"visual analogue pain scale, to evaluate patients' pain, form 0 to 10. more scores means more pain\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 9
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df3 =df2.groupby('outcome_type')"
      ],
      "metadata": {
        "id": "UYh8zP4NqHep"
      },
      "execution_count": 10,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Separate DataFrames using boolean indexing\n",
        "df3_primary = df[df['outcome_type'] == 'primary']\n",
        "df3_secondary = df[df['outcome_type'] == 'secondary']\n",
        "df3_other = df[df['outcome_type'] == 'other']"
      ],
      "metadata": {
        "id": "d5FAo52JqnmC"
      },
      "execution_count": 11,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from transformers import AutoTokenizer, AutoModel\n",
        "import torch\n",
        "from sklearn.metrics.pairwise import cosine_similarity\n",
        "import numpy as np\n",
        "import networkx as nx\n",
        "import pandas as pd\n",
        "\n",
        "# Load pre-trained model and tokenizer\n",
        "model_name = \"distilbert-base-uncased\"\n",
        "tokenizer = AutoTokenizer.from_pretrained(model_name)\n",
        "model = AutoModel.from_pretrained(model_name)\n",
        "\n",
        "def encode_sentences(sentences, tokenizer, model):\n",
        "    inputs = tokenizer(sentences, return_tensors='pt', truncation=True, padding=True)\n",
        "    with torch.no_grad():\n",
        "        outputs = model(**inputs)\n",
        "    embeddings = outputs.last_hidden_state.mean(dim=1)\n",
        "    return embeddings\n",
        "\n",
        "def compute_similarity_matrix(embeddings):\n",
        "    similarity_matrix = cosine_similarity(embeddings)\n",
        "    return similarity_matrix\n",
        "\n",
        "def cluster_sentences(similarity_matrix, threshold=0.35):\n",
        "    # Create a graph\n",
        "    G = nx.Graph()\n",
        "\n",
        "    # Add nodes\n",
        "    num_sentences = similarity_matrix.shape[0]\n",
        "    G.add_nodes_from(range(num_sentences))\n",
        "\n",
        "    # Add edges based on the similarity threshold\n",
        "    for i in range(num_sentences):\n",
        "        for j in range(i+1, num_sentences):\n",
        "            if similarity_matrix[i, j] > threshold:\n",
        "                G.add_edge(i, j)\n",
        "\n",
        "    # Find connected components (clusters)\n",
        "    clusters = list(nx.connected_components(G))\n",
        "    return clusters\n",
        "\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "pc66zeh76CFd",
        "outputId": "afc2202c-46e7-4ee7-db02-0417ff7e1843"
      },
      "execution_count": 12,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/huggingface_hub/utils/_token.py:89: UserWarning: \n",
            "The secret `HF_TOKEN` does not exist in your Colab secrets.\n",
            "To authenticate with the Hugging Face Hub, create a token in your settings tab (https://huggingface.co/settings/tokens), set it as secret in your Google Colab and restart your session.\n",
            "You will be able to reuse this secret in all of your notebooks.\n",
            "Please note that authentication is recommended but still optional to access public models or datasets.\n",
            "  warnings.warn(\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Data Cleaner Function\n",
        "import re\n",
        "from nltk.corpus import stopwords\n",
        "from nltk.tokenize import word_tokenize\n",
        "from nltk.stem import WordNetLemmatizer\n",
        "# Download NLTK stopwords if not already downloaded\n",
        "import nltk\n",
        "nltk.download('stopwords')\n",
        "nltk.download('punkt')\n",
        "custom_words =[\n",
        "'sdata','newlinetoken','edata'\n",
        "]\n",
        "# Data preprocessing\n",
        "stop_words = set(stopwords.words('english'))\n",
        "lemmatizer = WordNetLemmatizer()\n",
        "\n",
        "def preprocess_text(text):\n",
        "    tokens = word_tokenize(text.lower())  # Tokenization and lowercase\n",
        "    tokens = [lemmatizer.lemmatize(token) for token in tokens if token.isalpha()]  # Lemmatization and remove non-alphabetic tokens\n",
        "    tokens = [token for token in tokens if token not in stop_words]  # Remove stopwords\n",
        "    return ' '.join(tokens)\n",
        "\n",
        "def remove_words(words, custom_words):\n",
        "    # Initialize an empty list to store non-matching words\n",
        "    remaining_words = []\n",
        "\n",
        "    # Iterate through each word in the list\n",
        "    for word in words:\n",
        "        # Check if any of the substrings exist in the word\n",
        "        if not any(custom_word in word for custom_word in custom_words):\n",
        "            # If none of the substrings are present, add the word to the list of remaining words\n",
        "            remaining_words.append(word)\n",
        "\n",
        "    return remaining_words\n",
        "def clean_text(text):\n",
        "    # Convert to lowercase\n",
        "    text = text.lower()\n",
        "    # Remove special characters, punctuation, and numbers\n",
        "    text = re.sub(r'[^a-zA-Z\\s]', '', text)\n",
        "    # Tokenize the text\n",
        "    tokens = word_tokenize(text)\n",
        "    # Remove stopwords\n",
        "    tokens = [lemmatizer.lemmatize(token) for token in tokens if token.isalpha()]\n",
        "    stop_words = set(stopwords.words('english'))\n",
        "    filtered_tokens = [token for token in tokens if token not in stop_words]\n",
        "    filtered_words = remove_words(filtered_tokens,custom_words)\n",
        "    # Join the filtered tokens back into a string\n",
        "    cleaned_text = ' '.join(filtered_words)\n",
        "    return cleaned_text"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "eEUp1QO4J-lG",
        "outputId": "8deaa148-0233-49ab-d79a-45edfca38820"
      },
      "execution_count": 13,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Package stopwords is already up-to-date!\n",
            "[nltk_data] Downloading package punkt to /root/nltk_data...\n",
            "[nltk_data]   Package punkt is already up-to-date!\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import nltk\n",
        "nltk.download('wordnet')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "5_76zKB0KuQd",
        "outputId": "1e69adf3-87dc-4141-88f2-9557a5513c4d"
      },
      "execution_count": 14,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package wordnet to /root/nltk_data...\n",
            "[nltk_data]   Package wordnet is already up-to-date!\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "metadata": {},
          "execution_count": 14
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy\n",
        "from sklearn.feature_extraction.text import CountVectorizer\n",
        "df3_primary['measure_cleaned'] =df3_primary['measure'].apply(clean_text)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "OXCn-dTXKT3u",
        "outputId": "e9199acb-d737-4890-d74f-6c6b3302a0c1"
      },
      "execution_count": 15,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-15-712d5d67c5d6>:3: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df3_primary['measure_cleaned'] =df3_primary['measure'].apply(clean_text)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Sample DataFrame\n",
        "# df3_primary = pd.DataFrame(data)\n",
        "\n",
        "# Encode sentences\n",
        "sentences = df3_primary['measure_cleaned'].tolist()\n",
        "embeddings = encode_sentences(sentences, tokenizer, model)"
      ],
      "metadata": {
        "id": "Z5N5tZYl8O0t"
      },
      "execution_count": 16,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Compute similarity matrix\n",
        "similarity_matrix = compute_similarity_matrix(embeddings)\n",
        "# Convert similarity matrix to DataFrame for better visualization\n",
        "similarity_df = pd.DataFrame(similarity_matrix, columns=df3_primary.index, index=df3_primary.index)\n",
        "\n",
        "# Display the similarity matrix\n",
        "#print(similarity_df)"
      ],
      "metadata": {
        "collapsed": true,
        "id": "XrkoCrq6LwNX"
      },
      "execution_count": 17,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Define thresholds\n",
        "thresholds = np.arange(0.50, 1.05, 0.10)\n",
        "\n",
        "# Find pairs with similarity above each threshold\n",
        "similar_pairs_dict = {threshold: [] for threshold in thresholds}\n",
        "\n",
        "# Use NumPy to find indices of pairs above each threshold\n",
        "for threshold in thresholds:\n",
        "    indices = np.where(similarity_matrix >= threshold)\n",
        "    for i, j in zip(*indices):\n",
        "        if i < j:  # to avoid duplicate pairs and self-comparison\n",
        "            similar_pairs_dict[threshold].append((i, j, similarity_matrix[i, j]))\n",
        "\n"
      ],
      "metadata": {
        "id": "xn91Z3K7UNT1"
      },
      "execution_count": 18,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Categorize similar sentences based on the highest threshold they meet\n",
        "categories = {}\n",
        "for threshold in thresholds:\n",
        "    for i, j, similarity in similar_pairs_dict[threshold]:\n",
        "        if i not in categories:\n",
        "            categories[i] = []\n",
        "        categories[i].append((j, threshold, similarity))"
      ],
      "metadata": {
        "id": "UfkzunFlUaxw"
      },
      "execution_count": 19,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Display categorized sentences\n",
        "print(\"\\nCategorized sentences based on the highest threshold they meet:\")\n",
        "for category, values in categories.items():\n",
        "    print(f\"Category for Sentence {category + 1}:\")\n",
        "    print(df['measure'][category])\n",
        "    for value in values:\n",
        "        index, threshold, similarity = value\n",
        "        #print(f\"  Similar Sentence {index + 1} with similarity {similarity:.2f} at threshold {threshold}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ierDHN4kW2Gt",
        "outputId": "aad93108-7e6f-4dcd-f12b-24b34c401863"
      },
      "execution_count": 20,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[1;30;43mStreaming output truncated to the last 5000 lines.\u001b[0m\n",
            "Category for Sentence 692:\n",
            "Difference in biomarkers of cancer (change from baseline to 12-week follow-up)\n",
            "Category for Sentence 693:\n",
            "concentration of testosterone in plasma\n",
            "Category for Sentence 694:\n",
            "Mean LIC According to the Presence or Absence of Retrospective Hepatic Events\n",
            "Category for Sentence 695:\n",
            "Time from enrollment date to the onset of composite cerebrovascular events\n",
            "Category for Sentence 696:\n",
            "neuroendocrine (CRH) and immunological mediators (IL-1β, IL-6, Il-8, IL-10, IL-12, TNF-α, IFN-γ, G-CSF, GM-CSF)\n",
            "Category for Sentence 697:\n",
            "Adverse event(AE)\n",
            "Category for Sentence 698:\n",
            "Patients' satisfaction\n",
            "Category for Sentence 699:\n",
            "Superficial infection or Deep infection, defined as Synovial White Blood Cell (WBC) count > 4200 WBC/ml or Synovial WBC > 3000 WBC/ml & C-Reactive Protein (CRP) > 10 mg/dl & Erythrocyte Sedimentation Rate (ESR) > 30 mm/hr ;\n",
            "Category for Sentence 700:\n",
            "Change in diabetes support\n",
            "Category for Sentence 701:\n",
            "Body Weight\n",
            "Category for Sentence 702:\n",
            "Improved Pain Response, threshold and tolerance\n",
            "Category for Sentence 703:\n",
            "Sensory blockade of each dermatome L1, L2, L3, L4, L5, S1, S2, and S3 (cold, warmth, touch, pain)\n",
            "Category for Sentence 704:\n",
            "306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)\n",
            "Category for Sentence 705:\n",
            "Variability of CA125 measurements\n",
            "Category for Sentence 706:\n",
            "Safety and Tolerability of AG treatment\n",
            "Category for Sentence 707:\n",
            "Proportion of participants who undergo surgical resection\n",
            "Category for Sentence 708:\n",
            "Skin wrinkling grade\n",
            "Category for Sentence 709:\n",
            "Device-related re-hospitalizations\n",
            "Category for Sentence 710:\n",
            "Intestinal permeability baseline\n",
            "Category for Sentence 711:\n",
            "Patient's Assessment of Abdominal Discomfort\n",
            "Category for Sentence 712:\n",
            "progression-free survival\n",
            "Category for Sentence 713:\n",
            "Fall risk\n",
            "Category for Sentence 714:\n",
            "Percentage of Participants who Achieve ASDAS Clinically Important Improvement at Week 24\n",
            "Category for Sentence 715:\n",
            "Proportion of subjects with progression of GA\n",
            "Category for Sentence 716:\n",
            "Resected tissue assessed histologically for damage from novel electrode\n",
            "Category for Sentence 717:\n",
            "Seroresponse Rate of Vaccine Recipients at Day 29\n",
            "Category for Sentence 718:\n",
            "Change From Baseline in Weight at Week 8\n",
            "Category for Sentence 719:\n",
            "Breast-cancer-specific mortality\n",
            "Category for Sentence 720:\n",
            "Neuro-Quality of Life (Neuro-QOL) Positive Affect and Well-being v1.0\n",
            "Category for Sentence 721:\n",
            "Ocular Itching\n",
            "Category for Sentence 722:\n",
            "Volumetric analysis to evaluate soft tissue volume changes\n",
            "Category for Sentence 723:\n",
            "Graded and Redefined Assessment of Strength, Sensibility and Prehension test (GRASSP test)\n",
            "Category for Sentence 724:\n",
            "Change in hand grip strength\n",
            "Category for Sentence 725:\n",
            "Agreement between results of QuantiFERON-Gold-in-tube and probability of latent tuberculosis infection\n",
            "Category for Sentence 726:\n",
            "duration of survival without major amputation\n",
            "Category for Sentence 727:\n",
            "Change in absolute urine composition values and changes from baseline to the last post-dose time-point will be summarized for each treatment\n",
            "Category for Sentence 728:\n",
            "Time of Peak Concentration (Tmax-am)\n",
            "Category for Sentence 729:\n",
            "Transition Dyspnea Index (TDI) Focal Score on Day 29\n",
            "Category for Sentence 730:\n",
            "Global Assessment of Functioning - Symptoms (GAF-S)\n",
            "Category for Sentence 731:\n",
            "Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I)\n",
            "Category for Sentence 732:\n",
            "Mean number of dysphagia-free days\n",
            "Category for Sentence 733:\n",
            "Multi-Dimensional Fatigue Inventory (MFI) (Smets, Garssen, Bonke, & de Haes, 1995)\n",
            "Category for Sentence 734:\n",
            "Montreal Cognitive Assessment Scale\n",
            "Category for Sentence 735:\n",
            "Change From Baseline in FEV1 Over 90 Minutes After Albuterol/Placebo Administration\n",
            "Category for Sentence 736:\n",
            "Efficacy Secondary Outcome Measures in Period 1: Change from Baseline in TBUT at each visit in Period 1\n",
            "Category for Sentence 737:\n",
            "Platelet rise following platelet transfusion in 10 mL/kg versus 15 mL/kg.\n",
            "Category for Sentence 738:\n",
            "Six-month Overall survival\n",
            "Category for Sentence 739:\n",
            "Change From Baseline to Day 43 in Each YMRS Item Score No. 6\n",
            "Category for Sentence 740:\n",
            "Change in the level of plasma glucose of 2 hours post glucose-load (mmol/l)\n",
            "Category for Sentence 741:\n",
            "Number of neonates that need oral glucose supplementation\n",
            "Category for Sentence 742:\n",
            "Change in temporal summation of pain assessed by cuff pressure allometry at the lower leg of the test limb.\n",
            "Category for Sentence 743:\n",
            "End tidal CO2 measurement\n",
            "Category for Sentence 744:\n",
            "Left heart parameters - (E/e' ratio)\n",
            "Category for Sentence 745:\n",
            "Improvement in personal independence and productivity using questionnaire\n",
            "Category for Sentence 746:\n",
            "Proportion of patients reporting smoking at least one cigarette per day in the last 30 days.\n",
            "Category for Sentence 747:\n",
            "Analgesic requirement\n",
            "Category for Sentence 748:\n",
            "Anxiety/depressive symptoms\n",
            "Category for Sentence 749:\n",
            "Change of tinnitus handicap inventory total score (all baseline (-week 2, - week1, - day 3) vs. all follow-up visits (day 6, day 10, week 1, week 3, week 8))\n",
            "Category for Sentence 750:\n",
            "Efficacy after RRG001 injection\n",
            "Category for Sentence 751:\n",
            "Health-related Quality of Life\n",
            "Category for Sentence 752:\n",
            "Change from baseline in lower back pain (VAS)\n",
            "Category for Sentence 753:\n",
            "DASH Adherence as assessed by the Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)\n",
            "Category for Sentence 754:\n",
            "Dietary intake\n",
            "Category for Sentence 755:\n",
            "Frailty screening tool\n",
            "Category for Sentence 756:\n",
            "Changes in quality of the diet after each intervention with EVOO and the control intervention.\n",
            "Category for Sentence 757:\n",
            "Part A - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz)\n",
            "Category for Sentence 758:\n",
            "Overall survival (OS)\n",
            "Category for Sentence 759:\n",
            "Patient-reported outcome measure for quality of life in old age\n",
            "Category for Sentence 760:\n",
            "Change From Baseline in Corneometer Values Following Application of Test Regimen on Legs (Area 5 Compared to Area 6) at Day 15 and 29\n",
            "Category for Sentence 761:\n",
            "Effect on ovarian function\n",
            "Category for Sentence 762:\n",
            "Self rated post-concussion symptoms\n",
            "Category for Sentence 763:\n",
            "Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population\n",
            "Category for Sentence 764:\n",
            "Overall Survival\n",
            "Category for Sentence 765:\n",
            "6 Minute Walk Distance Changes\n",
            "Category for Sentence 766:\n",
            "Safety and tolerability evaluation - treatment-related adverse events will be assessed by CTCAE\n",
            "Category for Sentence 767:\n",
            "Clinical laboratory evaluations; haematology\n",
            "Category for Sentence 768:\n",
            "Cumulative Incidence of Disease Relapse\n",
            "Category for Sentence 769:\n",
            "Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events\n",
            "Category for Sentence 770:\n",
            "30 meters Sprint Test\n",
            "Category for Sentence 771:\n",
            "Phenotypic and isotypic classification of GP-responsive T and B cells, respectively\n",
            "Category for Sentence 772:\n",
            "Change in Treatment Interview\n",
            "Category for Sentence 773:\n",
            "Changes in Systolic Blood Pressure Measurements From Baseline to 3 Months\n",
            "Category for Sentence 774:\n",
            "Performance Differences - Changes in Oxygen Consumption\n",
            "Category for Sentence 775:\n",
            "Sleep Quality\n",
            "Category for Sentence 776:\n",
            "Difference between blood EETs concentration at baseline and after distal cutaneous heating for patients without the specified polymorphisms.\n",
            "Category for Sentence 777:\n",
            "Change in Mood Symptom Questionnaire Score\n",
            "Category for Sentence 778:\n",
            "Time to Reach Maximum Observed Plasma Concentration (Tmax)\n",
            "Category for Sentence 779:\n",
            "Number of Participants Achieving Treatment Success at 12 Months on Same Medication (Phase I, 6-12 Months)\n",
            "Category for Sentence 780:\n",
            "The incidence of major adverse events in 6 months and 12 months later after operation.\n",
            "Category for Sentence 781:\n",
            "Percentage of Participants Who Responded With a Decrease of at Least 30% in the Mean Brief Pain Inventory Worst Pain Numeric Rating Scale Score Among Participants Receiving Pexidartinib Compared With Those on Placebo at Week 25\n",
            "Category for Sentence 782:\n",
            "Description of patients with high-dose opioid therapy\n",
            "Category for Sentence 783:\n",
            "Change From Baseline in Brief Pain Inventory Short Form (BPI-SF) Individual Items and Interference Scores\n",
            "Category for Sentence 784:\n",
            "Treatment delay in days\n",
            "Category for Sentence 785:\n",
            "Change from Pain intensity at 3 months\n",
            "Category for Sentence 786:\n",
            "Best overall response (BOR) by IMWG Consensus Criteria\n",
            "Category for Sentence 787:\n",
            "Average Left Ventricular End-diastolic Dimension\n",
            "Category for Sentence 788:\n",
            "Likert Scale to record the percentage of improvement\n",
            "Category for Sentence 789:\n",
            "Change in cerebrospinal fluid examination\n",
            "Category for Sentence 790:\n",
            "Neck Disability Index (NDI)\n",
            "Category for Sentence 791:\n",
            "Total Insulin Use\n",
            "Category for Sentence 792:\n",
            "significant difference in cardiopulmonary exercise capacity during and after thoracic surgery\n",
            "Category for Sentence 793:\n",
            "gender\n",
            "Category for Sentence 794:\n",
            "Change in the frequency and severity of hot flushes.\n",
            "Category for Sentence 795:\n",
            "Late Positive Posterior ERP\n",
            "Category for Sentence 796:\n",
            "Graft function\n",
            "Category for Sentence 797:\n",
            "To measure changes in BP control as measured by clinic BP and 24hr BP monitoring with allopurinol compared with placebo\n",
            "Category for Sentence 798:\n",
            "Moist Desquamation at Radiation Treatment Site\n",
            "Category for Sentence 799:\n",
            "The change of fatigue perception by the patient through the BFI questionnaire\n",
            "Category for Sentence 800:\n",
            "Evaluate the time to progression\n",
            "Category for Sentence 801:\n",
            "Sensor Fits Well on Subjects Forehead\n",
            "Category for Sentence 802:\n",
            "Assessing DNA oxidation catabolites and branched fatty acyl esters of hydroxyl fatty acids (FAHFAs) in plasma samples\n",
            "Category for Sentence 803:\n",
            "Degree of fluctuation or fluctuation index ([Cmax - Ctau]/Css,avg) (DF) of BMS-986016\n",
            "Category for Sentence 804:\n",
            "Forego Additional Pain Medication\n",
            "Category for Sentence 805:\n",
            "modified (NYHA) functional class\n",
            "Category for Sentence 806:\n",
            "Effect of CYP3A4 inhibition on the Tmax of CNV2283325 (M14)\n",
            "Category for Sentence 807:\n",
            "Number of Participants Reporting Treatment-Emergent Phenotypic Drug Resistance\n",
            "Category for Sentence 808:\n",
            "EEG(Electroencephalography)\n",
            "Category for Sentence 809:\n",
            "Average Change From Baseline in Indirect Bilirubin at Weeks 16, 20 and 24\n",
            "Category for Sentence 810:\n",
            "Local Control Rate\n",
            "Category for Sentence 811:\n",
            "Changes in the varespladib blood levels and radioactivity in blood, urine and fecal samples\n",
            "Category for Sentence 812:\n",
            "Western Ontario and McMasters Universities (WOMAC)\n",
            "Category for Sentence 813:\n",
            "anion gap\n",
            "Category for Sentence 814:\n",
            "Number of patients who can successfully complete Head Impulse Test (HIT)\n",
            "Category for Sentence 815:\n",
            "Correct comprehension of information related to misoprostol and its use for first aid\n",
            "Category for Sentence 816:\n",
            "Mean Percentage Change in Abdominal Symptom Scores at Week 24.\n",
            "Category for Sentence 817:\n",
            "Adult ambulatory visit volume changes\n",
            "Category for Sentence 818:\n",
            "Incidence of participants with Major Adverse Cardiovascular Events (MACE)\n",
            "Category for Sentence 819:\n",
            "Changes in serum oxidant (hydrogen peroxide, reactive oxygen species) levels at month 6 and 12 as compared with baseline\n",
            "Category for Sentence 820:\n",
            "skin pH level\n",
            "Category for Sentence 821:\n",
            "Rate of Change on the ADAS-Cog 11.\n",
            "Category for Sentence 822:\n",
            "Polysomnographic measures of sleep\n",
            "Category for Sentence 823:\n",
            "Social Cognition Secondary Outcome 1: Fairness Sensitivity---------- Ultimatum Game\n",
            "Category for Sentence 824:\n",
            "Number of Participants With Vital Sign Results of Potential Clinical Importance (PCI): Weight\n",
            "Category for Sentence 825:\n",
            "Target Lesion Revascularization (TLR)\n",
            "Category for Sentence 826:\n",
            "Plasma Pharmacokinetic (PK) parameters of CM-101 - Time to Cmax (tmax)\n",
            "Category for Sentence 827:\n",
            "Functional exercise capacity at discharge (6MWT)\n",
            "Category for Sentence 828:\n",
            "Plasma Concentration of AZD0837 (Prodrug)\n",
            "Category for Sentence 829:\n",
            "To evaluate the impact of CardiCare™ on anxiety at 3 and 6 months versus baseline, in both groups.\n",
            "Category for Sentence 830:\n",
            "Immunoblotting\n",
            "Category for Sentence 831:\n",
            "triglyceride\n",
            "Category for Sentence 832:\n",
            "Lactate (mmol/l)\n",
            "Category for Sentence 833:\n",
            "Patient Satisfaction Question 1 at Post-treatment\n",
            "Category for Sentence 834:\n",
            "BOLD signal in the insula and somatosensory cortex measured by fMRI\n",
            "Category for Sentence 835:\n",
            "Neonatal Death\n",
            "Category for Sentence 836:\n",
            "Total Unchanged Drug (Ae_total) and Amount of Drug Excreted in Urine in a Time Intervals (Ae (t1-t2) for Gepotidacin\n",
            "Category for Sentence 837:\n",
            "Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation\n",
            "Category for Sentence 838:\n",
            "Changes of intestinal microflora abundance in feces\n",
            "Category for Sentence 839:\n",
            "Procedure Success\n",
            "Category for Sentence 840:\n",
            "Further organ failure based on systemic assessment\n",
            "Category for Sentence 841:\n",
            "Questionnaires will be utilized to look for a decrease in symptoms for Anxiety/Depression Reduced Symptoms for Anxiety/Depression\n",
            "Category for Sentence 842:\n",
            "Time to initiation of correct pathogen directed therapy\n",
            "Category for Sentence 843:\n",
            "Change in cardiac output after fluid expansion\n",
            "Category for Sentence 844:\n",
            "Therapy Attitudes Inventory\n",
            "Category for Sentence 845:\n",
            "Change in squat jump height\n",
            "Category for Sentence 846:\n",
            "Number of participants with Prostate specific antigen (PSA) response\n",
            "Category for Sentence 847:\n",
            "Mindfulness\n",
            "Category for Sentence 848:\n",
            "Changes in BMI From Baseline\n",
            "Category for Sentence 849:\n",
            "Surgical complications and impact on the patient's quality of life: surgical set-up\n",
            "Category for Sentence 850:\n",
            "Performance analysis of TEG6S kaolin parameters for the diagnosis of coagulation disorders in PPH.\n",
            "Category for Sentence 851:\n",
            "Change in Average 7-point SMPG Profiles From Baseline to Week 24\n",
            "Category for Sentence 852:\n",
            "Time until development of castration resistance\n",
            "Category for Sentence 853:\n",
            "Detection of PD-L1 expression\n",
            "Category for Sentence 854:\n",
            "Change in risk of falls and postural stability after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)\n",
            "Category for Sentence 855:\n",
            "The Patient Health Questionnaire-9 (PHQ-9)\n",
            "Category for Sentence 856:\n",
            "T Cell Immune Responses\n",
            "Category for Sentence 857:\n",
            "Safety of administering the ATIMP\n",
            "Category for Sentence 858:\n",
            "Safety and tolerability of daily oral BAL101553 based on the number of participants with ECG changes versus baseline\n",
            "Category for Sentence 859:\n",
            "Knee specific health questionnaire\n",
            "Category for Sentence 860:\n",
            "The partial onset (type I) seizure frequency reduction per week over the 16-week treatment period (titration and maintenance)\n",
            "Category for Sentence 861:\n",
            "Apparent Volume of Distribution During the Terminal Phase (Vz/F) Post-dose Period 1\n",
            "Category for Sentence 862:\n",
            "Toxicity Rate\n",
            "Category for Sentence 863:\n",
            "Difference in the volume of visceral fat compared to abdominal subcutaneous fat between symptomatic and asymptomatic DD groups\n",
            "Category for Sentence 864:\n",
            "accuracy of computer software in predicting soft tissue profile changes\n",
            "Category for Sentence 865:\n",
            "Serum Interleukin-6 (IL-6) Protein Concentration in Part 2 of the Study\n",
            "Category for Sentence 866:\n",
            "Embryo Transfer\n",
            "Category for Sentence 867:\n",
            "Inter-rater Agreement on Revascularization Strategy of Two Heart Teams Using an \"Angio-first\" Algorithm or a \"CT First\" Algorithm.\n",
            "Category for Sentence 868:\n",
            "Intercycle report : Liver in Cohort 2 - GGT\n",
            "Category for Sentence 869:\n",
            "Evaluate the effect of MLC901 as add on therapy to standard treatments for 6 months on cognitive function in patients with mild to moderate AD using Alzheimer's Disease Assessment Scale- cognitive subscale (ADAS- Cog).\n",
            "Category for Sentence 870:\n",
            "Look for an association between shear modulus assessed for pelvic floor muscles and perineal distension assessed by clinical and ultrasound assessment\n",
            "Category for Sentence 871:\n",
            "Change From Baseline in WPAI-PSO Score in Participants With a PASI Response of ≥75 to <90 at Week 24\n",
            "Category for Sentence 872:\n",
            "Changes in Constipation Assessment Scale (CAS) scores\n",
            "Category for Sentence 873:\n",
            "postoperative 2nd day CRP\n",
            "Category for Sentence 874:\n",
            "Potassium balance\n",
            "Category for Sentence 875:\n",
            "Lower body muscle strength\n",
            "Category for Sentence 876:\n",
            "Change from baseline in transcriptomic profile (mRNA) in adipose tissue biopsies\n",
            "Category for Sentence 877:\n",
            "To analyze DNA sequences of JCV\n",
            "Category for Sentence 878:\n",
            "Frequency of abnormal safety laboratory parameters (hematology, clinical chemistry, urinalysis and coagulation) and clinical parameters (blood pressure, pulse rate, temperature)\n",
            "Category for Sentence 879:\n",
            "Overall Survival (OS)\n",
            "Category for Sentence 880:\n",
            "Change in Activity\n",
            "Category for Sentence 881:\n",
            "Number of community member participants that attend the Community Engagement (CE) Training Program\n",
            "Category for Sentence 882:\n",
            "Regional Failure\n",
            "Category for Sentence 883:\n",
            "Mean number of CUA\n",
            "Category for Sentence 884:\n",
            "Change in clinical disease activity as measured by the Partial Mayo Score for Ulcerative Colitis.\n",
            "Category for Sentence 885:\n",
            "The safety (#2) of TSCS to improve autonomic control following acute SCI.\n",
            "Category for Sentence 886:\n",
            "Denture Teeth Calculus\n",
            "Category for Sentence 887:\n",
            "Change from Baseline in Body Temperature values.\n",
            "Category for Sentence 888:\n",
            "Musculoskeletal Pain\n",
            "Category for Sentence 889:\n",
            "Change in Pain Medication Desire Numeric Rating Scale\n",
            "Category for Sentence 890:\n",
            "Adverse Events and Adverse Drug reactions\n",
            "Category for Sentence 891:\n",
            "Complications\n",
            "Category for Sentence 892:\n",
            "Number of Participants Who Developed Skin Loss\n",
            "Category for Sentence 893:\n",
            "Patient satisfaction\n",
            "Category for Sentence 894:\n",
            "Mean Cost Per Participant Per Month at Month 12\n",
            "Category for Sentence 895:\n",
            "Number of participants who achieved smoking cessation/abstinence\n",
            "Category for Sentence 896:\n",
            "Description Overall Survival (OS) among the included patients\n",
            "Category for Sentence 897:\n",
            "Comparison of mid term course between pediatric right ventricular outflow tract recontruction with homograft and contegra\n",
            "Category for Sentence 898:\n",
            "significant reduction of depressive symptoms after the completion of treatment\n",
            "Category for Sentence 899:\n",
            "Number of patients with patency of target lesion\n",
            "Category for Sentence 900:\n",
            "EMG (electromyography) amplitude changes\n",
            "Category for Sentence 901:\n",
            "Near Stereoacuity - 3 Years\n",
            "Category for Sentence 902:\n",
            "Plasma PK of PF-06427878: Tmax, as data permit.\n",
            "Category for Sentence 903:\n",
            "Emotional dysegulation\n",
            "Category for Sentence 904:\n",
            "Change In Acute Medication Use\n",
            "Category for Sentence 905:\n",
            "Number of Participants With Ischemia Driven Target Vessel Revascularization (ID-TVR)\n",
            "Category for Sentence 906:\n",
            "progression-free survival(PFS)\n",
            "Category for Sentence 907:\n",
            "Number of Participants With Treatment emergent Genotypic Resistance Following Administration of SC injection\n",
            "Category for Sentence 908:\n",
            "initial pain\n",
            "Category for Sentence 909:\n",
            "Incidence of adverse events (Surgical Cohort and Non-Surgical Cohort)\n",
            "Category for Sentence 910:\n",
            "Symptom Burden Assessment\n",
            "Category for Sentence 911:\n",
            "Number of participants who are able to access MS specialist services as their needs change. Questionnaire\n",
            "Category for Sentence 912:\n",
            "Intrusive memory ratings\n",
            "Category for Sentence 913:\n",
            "Relapse Pattern\n",
            "Category for Sentence 914:\n",
            "Correlate changes in RV structure and function with prespecified biomarkers\n",
            "Category for Sentence 915:\n",
            "Evaluation of Pain and Functional Performance Determined by the Harris Hip Score\n",
            "Category for Sentence 916:\n",
            "Mean corpuscular hemoglobin (MCH)\n",
            "Category for Sentence 917:\n",
            "• Fall in Faecal Calprotectin\n",
            "Category for Sentence 918:\n",
            "Percentage of Participants With Seroprotection in HI Antibody Titer (Egg-Derived Antigen) of >=40: 21 Days After the Second Vaccination for 6-35 Months Old Group and 3-12 Years Old Group\n",
            "Category for Sentence 919:\n",
            "Children's HandExperience Questionnaire (CHEQ)\n",
            "Category for Sentence 920:\n",
            "Quality of life: EORTC QLQ30, STO22\n",
            "Category for Sentence 921:\n",
            "Child Dietary Intake\n",
            "Category for Sentence 922:\n",
            "Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin\n",
            "Category for Sentence 923:\n",
            "Understanding possible contamination between the groups\n",
            "Category for Sentence 924:\n",
            "Change From Baseline in Peak Forced Vital Capacity (at Week 8)\n",
            "Category for Sentence 925:\n",
            "Number of patients with seizures\n",
            "Category for Sentence 926:\n",
            "Loco-regional control\n",
            "Category for Sentence 927:\n",
            "Change in hsCRP levels at 24 weeks\n",
            "Category for Sentence 928:\n",
            "Percentage of Participants With Mutation Status\n",
            "Category for Sentence 929:\n",
            "Acute management of stroke:\n",
            "Category for Sentence 930:\n",
            "Fertilization rate\n",
            "Category for Sentence 931:\n",
            "Blood glucose (OGTT)\n",
            "Category for Sentence 932:\n",
            "Palatal Tissue Thickness\n",
            "Category for Sentence 933:\n",
            "Geometric Mean Titers Ratio of influenza vaccine antibodies (post-/pre-vaccination).\n",
            "Category for Sentence 934:\n",
            "5 year recurrence free survival rate\n",
            "Category for Sentence 935:\n",
            "Placenta previa ratio in pregnancies of pregnant women under the age of 16 ( group 1), over the age of 45 (group 2) and between the age of 25-35 (group 3).\n",
            "Category for Sentence 936:\n",
            "Pediatric Adverse Event Rating Scale (PAERS)\n",
            "Category for Sentence 937:\n",
            "To analyze the hemodynamic response during surgery\n",
            "Category for Sentence 938:\n",
            "Post GERD Symptom Severity\n",
            "Category for Sentence 939:\n",
            "Number of Patients Who Were Discontinued Due to Drug-related CAEs - Extension\n",
            "Category for Sentence 940:\n",
            "Seroprotection for B/Austria/1359417/2021 (B/Victoria lineage)-like virus strain (strain 3)\n",
            "Category for Sentence 941:\n",
            "OSWESTRY DISABILITY INDEX\n",
            "Category for Sentence 942:\n",
            "post-operative pain\n",
            "Category for Sentence 943:\n",
            "Percentage of Participants With HCV RNA < LLOQ On Treatment\n",
            "Category for Sentence 944:\n",
            "Safety as Assessed by Number of Participants With Constipation\n",
            "Category for Sentence 945:\n",
            "Change in Body Weight Per Unit Change in Thoracic Impedance\n",
            "Category for Sentence 946:\n",
            "Change in minute ventilation (VE)\n",
            "Category for Sentence 947:\n",
            "The correlation of hypoxia volume between hypoxia MR and F18-FMISO PET\n",
            "Category for Sentence 948:\n",
            "Changes in sperm parameters quality\n",
            "Category for Sentence 949:\n",
            "Crohn's Disease Related Secondary HRU in the 12 Months Post-Activation of C4T IBD Application (post-index)\n",
            "Category for Sentence 950:\n",
            "Disability\n",
            "Category for Sentence 951:\n",
            "Assess the Pharmacokinetics (PK) parameters for Cmax, maximum observed plasma concentration\n",
            "Category for Sentence 952:\n",
            "Plasma concentration versus time profile of MT-7117 after dosing.\n",
            "Category for Sentence 953:\n",
            "Intrathoracic Pressure\n",
            "Category for Sentence 954:\n",
            "Percentage of Participants With Objective Response\n",
            "Category for Sentence 955:\n",
            "Brief Pain Inventory\n",
            "Category for Sentence 956:\n",
            "Evaluation of motor block for the ulnar nerve at 10 minutes post injection assessed by a scale of motor function (0 = Complete paresis, 1 = Partial paresis, 2 = Normal motion)\n",
            "Category for Sentence 957:\n",
            "passive cervical range of motion (pCROM)\n",
            "Category for Sentence 958:\n",
            "Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by the questionnaire Respicheck.\n",
            "Category for Sentence 959:\n",
            "Work-related stress\n",
            "Category for Sentence 960:\n",
            "interincisor gap\n",
            "Category for Sentence 961:\n",
            "Inflammatory Parameter IL-1beta (nasal secretions: substudy)\n",
            "Category for Sentence 962:\n",
            "Immuno reaction on equine proteins\n",
            "Category for Sentence 963:\n",
            "Retention rates\n",
            "Category for Sentence 964:\n",
            "Percentage of patients who make appropriate decision to discontinue therapy or consult with a physician; the incidence of adverse experiences.\n",
            "Category for Sentence 965:\n",
            "change in Glasgow Coma Scale score\n",
            "Category for Sentence 966:\n",
            "TOLERABILITY of psychooncological intervention\n",
            "Category for Sentence 967:\n",
            "Change From Baseline in Global Total BML Score of the Index Knee MRI at Week 52\n",
            "Category for Sentence 968:\n",
            "Determine the toxicity profile of 11C-Choline administration in PET scans, therapeutic response and biochemical recurrence in patients treated with EBRT.\n",
            "Category for Sentence 969:\n",
            "The Alveolar-Arterial Oxygen Difference\n",
            "Category for Sentence 970:\n",
            "Patient Global Impression of Change\n",
            "Category for Sentence 971:\n",
            "Molecular minimal residual disease at 12 and 24 months\n",
            "Category for Sentence 972:\n",
            "Immune response against peptide P16_37-63\n",
            "Category for Sentence 973:\n",
            "Change in upper limb motor function\n",
            "Category for Sentence 974:\n",
            "Compare leukemia-free survival\n",
            "Category for Sentence 975:\n",
            "Percentage of Participants With EULAR Moderate Response at Months 3, 6, 9, 12, 18 and 24\n",
            "Category for Sentence 976:\n",
            "Characteristics of autoantibodies of DAT positive blood donors.\n",
            "Category for Sentence 977:\n",
            "Mean score in sialorrhea severity at end of treatment (day 90) measured by the sialorrhea scoring scale\n",
            "Category for Sentence 978:\n",
            "Differences in Intake\n",
            "Category for Sentence 979:\n",
            "Change in quality of life\n",
            "Category for Sentence 980:\n",
            "Relationship Between Epidermal Growth Factor Receptor (EGF-R) Mutational Analysis and Efficacy or Toxicity\n",
            "Category for Sentence 981:\n",
            "reduction of stress parameters\n",
            "Category for Sentence 982:\n",
            "Onset of 1st analgesic request\n",
            "Category for Sentence 983:\n",
            "Bispectral index(BIS)\n",
            "Category for Sentence 984:\n",
            "Phase II : Advanced Breast cancer: Assessment of the antitumor activity of avelumab in combination with IT JX-594 and metronomic cyclophosphamide Efficacy will be defined based on objective response under treatment following RECIST v1.1 criteria\n",
            "Category for Sentence 985:\n",
            "The incidence of adverse events\n",
            "Category for Sentence 986:\n",
            "Sphincter function\n",
            "Category for Sentence 987:\n",
            "Mean variation in the severity assessment score measured by ePOST from 1st injection (W0 or W6) to 2 weeks after the 5th injection\n",
            "Category for Sentence 988:\n",
            "Comfort While Working on Computer\n",
            "Category for Sentence 989:\n",
            "Udvalg Fur Kliniske Undersogesler (UKU)\n",
            "Category for Sentence 990:\n",
            "Index of behavioral problems\n",
            "Category for Sentence 991:\n",
            "Oxygen consumption (VO2) during 6 minute walk test\n",
            "Category for Sentence 992:\n",
            "VAS score at extubation time, 12 hours and 24 hours after operation\n",
            "Category for Sentence 993:\n",
            "Both cohorts: patient preference\n",
            "Category for Sentence 994:\n",
            "Sensitivity for lung cancer detection compared with CT-scan\n",
            "Category for Sentence 995:\n",
            "Changes in physical performance (numerical score) as determined by short physical performance battery (SPPB) in response to bed rest with and without ketone monoester (KET) supplementation.\n",
            "Category for Sentence 996:\n",
            "Change in CK-MB\n",
            "Category for Sentence 997:\n",
            "Pneumothorax\n",
            "Category for Sentence 998:\n",
            "Overall Survival: Expansion Cohort\n",
            "Category for Sentence 999:\n",
            "Non target lesion revascularization\n",
            "Category for Sentence 1000:\n",
            "Change from baseline in the CGI-BP-S (depression) score at each assessment point\n",
            "Category for Sentence 1001:\n",
            "CGM-derived Time in Range (TIR)\n",
            "Category for Sentence 1002:\n",
            "6-Minute Walk Test (6 MWT)\n",
            "Category for Sentence 1003:\n",
            "Differences in resource utilization and treatment cost.\n",
            "Category for Sentence 1004:\n",
            "fluid balance\n",
            "Category for Sentence 1005:\n",
            "Chicoric Acid status\n",
            "Category for Sentence 1006:\n",
            "clinical AF\n",
            "Category for Sentence 1007:\n",
            "Preschool Anxiety Scale-Revised - Total Score\n",
            "Category for Sentence 1008:\n",
            "The rate of Adverse events\n",
            "Category for Sentence 1009:\n",
            "Number of participants reporting immediate adverse events (AEs)\n",
            "Category for Sentence 1010:\n",
            "Pain evaluated with the FLACC scale\n",
            "Category for Sentence 1011:\n",
            "The presence of prostate cancer in the tissue obtained by prostate needle biopsy\n",
            "Category for Sentence 1012:\n",
            "Number of preterm birth\n",
            "Category for Sentence 1013:\n",
            "Clinical Outcome\n",
            "Category for Sentence 1014:\n",
            "This is NOT a clinical trial; thus no outcomes. Specimens from human subjects taken at clinical site and sent unidentified to laboratory for assays.\n",
            "Category for Sentence 1015:\n",
            "Postoperative rescue analgesic consumption\n",
            "Category for Sentence 1016:\n",
            "Change in Transcranial Magnetic Stimulation (TMS)\n",
            "Category for Sentence 1017:\n",
            "mRNA analyses in PBMC (RT-PCR)\n",
            "Category for Sentence 1018:\n",
            "Reactive hyperemia index (LnRHI)\n",
            "Category for Sentence 1019:\n",
            "The duration of gastrointestinal-related events.\n",
            "Category for Sentence 1020:\n",
            "Percentage Change in mPASI Score\n",
            "Category for Sentence 1021:\n",
            "Percentage of nights with events of sensor glucose above 180 mg/dl (10.0 mmol/L), 250 mg/dl (13.9 mmol/L), and 300 mg/dl (16.7 mmol/L) continuously for more than 0, 30, 60, and 120 minutes\n",
            "Category for Sentence 1022:\n",
            "Change from baseline to 15 days in patients with chronic low back pain (LBP) and acute exacerbation at study entry using Numerical Rating Scale for pain\n",
            "Category for Sentence 1023:\n",
            "Safety and tolerability measured through ECG\n",
            "Category for Sentence 1024:\n",
            "Recurrence rate\n",
            "Category for Sentence 1025:\n",
            "VCAM-1 gene expression\n",
            "Category for Sentence 1026:\n",
            "Immune Suppression Withdrawal\n",
            "Category for Sentence 1027:\n",
            "Incidence of CMV disease\n",
            "Category for Sentence 1028:\n",
            "Parts A and B: GMT of Serum RSV-A Neutralizing Abs up to Day 181\n",
            "Category for Sentence 1029:\n",
            "Average pain within the last 24 hours (VAS)\n",
            "Category for Sentence 1030:\n",
            "Clinical Status Since Last Visit\n",
            "Category for Sentence 1031:\n",
            "Hamilton Anxiety Rating Scale (HAM-A) change from week 0\n",
            "Category for Sentence 1032:\n",
            "Exercise Tolerance Test: Maximal Walking Distance\n",
            "Category for Sentence 1033:\n",
            "Pain and function Scores\n",
            "Category for Sentence 1034:\n",
            "Cmax of CKD-386\n",
            "Category for Sentence 1035:\n",
            "Number of pregnancies\n",
            "Category for Sentence 1036:\n",
            "BCVA\n",
            "Category for Sentence 1037:\n",
            "- To compare the safety and tolerability of one and two doses of influenza virus vaccine, trivalent,(CAIV-T) with placebo when administered intranasally\n",
            "Category for Sentence 1038:\n",
            "Continuous Glucose Monitor\n",
            "Category for Sentence 1039:\n",
            "Alterations of Caspofungin Area Under the curve (AUC) in septic patients admitted to the Intensive Care Unit (ICU).\n",
            "Category for Sentence 1040:\n",
            "Change in \"Infant Development\"assessed by Infant Behavioral Symptom scores:assessing scores behaviors and emotional capabilities\n",
            "Category for Sentence 1041:\n",
            "Change from baseline in tumor markers CA15-3\n",
            "Category for Sentence 1042:\n",
            "Change of Barthel Index(for Activities of Daily Living, ADL)\n",
            "Category for Sentence 1043:\n",
            "Exploratory correlative markers\n",
            "Category for Sentence 1044:\n",
            "Parts 1, 2 and 3: Number of Participants with Anti-Drug Antibodies to Talquetamab\n",
            "Category for Sentence 1045:\n",
            "adherence:% of days correct dose was taken\n",
            "Category for Sentence 1046:\n",
            "Time to introduction of weaning food\n",
            "Category for Sentence 1047:\n",
            "Frequency of protocol violation\n",
            "Category for Sentence 1048:\n",
            "functional outcome after TKA\n",
            "Category for Sentence 1049:\n",
            "Changes in levels of gut hormones\n",
            "Category for Sentence 1050:\n",
            "Effect on Clonogenic Myeloma Precursors\n",
            "Category for Sentence 1051:\n",
            "The objective response rate (ORR) of neoadjuvant therapy with pembrolizumab combined with standard chemotherapy\n",
            "Category for Sentence 1052:\n",
            "Baseline WHR of controls with different genotypes\n",
            "Category for Sentence 1053:\n",
            "Subjective Pain Assessment: Visual Analog Scale\n",
            "Category for Sentence 1054:\n",
            "It is expected between 0 and 9% of patients will have grade 3 or 4 toxicity.\n",
            "Category for Sentence 1055:\n",
            "Test of cognitive decline before surgery for clinical practise - TEGEST test\n",
            "Category for Sentence 1056:\n",
            "Short Form-12\n",
            "Category for Sentence 1057:\n",
            "Secondary validity analysis\n",
            "Category for Sentence 1058:\n",
            "Cardiac Index\n",
            "Category for Sentence 1059:\n",
            "• Percentage of patients with severe asthma who called for emergency medical care for asthma at the 3 year of follow-up;\n",
            "Category for Sentence 1060:\n",
            "Change 6-hour diuretic challenge response\n",
            "Category for Sentence 1061:\n",
            "Pulmonary tissue remodeling\n",
            "Category for Sentence 1062:\n",
            "Objective Response Rate (ORR)\n",
            "Category for Sentence 1063:\n",
            "Substance Use\n",
            "Category for Sentence 1064:\n",
            "Comorbidity\n",
            "Category for Sentence 1065:\n",
            "Interval doses of consumed morphia\n",
            "Category for Sentence 1066:\n",
            "Cause of the adrenal emergency\n",
            "Category for Sentence 1067:\n",
            "Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 52\n",
            "Category for Sentence 1068:\n",
            "controlled attenuation parameter (CAP) at each follow-up\n",
            "Category for Sentence 1069:\n",
            "Change in myocardial function\n",
            "Category for Sentence 1070:\n",
            "Proportion of Mirena users with menorrhagia\n",
            "Category for Sentence 1071:\n",
            "3-day dietary record (change)\n",
            "Category for Sentence 1072:\n",
            "Percentage of Participants With Antibody Titers ≥1:8 and ≥1:128 Measured by Serum Bactericidal Assay Using Baby Rabbit Complement (rSBA) Against Meningococcal Serogroups A, C, Y, and W 135 Before Vaccination With MenACYW Conjugate Vaccine or Menomune®\n",
            "Category for Sentence 1073:\n",
            "Operation time\n",
            "Category for Sentence 1074:\n",
            "Brain metastases-free survival\n",
            "Category for Sentence 1075:\n",
            "Progression Free Survival\n",
            "Category for Sentence 1076:\n",
            "Mean change in Physics performance on the assessment\n",
            "Category for Sentence 1077:\n",
            "Recurrence-free survival (RFS) rate\n",
            "Category for Sentence 1078:\n",
            "Time to Hospitalization due to Unstable Angina\n",
            "Category for Sentence 1079:\n",
            "SF-12\n",
            "Category for Sentence 1080:\n",
            "Patient Health Questionnaire-9 (PHQ-9)\n",
            "Category for Sentence 1081:\n",
            "number of daily finger triggering\n",
            "Category for Sentence 1082:\n",
            "Cohort 1: Change from Baseline in Body Surface Area Affected by Psoriasis at Week 48\n",
            "Category for Sentence 1083:\n",
            "Feedback\n",
            "Category for Sentence 1084:\n",
            "Wound healing and condition\n",
            "Category for Sentence 1085:\n",
            "Cmax(Peak Plasma Concentration)\n",
            "Category for Sentence 1086:\n",
            "Clinically significant changes from baseline in vital signs examination\n",
            "Category for Sentence 1087:\n",
            "Visual Acuity\n",
            "Category for Sentence 1088:\n",
            "Non-Relapse Mortality (NRM)\n",
            "Category for Sentence 1089:\n",
            "Degree of glottic visualization\n",
            "Category for Sentence 1090:\n",
            "Change in Body Image Questionnaire\n",
            "Category for Sentence 1091:\n",
            "Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting (Academic Research Consortium(ARC))\n",
            "Category for Sentence 1092:\n",
            "ankle joint ROM\n",
            "Category for Sentence 1093:\n",
            "Median time to a request for rescue medication\n",
            "Category for Sentence 1094:\n",
            "Multiple Ascending Dose Multiple Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)\n",
            "Category for Sentence 1095:\n",
            "Change from baseline in OFF time based on a standardized PD diary\n",
            "Category for Sentence 1096:\n",
            "Relevant parenchymatous brain injury on postoperative MRI\n",
            "Category for Sentence 1097:\n",
            "proportion of epithelium vs stroma\n",
            "Category for Sentence 1098:\n",
            "Everyday functioning by using Developmental disabilities modification of the Children's Global Assessment scale (DD-CGAS)\n",
            "Category for Sentence 1099:\n",
            "memory performance tests and functional activity\n",
            "Category for Sentence 1100:\n",
            "Mean Luminal Area\n",
            "Category for Sentence 1101:\n",
            "PD endpoint for ESN364: Progesterone (P) level in plasma\n",
            "Category for Sentence 1102:\n",
            "stroke distance\n",
            "Category for Sentence 1103:\n",
            "Patient weight\n",
            "Category for Sentence 1104:\n",
            "Change in Knee Pain (WOMAC)\n",
            "Category for Sentence 1105:\n",
            "Protein Supplementation (PS) Rate\n",
            "Category for Sentence 1106:\n",
            "Change in serum C-peptide from baseline\n",
            "Category for Sentence 1107:\n",
            "Detection of \"clinically significant cancer\" (using definition A, i.e. Gleason ≥7 cancers) in at least one core of SB or TB.\n",
            "Category for Sentence 1108:\n",
            "Change From Baseline in Patient-Reported Outcomes (PROs) in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30)\n",
            "Category for Sentence 1109:\n",
            "505 Agility test\n",
            "Category for Sentence 1110:\n",
            "Number of Participants With Solicited Adverse Events\n",
            "Category for Sentence 1111:\n",
            "EPIC bowel domain\n",
            "Category for Sentence 1112:\n",
            "Device Placement Success Rate\n",
            "Category for Sentence 1113:\n",
            "FACIT-Fatigue Change From Baseline to 13-weeks.\n",
            "Category for Sentence 1114:\n",
            "Sleep quality as measured by daily morning sleep log\n",
            "Category for Sentence 1115:\n",
            "Improvement in pain\n",
            "Category for Sentence 1116:\n",
            "Number of Participants With Concurrent RA Extra-articular Symptoms\n",
            "Category for Sentence 1117:\n",
            "Minimal Lumen Area\n",
            "Category for Sentence 1118:\n",
            "Loss of HBeAg\n",
            "Category for Sentence 1119:\n",
            "change in electrical impedance measures\n",
            "Category for Sentence 1120:\n",
            "Change from baseline in International Physical Activity Questionnaire (IPAQ) scoring\n",
            "Category for Sentence 1121:\n",
            "Need for facilitated dental treatment and follow up in the PDHS\n",
            "Category for Sentence 1122:\n",
            "Part A: Confirmed Best Overall Response (BOR) According to RECIST v1.1 Criteria\n",
            "Category for Sentence 1123:\n",
            "Interferon-induced transmembrane protein expression in platelets\n",
            "Category for Sentence 1124:\n",
            "Pulse Transit Time (PTT)\n",
            "Category for Sentence 1125:\n",
            "Monitoring of safety and tolerability through assessment of vital signs, ECG, clinical safety laboratory and adverse events\n",
            "Category for Sentence 1126:\n",
            "Content of coaching interactions\n",
            "Category for Sentence 1127:\n",
            "Changes in Heart Function as Measured by Echocardiography, Left Ventricular Ejection Fraction (LVEF), From Baseline to Week 12\n",
            "Category for Sentence 1128:\n",
            "Number of maternal participants that experience intrauterine growth restriction\n",
            "Category for Sentence 1129:\n",
            "Change in Inhibitory Control during Experimental Sessions\n",
            "Category for Sentence 1130:\n",
            "To compare progression-free survival between treatment arms\n",
            "Category for Sentence 1131:\n",
            "3D reconstruction with 15 anatomical and biomechanical parameter of the lower limb\n",
            "Category for Sentence 1132:\n",
            "Percentage of Participants Achieving at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in Patient's Global Assessment of Skin Pain (NRS30) - At Worst at Week 2 Among Participants With Baseline Numeric Rating Scale (NRS) >=3\n",
            "Category for Sentence 1133:\n",
            "Change in diarrhea duration\n",
            "Category for Sentence 1134:\n",
            "Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score-Trajectory\n",
            "Category for Sentence 1135:\n",
            "Change in self-reported suicidal ideation using the Beck Scale for Suicide Ideation (BSI), from baseline (Pre) to 6 months follow-up.\n",
            "Category for Sentence 1136:\n",
            "Severity of pushing behavior\n",
            "Category for Sentence 1137:\n",
            "Elimination half life (t½) of KH001 single and multiple ascending dose\n",
            "Category for Sentence 1138:\n",
            "Neck Disability Index score change from baseline\n",
            "Category for Sentence 1139:\n",
            "AUC0-24 of everolimus after single dose\n",
            "Category for Sentence 1140:\n",
            "Change in surrogate markers of nutrition\n",
            "Category for Sentence 1141:\n",
            "One- and two-year overall survival rates\n",
            "Category for Sentence 1142:\n",
            "The change in asthma control questionnaire (ACQ) between immediate BT treated and control group (N=20, randomized)\n",
            "Category for Sentence 1143:\n",
            "Clinically significant changes in urinalysis\n",
            "Category for Sentence 1144:\n",
            "Patient Distress at 2 Month Follow-up (GAD-7)\n",
            "Category for Sentence 1145:\n",
            "Metabolic response to radiation therapy\n",
            "Category for Sentence 1146:\n",
            "Overall survival\n",
            "Category for Sentence 1147:\n",
            "School indicators: grade repitition\n",
            "Category for Sentence 1148:\n",
            "Change in height of the alveolar process\n",
            "Category for Sentence 1149:\n",
            "Conditioned pain modulation (CPM) efficiency, a physiological parameter calculated as the percentage difference between the average pain intensity (0-10) reported during a thermode (heat) test before and after a cold water submersion bath test.\n",
            "Category for Sentence 1150:\n",
            "Estradiol - Week 16\n",
            "Category for Sentence 1151:\n",
            "Presence of a Major Depressive Episode, Dysthymia or Depressive Disorder NOS on the K-SADS-PL\n",
            "Category for Sentence 1152:\n",
            "Number of patients with a treatment duration of 7-12 months (Saxenda® only)\n",
            "Category for Sentence 1153:\n",
            "Toxicity and Tolerability of the Bevacizumab and Lenalidomide Combination\n",
            "Category for Sentence 1154:\n",
            "Myocardial infarction\n",
            "Category for Sentence 1155:\n",
            "Accurate Predication of the Presence or Absence of Bone Invasion by Oral Squamous Cell Carcinoma by Helical CT, PET/CT, MRI and CBCT\n",
            "Category for Sentence 1156:\n",
            "Evaluation of central sensitization\n",
            "Category for Sentence 1157:\n",
            "Percent Change from Baseline in SALT Score\n",
            "Category for Sentence 1158:\n",
            "Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 2\n",
            "Category for Sentence 1159:\n",
            "PK parameters of AKB-6548 metabolites: Terminal elimination rate constant (λz)\n",
            "Category for Sentence 1160:\n",
            "Number of participants with abnormal Cholesterol values (in mmol/L)\n",
            "Category for Sentence 1161:\n",
            "Vital signs\n",
            "Category for Sentence 1162:\n",
            "Time to first extubation\n",
            "Category for Sentence 1163:\n",
            "Assess the serum or plasma levels of five vitamins and four minerals\n",
            "Category for Sentence 1164:\n",
            "Angiogenesis\n",
            "Category for Sentence 1165:\n",
            "Safety Population: Mean Change From Baseline in Hemoglobin at Week 120\n",
            "Category for Sentence 1166:\n",
            "Percentage of participants agreeing or strongly agreeing with helpfulness of CC web application.\n",
            "Category for Sentence 1167:\n",
            "Linaprazan Glurate and Linaprazan PK parameters after single and repeated administration of Linaprazan Glurate\n",
            "Category for Sentence 1168:\n",
            "Gastrointestinal Health as measured by the gastrointestinal symptom rating scale at 4 months\n",
            "Category for Sentence 1169:\n",
            "Percent Change in Baseline Treatment-targeted SEBs Tumor Size From Baseline\n",
            "Category for Sentence 1170:\n",
            "Multivariate linear regression analysis of HAE clinical status and psychometric parameters\n",
            "Category for Sentence 1171:\n",
            "Part 1 (Dose Escalation Phase) - Pharmacokinetics of SKL27969\n",
            "Category for Sentence 1172:\n",
            "Eye movement features extracted by machine learning\n",
            "Category for Sentence 1173:\n",
            "On the images 82Rb PET/CT stress MBF\n",
            "Category for Sentence 1174:\n",
            "Drugs_neuromuscular blocking agents\n",
            "Category for Sentence 1175:\n",
            "Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose\n",
            "Category for Sentence 1176:\n",
            "the POST scores\n",
            "Category for Sentence 1177:\n",
            "Progression Free Survival as Determined by Independent Response Committee [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Final Analysis\n",
            "Category for Sentence 1178:\n",
            "Change From Baseline in sPGA Score at Weeks 2, 4, 6, 10, and 12\n",
            "Category for Sentence 1179:\n",
            "Plasma nitrite concentration\n",
            "Category for Sentence 1180:\n",
            "Change From Baseline J-Tpeakc With \"Balanced Ion Channel\" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir)\n",
            "Category for Sentence 1181:\n",
            "Bivariate Contour Ellipse Area (BCEA) analysis with microperimetry\n",
            "Category for Sentence 1182:\n",
            "Timed 25-Foot Walk Test\n",
            "Category for Sentence 1183:\n",
            "Duration of Overall Response\n",
            "Category for Sentence 1184:\n",
            "Screw resorption\n",
            "Category for Sentence 1185:\n",
            "Improvement of OCD symptoms will be intended as a rate of more then 1/3 on the Y-BOCS total score.\n",
            "Category for Sentence 1186:\n",
            "Minimum lumen diameter (MLD)\n",
            "Category for Sentence 1187:\n",
            "Percentage of Participants Who Achieved SRH Area ≥25mm2 Against Each of the Three Vaccine Strains After One Vaccination of FLUAD\n",
            "Category for Sentence 1188:\n",
            "Number of patients requiring an oral treatment for hypoglycemia\n",
            "Category for Sentence 1189:\n",
            "Cognitive function assessment\n",
            "Category for Sentence 1190:\n",
            "Overall survival\n",
            "Category for Sentence 1191:\n",
            "Change in IL-23 From Baseline.\n",
            "Category for Sentence 1192:\n",
            "Plasma GLP-1 iAUC (ARMs A and B)\n",
            "Category for Sentence 1193:\n",
            "Additional assessments of incontinence episode frequency using various standardized instruments will be performed.\n",
            "Category for Sentence 1194:\n",
            "Digit Symbol-Substitution-Test for the incidence of postoperative cognitive dysfunction (POCD)\n",
            "Category for Sentence 1195:\n",
            "DASH Outcome Measure\n",
            "Category for Sentence 1196:\n",
            "Up & Go Test - T2\n",
            "Category for Sentence 1197:\n",
            "measurement of range of motions in tasks with xsens motion capture system\n",
            "Category for Sentence 1198:\n",
            "Number of Participants Reporting A Solicited Injection Site or Systemic Reactions Following Vaccination With A Typhoid Vi Polysaccharide Vaccine\n",
            "Category for Sentence 1199:\n",
            "Efficacy and safety of Regpara in chronic dialysis patients with high blood levels of parathyroid\n",
            "Category for Sentence 1200:\n",
            "Height (CVD risk factors improvement assessment)\n",
            "Category for Sentence 1201:\n",
            "Parent participation in care\n",
            "Category for Sentence 1202:\n",
            "Percent Change in PSA\n",
            "Category for Sentence 1203:\n",
            "Cumulated Ambulation Score\n",
            "Category for Sentence 1204:\n",
            "Visual Analogue Scale score\n",
            "Category for Sentence 1205:\n",
            "Frequency and severity of adverse events (AE)s and serious adverse events (SAE)s from signed consent form to end of study (visit 4 / follow-up visit)\n",
            "Category for Sentence 1206:\n",
            "The diagnostic sensitivity of gastrointestinal diseases with deep learning algorithm.\n",
            "Category for Sentence 1207:\n",
            "Incidence of Treatment-Emergent Adverse Events (safety and tolerability)\n",
            "Category for Sentence 1208:\n",
            "Cough numeric rating scales (NRS)\n",
            "Category for Sentence 1209:\n",
            "Area Under the Plasma Analyte Concentration Versus Time Curve of Seltorexant from Time Zero to Infinite time (AUC [0-Infinity])\n",
            "Category for Sentence 1210:\n",
            "Change From Baseline in cTnI at Days 2 and 4\n",
            "Category for Sentence 1211:\n",
            "Placenta ratio of choline to lipid\n",
            "Category for Sentence 1212:\n",
            "Incidence rate of TEAE, ADR, SAE and AESI of each cycle\n",
            "Category for Sentence 1213:\n",
            "Telmisartan, Amlodipine, Rosuvastatin Cmin\n",
            "Category for Sentence 1214:\n",
            "Number of Subjects With Any Serious Adverse Events (SAEs) During the Entire Duration of the Study\n",
            "Category for Sentence 1215:\n",
            "Co-Primary Effectiveness Endpoint 2: Percent of Total Body Weight Loss (TBWL) Comparison Between Treatment and Control group\n",
            "Category for Sentence 1216:\n",
            "Concentration and titer of serum neutralizing antibodies\n",
            "Category for Sentence 1217:\n",
            "Change in isometric knee extensor strength\n",
            "Category for Sentence 1218:\n",
            "Cancer related fatigue\n",
            "Category for Sentence 1219:\n",
            "NRS score at rest and activity\n",
            "Category for Sentence 1220:\n",
            "Count of Participants Who Report of Less Discomfort in the Eye That Received the Proparacaine Hydrochloride Anesthetic During Probing\n",
            "Category for Sentence 1221:\n",
            "Frequency of cardio-respiratory side effects\n",
            "Category for Sentence 1222:\n",
            "Mean residence time of BI 2536 BS in the body after intravenous administration (MRT)\n",
            "Category for Sentence 1223:\n",
            "Biosamples (Blood B)\n",
            "Category for Sentence 1224:\n",
            "Predicted Time to Rescue a Patient From Simulated Opioid-induced Respiratory Depression From Fentanyl for a Medium Overdose Scenario\n",
            "Category for Sentence 1225:\n",
            "Correlation of BMPR2 Expression with right ventricular function\n",
            "Category for Sentence 1226:\n",
            "The Chinese CHIP data (treatment group only)\n",
            "Category for Sentence 1227:\n",
            "Post-operative food tolerance by means of the food tolerance questionnaire\n",
            "Category for Sentence 1228:\n",
            "Changes in self-compassion level estimated by the Self-Compassion Scale (SCS)\n",
            "Category for Sentence 1229:\n",
            "Percentage of Patients Requiring Rescue Therapy During the Double-blind Period\n",
            "Category for Sentence 1230:\n",
            "The secondary endpoints will assess the effect of the Investigational Product on:\n",
            "Category for Sentence 1231:\n",
            "Observed Serum Drug Concentration for CAT-354 28 Days (C28) After First Dose\n",
            "Category for Sentence 1232:\n",
            "Questionnaire Recording Success Rate\n",
            "Category for Sentence 1233:\n",
            "Pathologic and radiologic findings\n",
            "Category for Sentence 1234:\n",
            "Reduction in absence from work by parents over the whole study period\n",
            "Category for Sentence 1235:\n",
            "Change in Beck Anxiety Inventory (BAI-II) between Timepoints\n",
            "Category for Sentence 1236:\n",
            "Changes From Baseline for Wall Motion Score Index at Day (WMSI) as Measured by Cardiac Magnetic Resonance at Day 7\n",
            "Category for Sentence 1237:\n",
            "Percent Change in the 16-item Quick Inventory of Depression Symptomology (QIDS-C16) Score From Baseline to 8 Weeks\n",
            "Category for Sentence 1238:\n",
            "Tabaco consumption (CVD risk factors improvement assessment)\n",
            "Category for Sentence 1239:\n",
            "Erythrocyte Mean Corpuscular Hemoglobin (HGB) Concentration: Week 12\n",
            "Category for Sentence 1240:\n",
            "Bone volume-stable results six months following augmentation procedures [ demonstrated by X-ray evaluation].\n",
            "Category for Sentence 1241:\n",
            "Regional failure utilizing RECIST v1.1 for HCC.\n",
            "Category for Sentence 1242:\n",
            "Diagnostic performance of the SENSEI® laparoscopic tethered gamma probe for detecting SLNs\n",
            "Category for Sentence 1243:\n",
            "Area under the concentration-time curve (AUC) of NXP900\n",
            "Category for Sentence 1244:\n",
            "Achieve excellent compliance and minimal toxicity with consumption of the strawberry gummies.\n",
            "Category for Sentence 1245:\n",
            "Incidence of NCI CTC Toxicity III°/IV° and severe bleedings\n",
            "Category for Sentence 1246:\n",
            "Exploratory Study Objectives to measure biological correlates of efficacy (expressed ADA enzyme in erythrocytes)\n",
            "Category for Sentence 1247:\n",
            "Estimate 2 year overall survival(OS) after infusion of CD38/CD33/CD56/CD123/ CD117/CD133/CD34/Mucl-CART and sequential treatment\n",
            "Category for Sentence 1248:\n",
            "Duration of response in patients with objective response up to M24 after the start of study treatment (i.e., C1:1D1)\n",
            "Category for Sentence 1249:\n",
            "change in Quality of Life\n",
            "Category for Sentence 1250:\n",
            "Evaluation of balance\n",
            "Category for Sentence 1251:\n",
            "Level of IL-6\n",
            "Category for Sentence 1252:\n",
            "Change in Vasomotor Symptoms from Baseline (Time 1) to Time 2\n",
            "Category for Sentence 1253:\n",
            "Gamma-glutamyl transferase\n",
            "Category for Sentence 1254:\n",
            "Change in high-sensitive C-reactive protein (hsCRP)\n",
            "Category for Sentence 1255:\n",
            "Proportion of subjects with treatment success of target toenail\n",
            "Category for Sentence 1256:\n",
            "Postoperative complications\n",
            "Category for Sentence 1257:\n",
            "Change from baseline in pre-dose morning Forced Expiratory Volume in the 1st second (FEV1) at Week 28\n",
            "Category for Sentence 1258:\n",
            "Change in walking performance\n",
            "Category for Sentence 1259:\n",
            "Adolescent satisfaction assessed by the Client Satisfaction Questionnaire (CSQ)\n",
            "Category for Sentence 1260:\n",
            "thiamine\n",
            "Category for Sentence 1261:\n",
            "Change in Brief Pain Inventory\n",
            "Category for Sentence 1262:\n",
            "Quality of Life at 4 months measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)\n",
            "Category for Sentence 1263:\n",
            "Change in liver fat (hepatic fat fraction)\n",
            "Category for Sentence 1264:\n",
            "Acute/Active Rejection\n",
            "Category for Sentence 1265:\n",
            "Change in maternal dietary diversity\n",
            "Category for Sentence 1266:\n",
            "Refraction with the auto-refractor tonometry\n",
            "Category for Sentence 1267:\n",
            "Composite of post-operative cardiac complications at 30 days\n",
            "Category for Sentence 1268:\n",
            "Feasibility and acceptability of implementing preference assessment\n",
            "Category for Sentence 1269:\n",
            "Change in Glycoalbumin\n",
            "Category for Sentence 1270:\n",
            "Change in Caregiver-Targeted Quality of Life Measure Score - Worry Scale\n",
            "Category for Sentence 1271:\n",
            "Participant and provider experience\n",
            "Category for Sentence 1272:\n",
            "Left Ventricular End Systolic Dimension (LVESD)\n",
            "Category for Sentence 1273:\n",
            "Part 1: Change From Baseline in Temperature\n",
            "Category for Sentence 1274:\n",
            "Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Open Label Baseline to 6 Months\n",
            "Category for Sentence 1275:\n",
            "Systolic and diastolic blood pressure (Peer buddy System)\n",
            "Category for Sentence 1276:\n",
            "Complications\n",
            "Category for Sentence 1277:\n",
            "Postthrombotic syndrome (PTS) using Villalta's scale\n",
            "Category for Sentence 1278:\n",
            "Participation\n",
            "Category for Sentence 1279:\n",
            "Patient-Reported Outcomes\n",
            "Category for Sentence 1280:\n",
            "Tmax of Retifanlimab at Steady-state\n",
            "Category for Sentence 1281:\n",
            "Diagnosis of cerebral amyloid angiopathy based on V2.0 BOSTON criteria\n",
            "Category for Sentence 1282:\n",
            "Oxygenation (PO2/FIO2 ratio)\n",
            "Category for Sentence 1283:\n",
            "Adherence to treatment measured by the Morisky-Green questionnaire\n",
            "Category for Sentence 1284:\n",
            "Pharmacological Enhancement of Specific Sleep Parameters\n",
            "Category for Sentence 1285:\n",
            "Phase 1: Number of Participants With Clinically Significant Laboratory Values\n",
            "Category for Sentence 1286:\n",
            "Gracely Sensory Scale Pain Rating Changes in Response to Lidocaine and Capsaicin Creams and tDCS\n",
            "Category for Sentence 1287:\n",
            "Time to Cmax (Tmax) of SC-007\n",
            "Category for Sentence 1288:\n",
            "Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12\n",
            "Category for Sentence 1289:\n",
            "lung injury score\n",
            "Category for Sentence 1290:\n",
            "Duration of Surgery\n",
            "Category for Sentence 1291:\n",
            "Pharmacokinetics: Area under concentration time curve of RO4917838\n",
            "Category for Sentence 1292:\n",
            "Functionality\n",
            "Category for Sentence 1293:\n",
            "Cognitive Function - Attention, Focus\n",
            "Category for Sentence 1294:\n",
            "Number of Injurious Fallers\n",
            "Category for Sentence 1295:\n",
            "Clinical evolution of patients\n",
            "Category for Sentence 1296:\n",
            "Change in severity of symptoms based on questionnaire.\n",
            "Category for Sentence 1297:\n",
            "United States (US): Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 12\n",
            "Category for Sentence 1298:\n",
            "Cobb's Angle\n",
            "Category for Sentence 1299:\n",
            "Clinician Perception Score- Patient Response to Therapy\n",
            "Category for Sentence 1300:\n",
            "The absolute bioavailability (F, PO vs IV from Part 1) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404\n",
            "Category for Sentence 1301:\n",
            "Wound Healing by Numerical Scales for Oedema Postoperative Day 2.\n",
            "Category for Sentence 1302:\n",
            "Change in fasting plasma low density lipoprotein (LDL) concentrations, to be assessed by blood analysis\n",
            "Category for Sentence 1303:\n",
            "High-Density Lipoprotein (HDL) Levels by Visit\n",
            "Category for Sentence 1304:\n",
            "Relationship Between Vascular Endothelial Dysfunction and Beat-to-beat Blood Pressure Variability in Patients With OSAS\n",
            "Category for Sentence 1305:\n",
            "Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECGs)\n",
            "Category for Sentence 1306:\n",
            "Mean Score on Unified Parkinson's Disease Rating Scale (UPDRS)\n",
            "Category for Sentence 1307:\n",
            "Platelet Reactivity Index\n",
            "Category for Sentence 1308:\n",
            "Change From Baseline to Endpoint in EuroQol-5 Dimension-5 Level (EQ-5D-5L): Index Score\n",
            "Category for Sentence 1309:\n",
            "Psychomotor\n",
            "Category for Sentence 1310:\n",
            "Cardiac Index (CI)\n",
            "Category for Sentence 1311:\n",
            "Sleep and insomnia\n",
            "Category for Sentence 1312:\n",
            "Duration of Response (DOR) of CD70 CAR-T treatment in patients with CD70-positive advanced malignancies[Effectiveness]\n",
            "Category for Sentence 1313:\n",
            "Change from Baseline in statistical and clinical measures on the Family Assessment Device (FAD) at Week 60\n",
            "Category for Sentence 1314:\n",
            "incidence of readmissions within 30 days caused by ADE's due to anticoagulants\n",
            "Category for Sentence 1315:\n",
            "To determine the medium/long-term effect of SIS on recurrence rates after laparoscopic PEH repair.\n",
            "Category for Sentence 1316:\n",
            "Daily and total mg of opiate pain medication and any other over the counter alternate pain medication.\n",
            "Category for Sentence 1317:\n",
            "Percentage of Participants With no Progression of Joint Space Narrowing at Week 52\n",
            "Category for Sentence 1318:\n",
            "Measurement of biomarkers as in detailed description of the study section\n",
            "Category for Sentence 1319:\n",
            "Cmax for AZD9291 and it's Metabolites AZ5104 and AZ7550\n",
            "Category for Sentence 1320:\n",
            "Multiple Sclerosis Walking Scale 12 (MSWS12)\n",
            "Category for Sentence 1321:\n",
            "6-minute walk test\n",
            "Category for Sentence 1322:\n",
            "change in the level of Follicle stimulating hormone(FSH)\n",
            "Category for Sentence 1323:\n",
            "Change of baseline flow velocity\n",
            "Category for Sentence 1324:\n",
            "To assess the prevalence of preoperative iron deficiency according to the surgical field\n",
            "Category for Sentence 1325:\n",
            "Change from baseline in Physical activity on Actigraph GT9X accelerometers at 10 months\n",
            "Category for Sentence 1326:\n",
            "Procedure success\n",
            "Category for Sentence 1327:\n",
            "Percentage of Participants With Biochemical Failure\n",
            "Category for Sentence 1328:\n",
            "Number of Participants with Unsolicited AEs at 28 Days Post-vaccination 2\n",
            "Category for Sentence 1329:\n",
            "fasting blood glucose\n",
            "Category for Sentence 1330:\n",
            "Change in lipopolysaccharide (LPS) (Baseline and Post-Discharge Follow-up)\n",
            "Category for Sentence 1331:\n",
            "Incidence of elevated liver function tests\n",
            "Category for Sentence 1332:\n",
            "Proportion of small consumers of fruits and vegetables among children\n",
            "Category for Sentence 1333:\n",
            "quality of life improvement in score\n",
            "Category for Sentence 1334:\n",
            "Phase 1: Rate of Persistent AF Acute Procedural Success\n",
            "Category for Sentence 1335:\n",
            "A difference in the term (37 completed weeks of gestation), singleton live birth rate in women undergoing IVF/ICSI treatment following endometrial biopsy versus control subjects.\n",
            "Category for Sentence 1336:\n",
            "Temperature at Which Ablation of(SSEP)Occurs\n",
            "Category for Sentence 1337:\n",
            "Measurement of vitamin B1\n",
            "Category for Sentence 1338:\n",
            "Disease Control Rate (DCR) per RECIST 1.1\n",
            "Category for Sentence 1339:\n",
            "Reduction of the Use of Topical Steroids\n",
            "Category for Sentence 1340:\n",
            "Kidney health endpoints that are specific to each individual trial\n",
            "Category for Sentence 1341:\n",
            "Complete metabolic response (CMR) rate (Dose Expansion)\n",
            "Category for Sentence 1342:\n",
            "Part 2 (Main Study): Time to Deterioration (TTD) in HRQoL Score Using EORTC QLQ-C30\n",
            "Category for Sentence 1343:\n",
            "Change in Geriatric Depression Scale (GDS) - Short Form in the Caregivers\n",
            "Category for Sentence 1344:\n",
            "C-reactive protein\n",
            "Category for Sentence 1345:\n",
            "Non-pancreatic associated complications\n",
            "Category for Sentence 1346:\n",
            "Change in Dietary Diversity - mother and child\n",
            "Category for Sentence 1347:\n",
            "Change in high-density lipoprotein (HDL-C)\n",
            "Category for Sentence 1348:\n",
            "Participants' Assessment of Work Activities Impairment: Work Productivity and Activity Impairment: Rheumatoid Arthritis (WPAI-RA) Score\n",
            "Category for Sentence 1349:\n",
            "Changes from baseline in plasma CKD-508 concentrations in time after dosing\n",
            "Category for Sentence 1350:\n",
            "Change in passive range of motion (PROM)\n",
            "Category for Sentence 1351:\n",
            "Treatment related immune responses\n",
            "Category for Sentence 1352:\n",
            "Cost Effectiveness\n",
            "Category for Sentence 1353:\n",
            "Diagnostic sensitivity\n",
            "Category for Sentence 1354:\n",
            "Mini-Balance Evaluation Systems Test\n",
            "Category for Sentence 1355:\n",
            "Digit Span Backward Test\n",
            "Category for Sentence 1356:\n",
            "Length of hospital stay in days\n",
            "Category for Sentence 1357:\n",
            "Overall Response Measured as Overall Response Rate (ORR) at Week 30 for BI 695500 Versus Rituximab\n",
            "Category for Sentence 1358:\n",
            "Cutaneous tolerability\n",
            "Category for Sentence 1359:\n",
            "Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm\n",
            "Category for Sentence 1360:\n",
            "Change From Baseline to 24 Week Endpoint in Body Weight\n",
            "Category for Sentence 1361:\n",
            "number of patients with cutaneous severity\n",
            "Category for Sentence 1362:\n",
            "Correlation between the percentage of tumor-infiltrating lymphocytes (TILs) and PFS\n",
            "Category for Sentence 1363:\n",
            "Pain interference\n",
            "Category for Sentence 1364:\n",
            "Prevalence of Treatment Failures\n",
            "Category for Sentence 1365:\n",
            "Postoperative Fentanyl consumption\n",
            "Category for Sentence 1366:\n",
            "Half-life of Paclitaxel in the Pilot Part of the Study\n",
            "Category for Sentence 1367:\n",
            "Frequency of adverse events (AEs)\n",
            "Category for Sentence 1368:\n",
            "Change in oxidative stress markers\n",
            "Category for Sentence 1369:\n",
            "Postoperative Blood Loss\n",
            "Category for Sentence 1370:\n",
            "Gastrointestinal motor function and transit\n",
            "Category for Sentence 1371:\n",
            "Quality of life using the PAC-QOL questionnaire\n",
            "Category for Sentence 1372:\n",
            "Feasibility - Site level: MCD Approval\n",
            "Category for Sentence 1373:\n",
            "Number of Participants With Treatment Switch or Discontinuation\n",
            "Category for Sentence 1374:\n",
            "Mean Change From Baseline in Body Weight at Week 12\n",
            "Category for Sentence 1375:\n",
            "The change of the subjective symptom survey result after 3-month medical treatment.\n",
            "Category for Sentence 1376:\n",
            "Change from Baseline White Blood Cell Count at Time of Surgery\n",
            "Category for Sentence 1377:\n",
            "Single Assessment Numerical Evaluation: Enrollment\n",
            "Category for Sentence 1378:\n",
            "Cost-effectiveness\n",
            "Category for Sentence 1379:\n",
            "Reperfusion injury determined by peak AST\n",
            "Category for Sentence 1380:\n",
            "Dose Normalized Cmin,ss of Perampanel During the Maintenance Period of the Core Phase for EIAED Participants\n",
            "Category for Sentence 1381:\n",
            "Time-to-first complication\n",
            "Category for Sentence 1382:\n",
            "Number of Attempts Before Entering Trachea\n",
            "Category for Sentence 1383:\n",
            "Definite or probable relapse within 21 days post-antibiotic completion as per intention to treat\n",
            "Category for Sentence 1384:\n",
            "Proportion of Biochemical pregnancies (determined by serum B-hCG levels)\n",
            "Category for Sentence 1385:\n",
            "Percentage change in body weight at 6 months.\n",
            "Category for Sentence 1386:\n",
            "Incidence of treatment-emergent adverse events\n",
            "Category for Sentence 1387:\n",
            "presence of carbapenem-resistant gram-negative bacteria at the end of carbapenem treatment in faeces of patients who were free of carbapenem-resistant gram-negative bacteria before the beginning of treatment\n",
            "Category for Sentence 1388:\n",
            "AUC glucose/insulin/glucagon\n",
            "Category for Sentence 1389:\n",
            "Operative parameters bleeding\n",
            "Category for Sentence 1390:\n",
            "Systolic and diastolic blood pressure (mmHg)\n",
            "Category for Sentence 1391:\n",
            "Cohort C: intracranial duration of complete response (iDCR)\n",
            "Category for Sentence 1392:\n",
            "Change in Target Lesion Scoring Evaluated at Baseline and 4 Weeks\n",
            "Category for Sentence 1393:\n",
            "Renal insufficiency - 3\n",
            "Category for Sentence 1394:\n",
            "Weight Gain\n",
            "Category for Sentence 1395:\n",
            "Serum levels of free Oncostatin M (OSM)\n",
            "Category for Sentence 1396:\n",
            "Age\n",
            "Category for Sentence 1397:\n",
            "Psychological impact scores: quality of life (EQ5D)\n",
            "Category for Sentence 1398:\n",
            "Change from baseline of mental health-related functional impairment in 6 months\n",
            "Category for Sentence 1399:\n",
            "Duration of hospital stay\n",
            "Category for Sentence 1400:\n",
            "Urinalysis data over time\n",
            "Category for Sentence 1401:\n",
            "Number of Cycles With Ovulation Dysfunction When Taken After Ovulation: Extended Luteal Phase\n",
            "Category for Sentence 1402:\n",
            "Proportion of participants with clinical laboratory abnormalities\n",
            "Category for Sentence 1403:\n",
            "Molecular genotype of recurrent cancers\n",
            "Category for Sentence 1404:\n",
            "Number and type of adverse events in Novel versus standard infusion protocol\n",
            "Category for Sentence 1405:\n",
            "patient satisfaction\n",
            "Category for Sentence 1406:\n",
            "Blood pressure\n",
            "Category for Sentence 1407:\n",
            "Percentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Diastolic Blood Pressure\n",
            "Category for Sentence 1408:\n",
            "Modified plaque index\n",
            "Category for Sentence 1409:\n",
            "Chronic Pain Acceptance Questionnaire-8 (CPAQ-8)\n",
            "Category for Sentence 1410:\n",
            "Change in Pedalo Sensamove Balance Test from baseline to week 6\n",
            "Category for Sentence 1411:\n",
            "Survival after pacemaker implantation\n",
            "Category for Sentence 1412:\n",
            "Joint pain (intervention group)\n",
            "Category for Sentence 1413:\n",
            "Absolute Change in Mean Pain From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment(Day1-28), Second Cycle Under Study Treatment(Day29-56),Third Cycle Under Study Treatment (Day57-84) as Measured on NRS by Question1 of ESD\n",
            "Category for Sentence 1414:\n",
            "Time to Negative SARS-CoV-2 PCR From Baseline Through Day 29\n",
            "Category for Sentence 1415:\n",
            "Levels of cytokines and other inflammatory markers in peripheral blood\n",
            "Category for Sentence 1416:\n",
            "Incidence of acute kidney injury (AKI)\n",
            "Category for Sentence 1417:\n",
            "Time spent in the different sleep stages (% of total sleep time): Sleep stage N1, Sleep stage N2, Sleep stage N3 and Rapid Eye Movement (REM) sleep\n",
            "Category for Sentence 1418:\n",
            "Fetal Doppler Indices middle cerebral\n",
            "Category for Sentence 1419:\n",
            "Overall survival\n",
            "Category for Sentence 1420:\n",
            "Respiratory Exchange Ratio\n",
            "Category for Sentence 1421:\n",
            "Change in physical function-NIH Toolbox\n",
            "Category for Sentence 1422:\n",
            "Short-term effects of intervention on Latency to Affect recognition\n",
            "Category for Sentence 1423:\n",
            "Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population\n",
            "Category for Sentence 1424:\n",
            "Progression-free survival\n",
            "Category for Sentence 1425:\n",
            "Jebsen Taylor Hand Function Test (JTEFT)\n",
            "Category for Sentence 1426:\n",
            "PK: Time to Decrease in Concentration by Half (T1/2) of XmAb27564 after a single dose, due to elimination\n",
            "Category for Sentence 1427:\n",
            "Stop-Bang questionnaire as screening tool\n",
            "Category for Sentence 1428:\n",
            "DMFT caries index\n",
            "Category for Sentence 1429:\n",
            "Part 1: Change From Baseline in Hematology Parameter: Erythrocytes\n",
            "Category for Sentence 1430:\n",
            "In Non-responders, the Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.\n",
            "Category for Sentence 1431:\n",
            "Changes in temperature as degree C following administration of [18F]GEH121224\n",
            "Category for Sentence 1432:\n",
            "Change of Asthma Control Using the Asthma Control Test (ACT) Questionnaire Total Score From Baseline to Interim (80 mg), End of Up-Dosing (300 mg) and Study Exit, Ages 12-17\n",
            "Category for Sentence 1433:\n",
            "Running-related injuries (RRI)\n",
            "Category for Sentence 1434:\n",
            "Effectiveness of eye drop basd on athlete's opinion/experience during a one hour practice session\n",
            "Category for Sentence 1435:\n",
            "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).\n",
            "Category for Sentence 1436:\n",
            "Weight\n",
            "Category for Sentence 1437:\n",
            "Clinical Global Impression Score for the measurement of change over time of the illness' severity\n",
            "Category for Sentence 1438:\n",
            "Maximum Tolerated Dose (Phase 1b)\n",
            "Category for Sentence 1439:\n",
            "Patient Health Questionnaire-9\n",
            "Category for Sentence 1440:\n",
            "Number of Participants With Biochemically Verified Smoking Abstinence at Week 12\n",
            "Category for Sentence 1441:\n",
            "Determination of AUC0-∞\n",
            "Category for Sentence 1442:\n",
            "postoperative measures for 60th minute-5c\n",
            "Category for Sentence 1443:\n",
            "Subject's satisfaction rate after injection\n",
            "Category for Sentence 1444:\n",
            "Distance walking\n",
            "Category for Sentence 1445:\n",
            "To evaluate the usability of the device in the OR environment.\n",
            "Category for Sentence 1446:\n",
            "Assessment of Association of PD-L1 Expression with Clinical Benefit Rate\n",
            "Category for Sentence 1447:\n",
            "Proportion of Fecal Secretory (CDCA + DCA) Bile Acid as Measured in a Random Stool Sample by a Validated Laboratory Assay.\n",
            "Category for Sentence 1448:\n",
            "Changes in demoralization assessed by questionnaires (Demoralization Scale II (DS-II)) compared with active placebo\n",
            "Category for Sentence 1449:\n",
            "consequences of initial sub-optimal cares\n",
            "Category for Sentence 1450:\n",
            "Evaluate the effects of the study treatment on CD4+/8+ T cell ratios in two groups\n",
            "Category for Sentence 1451:\n",
            "University Hospital of North Northway Questionnaire\n",
            "Category for Sentence 1452:\n",
            "Area Under the Plasma Concentration-time Curve Extrapolated (AUCExt) of Moxetumomab Pasudotox\n",
            "Category for Sentence 1453:\n",
            "Change From Baseline in Body Weight\n",
            "Category for Sentence 1454:\n",
            "Time to maximum plasma concentration (Tmax)\n",
            "Category for Sentence 1455:\n",
            "Incidence of treatment related adverse events for experimental group compared to control group.\n",
            "Category for Sentence 1456:\n",
            "Disease free survival\n",
            "Category for Sentence 1457:\n",
            "Radiologic Response Rate Of Cryoablation\n",
            "Category for Sentence 1458:\n",
            "Proportion of dropouts due to inadequate analgesia judged by patients or investigator during the period between Hour 3 and Hour 24 of system application\n",
            "Category for Sentence 1459:\n",
            "SPID (Sum Pain Intensity Difference)\n",
            "Category for Sentence 1460:\n",
            "Antibody concentrations for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies\n",
            "Category for Sentence 1461:\n",
            "Gemigliptin Cmax,ss Geometric Mean Ratio (and 90%CI)\n",
            "Category for Sentence 1462:\n",
            "Assess safety\n",
            "Category for Sentence 1463:\n",
            "Change in IL-17A concentrations\n",
            "Category for Sentence 1464:\n",
            "Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase (Vz/F) for AZD4831\n",
            "Category for Sentence 1465:\n",
            "Score of Disinhibition\n",
            "Category for Sentence 1466:\n",
            "Percentage of Patients on Invasive Mechanical Ventilation\n",
            "Category for Sentence 1467:\n",
            "Changes in plasma agouti related regulatory proteins.\n",
            "Category for Sentence 1468:\n",
            "Percentage of participants with ocular AESIs during the intermediate postoperative period\n",
            "Category for Sentence 1469:\n",
            "Change in SGOT/ALT (U/L) From Baseline After Treatment\n",
            "Category for Sentence 1470:\n",
            "Boston Grade of Activity in Lichen Planopilaris (Boston GOAL)\n",
            "Category for Sentence 1471:\n",
            "Toxicity Profile\n",
            "Category for Sentence 1472:\n",
            "TSH receptor antibody (TRAb) levels\n",
            "Category for Sentence 1473:\n",
            "Presence of Fear of falling\n",
            "Category for Sentence 1474:\n",
            "Sarcopenia Status\n",
            "Category for Sentence 1475:\n",
            "C-reaction Protein (CRP)\n",
            "Category for Sentence 1476:\n",
            "Between-group differences in mean change in the levels of depression from baseline to T1, and from baseline to T2.\n",
            "Category for Sentence 1477:\n",
            "Supporter distress in helping at 1 month post-baseline (self report)\n",
            "Category for Sentence 1478:\n",
            "Number of Participants With Clinically Significant Safety Laboratory Tests Values.\n",
            "Category for Sentence 1479:\n",
            "The Continous Performance Test + Activity test\n",
            "Category for Sentence 1480:\n",
            "Incidence of related non expected adverse events\n",
            "Category for Sentence 1481:\n",
            "To assess the anti-scarring potential of intradermal Juvista in a young female population.\n",
            "Category for Sentence 1482:\n",
            "Composite endpoint \"adherence\" assessed as the \"number of clinical visits that were missed\" / \"number of drop-outs\" and \"number of patients crossing over to the plaster cast group\"\n",
            "Category for Sentence 1483:\n",
            "Change in Caregiver Self-Efficacy\n",
            "Category for Sentence 1484:\n",
            "Change in Western Ontario and McMaster Osteoarthritis Index score\n",
            "Category for Sentence 1485:\n",
            "Incidence of adverse events\n",
            "Category for Sentence 1486:\n",
            "Inter-reader agreement for all modalities\n",
            "Category for Sentence 1487:\n",
            "Change From Baseline in European Quality of life (Qol)-Group (EQ)-5D Questionnaire\n",
            "Category for Sentence 1488:\n",
            "Berg balance scale\n",
            "Category for Sentence 1489:\n",
            "ESSDAI improvement\n",
            "Category for Sentence 1490:\n",
            "Response duration, time to progression, median survival time, and safety\n",
            "Category for Sentence 1491:\n",
            "Time to neurocognitive failure\n",
            "Category for Sentence 1492:\n",
            "Change from Baseline in uric acid to all assessments during the study\n",
            "Category for Sentence 1493:\n",
            "Prostate-specific antigen (PSA) response rates based on Prostate Cancer Working Group 3 (PCWG3) criteria.\n",
            "Category for Sentence 1494:\n",
            "Total cholesterol\n",
            "Category for Sentence 1495:\n",
            "Number of sport units per week, sport disciplines practiced\n",
            "Category for Sentence 1496:\n",
            "Change in quality of life\n",
            "Category for Sentence 1497:\n",
            "Auditory Hallucination Rating Scale (AHRS)\n",
            "Category for Sentence 1498:\n",
            "QLES-SF: Comparison of Quality of Life Enjoyment and Satisfaction Scores Among iCBT, sCBT, and TAU Groups From Baseline to 1, 3, and 6 Month Follow Ups\n",
            "Category for Sentence 1499:\n",
            "For Deformity Subjects Only: Change in Coronal Alignment and Sagittal Vertical Axis From Baseline at the 12-month Visit.\n",
            "Category for Sentence 1500:\n",
            "interoceptive function\n",
            "Category for Sentence 1501:\n",
            "Change in Disposition\n",
            "Category for Sentence 1502:\n",
            "Correlation of surfactant protein genetic variants with severity of COVID-19 infection\n",
            "Category for Sentence 1503:\n",
            "Extension Study: Percent Change From Baseline in the Affected BSA at Week 40\n",
            "Category for Sentence 1504:\n",
            "myeloid PTP1B activity\n",
            "Category for Sentence 1505:\n",
            "Dyadic Parent Child Interaction Coding System (DPICS)\n",
            "Category for Sentence 1506:\n",
            "Persistent Chest Pain Symptoms: WISE female angina Questionnaire\n",
            "Category for Sentence 1507:\n",
            "Sugar test for intestinal permeability after prebiotic consumption in substudy\n",
            "Category for Sentence 1508:\n",
            "Parts A and B: PFS Rate at Months 6 and 12\n",
            "Category for Sentence 1509:\n",
            "Patient treatment satisfaction according to NRS\n",
            "Category for Sentence 1510:\n",
            "Plasma glucose concentration-time profiles (pharmacodynamics parameter)\n",
            "Category for Sentence 1511:\n",
            "Diabetes Empowerment Scale-Short Form\n",
            "Category for Sentence 1512:\n",
            "Blood concentrations of amoxicillin-clavulanate.\n",
            "Category for Sentence 1513:\n",
            "Morning Pre-Dose Trough FEV1 on Day 29\n",
            "Category for Sentence 1514:\n",
            "Changes in the faecal microbiota composition by Next Generation Sequencing (NGS)\n",
            "Category for Sentence 1515:\n",
            "reason for colonoscopy cancellation\n",
            "Category for Sentence 1516:\n",
            "Clinical response rate (CR or PR)\n",
            "Category for Sentence 1517:\n",
            "Time to recurrence\n",
            "Category for Sentence 1518:\n",
            "Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D)\n",
            "Category for Sentence 1519:\n",
            "SEDopt\n",
            "Category for Sentence 1520:\n",
            "Patient With Chronic Discomfort at 6 Years After Operation\n",
            "Category for Sentence 1521:\n",
            "Phase 3: Duration of hospitalization\n",
            "Category for Sentence 1522:\n",
            "Bowel habit at baseline\n",
            "Category for Sentence 1523:\n",
            "Change in PROMIS Pain Intensity - Short Form 3a V1.0\n",
            "Category for Sentence 1524:\n",
            "Assess The Value Of Supine MRI For Radiologists Performing Second Look US Examinations/ Biopsies Following Identification Of New Lesions on MRI, And Performing Preoperative Lesion Localization Using Supine MRI Guidance\n",
            "Category for Sentence 1525:\n",
            "Incidence of chronic GvHD and grading\n",
            "Category for Sentence 1526:\n",
            "Total sleep time\n",
            "Category for Sentence 1527:\n",
            "Phase I: Safety and tolerability of ASP8273 as assessed by vital signs\n",
            "Category for Sentence 1528:\n",
            "Cross sectional area of type II muscle fibers\n",
            "Category for Sentence 1529:\n",
            "Comprehensive metabolic panel blood test\n",
            "Category for Sentence 1530:\n",
            "Kicking\n",
            "Category for Sentence 1531:\n",
            "Carbon dioxide (CO2) and oxygen (O2) monitoring\n",
            "Category for Sentence 1532:\n",
            "Discharge destination following successful weaning\n",
            "Category for Sentence 1533:\n",
            "Surgical Localization - Duration of Localization\n",
            "Category for Sentence 1534:\n",
            "Number of episodes of severe malaria\n",
            "Category for Sentence 1535:\n",
            "FFA (free fatty acid)\n",
            "Category for Sentence 1536:\n",
            "Feasibility of the gastroenteric anastomosis\n",
            "Category for Sentence 1537:\n",
            "Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 24\n",
            "Category for Sentence 1538:\n",
            "EHS 1\n",
            "Category for Sentence 1539:\n",
            "Change in the participants' self-rated overall level of medicines burden\n",
            "Category for Sentence 1540:\n",
            "Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)\n",
            "Category for Sentence 1541:\n",
            "Hospital Acquired Infection as measured by positive epidemiologic surveillance report for VAE (including VAP), bacteremia, sepsis\n",
            "Category for Sentence 1542:\n",
            "Absolute Values of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DSBP) in Participants\n",
            "Category for Sentence 1543:\n",
            "Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)\n",
            "Category for Sentence 1544:\n",
            "Evaluation of the clinical performance of bulk-fill composite about placement technique (bulk-filling and incremental) in Class II carious lesions using FDI and USPHS criteria.\n",
            "Category for Sentence 1545:\n",
            "Number of participants with end-stage kidney disease (ESKD), a sustained decline in eGFR to <10 mL/min/1.73m2, renal death, or a sustained decline of ≥40% in eGFR from randomization\n",
            "Category for Sentence 1546:\n",
            "change in left ventricle end-systolic volume (LVESV) from base line to 6 months follow-up measured by echocardiography and computerized tomography\n",
            "Category for Sentence 1547:\n",
            "Overall survival at 1 year\n",
            "Category for Sentence 1548:\n",
            "Major Cardiovascular Events\n",
            "Category for Sentence 1549:\n",
            "Clinical response rates based on signs and symptoms at posttherapy visit.\n",
            "Category for Sentence 1550:\n",
            "Reason for treatment discontinuation\n",
            "Category for Sentence 1551:\n",
            "ROM\n",
            "Category for Sentence 1552:\n",
            "Investigating the effectiveness of autologous AT-MSC in treating SCI patients.\n",
            "Category for Sentence 1553:\n",
            "Psychosocial Functioning- The Brief Inventory of Psychosocial Functioning (IPF-Brief)\n",
            "Category for Sentence 1554:\n",
            "Molecular Analysis of Serial Biopsies\n",
            "Category for Sentence 1555:\n",
            "Evolution of glucose sensor use compared to before lockdown.\n",
            "Category for Sentence 1556:\n",
            "CGM Episodes of Hypoglycemia\n",
            "Category for Sentence 1557:\n",
            "Level of stigma related to cervical cancer\n",
            "Category for Sentence 1558:\n",
            "Subjective assessment of physical activity by the subject (Baeckley).\n",
            "Category for Sentence 1559:\n",
            "Actigraphy (i.e., sleep onset latency measure).\n",
            "Category for Sentence 1560:\n",
            "Length of mechanical ventilation\n",
            "Category for Sentence 1561:\n",
            "Intensity of behavioural symptoms assessed with the a Behavioral questionnaire based on the Neuropsychiatric Inventory Questionnaire (NPI-Q) and the Agitated Behavior in Dementia scale (ABID)\n",
            "Category for Sentence 1562:\n",
            "Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)\n",
            "Category for Sentence 1563:\n",
            "Intratumoral Levels of Specific Biomarkers\n",
            "Category for Sentence 1564:\n",
            "Coronavirus disease\n",
            "Category for Sentence 1565:\n",
            "Foot function questionnaire\n",
            "Category for Sentence 1566:\n",
            "Short form-12 mental component score\n",
            "Category for Sentence 1567:\n",
            "Duration of Response (DoR)\n",
            "Category for Sentence 1568:\n",
            "Efficiency\n",
            "Category for Sentence 1569:\n",
            "Total blood loss\n",
            "Category for Sentence 1570:\n",
            "Mean Change in Standardized Best-corrected Visual Acuity (BCVA) Between Baseline and 9 Months\n",
            "Category for Sentence 1571:\n",
            "ultrasound ultrasensitive doppler measurements\n",
            "Category for Sentence 1572:\n",
            "Mean days of antibiotics prescribed\n",
            "Category for Sentence 1573:\n",
            "Number of Participants With the Indicated Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry Intensity in the Randomized Part of the Study\n",
            "Category for Sentence 1574:\n",
            "Serum Endocannabinoid Levels\n",
            "Category for Sentence 1575:\n",
            "Change in Foot Health Status Questionnaire pain domain\n",
            "Category for Sentence 1576:\n",
            "Number of facial actinic keratosis\n",
            "Category for Sentence 1577:\n",
            "Balance Analysis - Stabilometric data - Velocity antero-posterior and Velocity medio-lateral (VelocityAP and VelocityML)\n",
            "Category for Sentence 1578:\n",
            "Efficacy: Very Good Partial Response (VGPR) or Better Rate\n",
            "Category for Sentence 1579:\n",
            "Motivation for doing physical activity in the Experimental Group\n",
            "Category for Sentence 1580:\n",
            "Change from baseline in hepatic fat fraction assessed by MRI-PDFF\n",
            "Category for Sentence 1581:\n",
            "Procedure success defined as achievement of a final diameter stenosis of <50% (by QCA) using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay;\n",
            "Category for Sentence 1582:\n",
            "Utilization of intervention content\n",
            "Category for Sentence 1583:\n",
            "Intermuscular coordination\n",
            "Category for Sentence 1584:\n",
            "ICU and hospital length of stay\n",
            "Category for Sentence 1585:\n",
            "Anthropometrics\n",
            "Category for Sentence 1586:\n",
            "Root resorption of mandibular anteriors\n",
            "Category for Sentence 1587:\n",
            "Overall response rate (ORR)\n",
            "Category for Sentence 1588:\n",
            "Area Under The Curve (AUC) of TL118\n",
            "Category for Sentence 1589:\n",
            "Laboratory safety parameters\n",
            "Category for Sentence 1590:\n",
            "Peds-QL 4.0 and 3.0 (quality of life assessments)\n",
            "Category for Sentence 1591:\n",
            "Number of Participants With Dose-limiting Toxicities (DLT)\n",
            "Category for Sentence 1592:\n",
            "Skin melanin index\n",
            "Category for Sentence 1593:\n",
            "Number of Patients With Notable Increase in QRS Intervals\n",
            "Category for Sentence 1594:\n",
            "bone level changes\n",
            "Category for Sentence 1595:\n",
            "Radiographic Evaluation\n",
            "Category for Sentence 1596:\n",
            "Effectiveness of contour augmentation\n",
            "Category for Sentence 1597:\n",
            "Frequency count of reported memory failures from EMA & daily diaries\n",
            "Category for Sentence 1598:\n",
            "The sensitivity of sitting perfusion index to predict post-spinal anesthesia hypotension in caesarian section.\n",
            "Category for Sentence 1599:\n",
            "Change in infant expressive vocabulary\n",
            "Category for Sentence 1600:\n",
            "Measurement of placental volume\n",
            "Category for Sentence 1601:\n",
            "Comparison of the repeatability of CNVA measured by the RHMS Visual Acuity Module and the Reference Chart\n",
            "Category for Sentence 1602:\n",
            "Executive function by report: Emotional Control\n",
            "Category for Sentence 1603:\n",
            "Treatment Intensification\n",
            "Category for Sentence 1604:\n",
            "Recruitment Rate\n",
            "Category for Sentence 1605:\n",
            "Disease-free Survival\n",
            "Category for Sentence 1606:\n",
            "Change in Pain Intensity\n",
            "Category for Sentence 1607:\n",
            "Summary of Treatment Emergent Adverse Events During the Active Treatment-Extension Phase\n",
            "Category for Sentence 1608:\n",
            "Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\n",
            "Category for Sentence 1609:\n",
            "mean ABP\n",
            "Category for Sentence 1610:\n",
            "marginal adaptation\n",
            "Category for Sentence 1611:\n",
            "Number of Participants with Serious Adverse Events (SAEs), or Medically Attended AEs (MAAEs), or AEs Leading to Early Termination, or Adverse Events of Special Interest (AESIs)\n",
            "Category for Sentence 1612:\n",
            "Immunology\n",
            "Category for Sentence 1613:\n",
            "Change in alkaline phosphatase (ALP)\n",
            "Category for Sentence 1614:\n",
            "Tendon vascularisation examination.\n",
            "Category for Sentence 1615:\n",
            "Percentage of subjects with a weekly average increase of 1 or more Spontaneous Bowel Movement (SBM), Bowel Movement (BM) during the 12-week treatment phase as compared to the baseline\n",
            "Category for Sentence 1616:\n",
            "Number of Participants With Dose-limiting Toxicities (DLTs)\n",
            "Category for Sentence 1617:\n",
            "Change in Body Mass Index (BMI) in response to dietary fibre\n",
            "Category for Sentence 1618:\n",
            "Duration of Response for Patients Achieving a Reduction of Mean GH Level to <2.5 μg/L and the Normalization of IGF-1 at Month 12 (No. of Responders: Pasireotide LAR = 51, Octreotide LAR = 32)\n",
            "Category for Sentence 1619:\n",
            "Change From Baseline in Biochemistry: Sodium\n",
            "Category for Sentence 1620:\n",
            "Drug Abuse Screening Test\n",
            "Category for Sentence 1621:\n",
            "Shoulder Pain and Disability Index (SPADI)\n",
            "Category for Sentence 1622:\n",
            "Change in catecholamines from baseline\n",
            "Category for Sentence 1623:\n",
            "All-cause mortality\n",
            "Category for Sentence 1624:\n",
            "Incidence of stroke\n",
            "Category for Sentence 1625:\n",
            "Incidence of Treatment-Emergent Adverse Events\n",
            "Category for Sentence 1626:\n",
            "Re-admission rate 30-day re-admission rate\n",
            "Category for Sentence 1627:\n",
            "MACE (Major Adverse Cardiac Events)\n",
            "Category for Sentence 1628:\n",
            "Polysomnography\n",
            "Category for Sentence 1629:\n",
            "Mortality at hospital discharge\n",
            "Category for Sentence 1630:\n",
            "International Physical Activity Questionnaire-Short Form (IPAQ-S)\n",
            "Category for Sentence 1631:\n",
            "Rate of Participant Retention\n",
            "Category for Sentence 1632:\n",
            "Duration of response in Phase 1b, defined as the time (in days) from the date of first response to treatment (CR, sCR, VGPR, PR) to the date of disease progression or death\n",
            "Category for Sentence 1633:\n",
            "Scandinavian Stroke Scale (SSS)\n",
            "Category for Sentence 1634:\n",
            "The mean change in fasting glucose\n",
            "Category for Sentence 1635:\n",
            "Satisfaction to the Zentangle programme\n",
            "Category for Sentence 1636:\n",
            "time to first request for analgesia\n",
            "Category for Sentence 1637:\n",
            "Demographic Data\n",
            "Category for Sentence 1638:\n",
            "PK for plasma of INCB000928: AUC0-t\n",
            "Category for Sentence 1639:\n",
            "Vital signs measurements\n",
            "Category for Sentence 1640:\n",
            "Variation in blood glucose after estriol use\n",
            "Category for Sentence 1641:\n",
            "PaO2/FiO2\n",
            "Category for Sentence 1642:\n",
            "To study the cancer survivorship experience(as binary responses)\n",
            "Category for Sentence 1643:\n",
            "Change in Biomarkers of NAFLD: Cytokeratin (CK)-18\n",
            "Category for Sentence 1644:\n",
            "Duration of response (DOR)\n",
            "Category for Sentence 1645:\n",
            "Change in self-reported physical activity\n",
            "Category for Sentence 1646:\n",
            "Godin-Shephard Leisure-Time Physical Activity Questionnaire\n",
            "Category for Sentence 1647:\n",
            "Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Scores at Week 1, Week 2 and Week 3: Stage 1\n",
            "Category for Sentence 1648:\n",
            "Number of Participants Undergoing Salvage Craniotomy\n",
            "Category for Sentence 1649:\n",
            "Perfusion dynamics following surgical procedures\n",
            "Category for Sentence 1650:\n",
            "Appropriateness of CT imaging\n",
            "Category for Sentence 1651:\n",
            "Treatment procedural and short-term post-treatment safety profile\n",
            "Category for Sentence 1652:\n",
            "Evaluate the impact of oral nutritional supplementation on the quality of life of the patient\n",
            "Category for Sentence 1653:\n",
            "The concentration of serotonin\n",
            "Category for Sentence 1654:\n",
            "Number of Adverse Skin Reactions\n",
            "Category for Sentence 1655:\n",
            "Overall Disease Control Rate\n",
            "Category for Sentence 1656:\n",
            "Collection of diseased and non-diseased tissue, blood, and other body fluids\n",
            "Category for Sentence 1657:\n",
            "Gender differences in examination results\n",
            "Category for Sentence 1658:\n",
            "Average worst pain score with movement over 7 days\n",
            "Category for Sentence 1659:\n",
            "Proportion of treatment-emergent adverse events (TEAE)\n",
            "Category for Sentence 1660:\n",
            "Recommended Dose of ADCT-402 for Part 2\n",
            "Category for Sentence 1661:\n",
            "Change in global risk from baseline to 3 and 9 months, as evaluated by the SCORE algorithm\n",
            "Category for Sentence 1662:\n",
            "Stroke Prevention in Atrial Fibrillation in Asia\n",
            "Category for Sentence 1663:\n",
            "Rate of adverse event\n",
            "Category for Sentence 1664:\n",
            "Superiority of CBCT\n",
            "Category for Sentence 1665:\n",
            "Best Overall Response (Crossover Treatment)\n",
            "Category for Sentence 1666:\n",
            "Percent of successful blocks for operation (success operation)\n",
            "Category for Sentence 1667:\n",
            "Overall Survival\n",
            "Category for Sentence 1668:\n",
            "maximum concentration, Area under the concentration-time curve from zero to infinity\n",
            "Category for Sentence 1669:\n",
            "Change in aspartate transaminase (AST)\n",
            "Category for Sentence 1670:\n",
            "Overall Survival\n",
            "Category for Sentence 1671:\n",
            "Duration of noninvasive ventilation\n",
            "Category for Sentence 1672:\n",
            "Percentage of Participants with at Least One Adverse Event (AE), Serious Adverse Event (SAE), and AE of special interest (AESI)\n",
            "Category for Sentence 1673:\n",
            "Determine the sensitivity and specificity of the CIBI in cHSIL\n",
            "Category for Sentence 1674:\n",
            "Progression free survival\n",
            "Category for Sentence 1675:\n",
            "Treatment request by the patient during the care\n",
            "Category for Sentence 1676:\n",
            "Percentage of Participants in the Test Lens Group Agreeing With the Statement \"Provide Clear Vision Throughout the Day\"\n",
            "Category for Sentence 1677:\n",
            "Genotype/phenotype correlation of Y-linked AZF candidates and estrogen-related genes\n",
            "Category for Sentence 1678:\n",
            "Clinical Performance by Cvar & Ryge Scores\n",
            "Category for Sentence 1679:\n",
            "Aqueductal CSF flow\n",
            "Category for Sentence 1680:\n",
            "Percentage of time in Closed Loop\n",
            "Category for Sentence 1681:\n",
            "Area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC [0-t]) and to infinity (AUC [0-infinity]) of GSK256066 at Day 1 and Day 14\n",
            "Category for Sentence 1682:\n",
            "Change in Craving from Peak Craving to the Craving Observed During Pleasant, Compared to Neutral, Olfactory Cues as Measured by a Pressure-Sensitive Squeeze Device\n",
            "Category for Sentence 1683:\n",
            "Neurocognition\n",
            "Category for Sentence 1684:\n",
            "Overall survival (OS)\n",
            "Category for Sentence 1685:\n",
            "Time to organ response\n",
            "Category for Sentence 1686:\n",
            "Isocinetic evaluation\n",
            "Category for Sentence 1687:\n",
            "Clinical response to treatment\n",
            "Category for Sentence 1688:\n",
            "Symptom response (yes/no)\n",
            "Category for Sentence 1689:\n",
            "Correlation between EQ5D-5L and IMPACT III questionnaire in adolescents\n",
            "Category for Sentence 1690:\n",
            "Adherence to standard of care for hereditary breast and ovarian cancer (HBOC) and Lynch syndromes\n",
            "Category for Sentence 1691:\n",
            "Occurence of arrhythmias\n",
            "Category for Sentence 1692:\n",
            "Primary Effectiveness Endpoint\n",
            "Category for Sentence 1693:\n",
            "Pre lens and post lens tear film thickness\n",
            "Category for Sentence 1694:\n",
            "Biochemical Response\n",
            "Category for Sentence 1695:\n",
            "LDL\n",
            "Category for Sentence 1696:\n",
            "Major bleeding\n",
            "Category for Sentence 1697:\n",
            "Blood pressure\n",
            "Category for Sentence 1698:\n",
            "Psychosocial outcomes\n",
            "Category for Sentence 1699:\n",
            "Changes in hepatic insulin sensitivity by AZD4017 when given with prednisolone (20mg) compared to prednisolone (20mg) given alone.\n",
            "Category for Sentence 1700:\n",
            "The main objective is to build a database with the necessary, relevant and quality data that will allow the development of a diagnostic and therapeutic aid in endodontics.\n",
            "Category for Sentence 1701:\n",
            "Location as a moderator variable\n",
            "Category for Sentence 1702:\n",
            "Ferritin\n",
            "Category for Sentence 1703:\n",
            "Proportion of participants we can establish number of days alive and well out of hospital\n",
            "Category for Sentence 1704:\n",
            "Balance (measure 2)\n",
            "Category for Sentence 1705:\n",
            "Time until all-cause death or all-cause hospitalization\n",
            "Category for Sentence 1706:\n",
            "Overall Survival\n",
            "Category for Sentence 1707:\n",
            "Renal function test\n",
            "Category for Sentence 1708:\n",
            "Proportion of patients achieving low disease activity (LDA) defined as psoriatic arthritis disease activity score (PASDAS) score ≤3.2\n",
            "Category for Sentence 1709:\n",
            "Change in ventilatory efficiency (V'E/V'CO2 slope and nadir)\n",
            "Category for Sentence 1710:\n",
            "The Percentage of Subjects Achieving American College of Rheumatology (ACR) 20 Improvement\n",
            "Category for Sentence 1711:\n",
            "Change in Inhibitory modulation conditioned by pain (Kpa)\n",
            "Category for Sentence 1712:\n",
            "Time to first skeletal-related event (SRE)\n",
            "Category for Sentence 1713:\n",
            "90-day all-cause mortality\n",
            "Category for Sentence 1714:\n",
            "Stroke Impact Scale\n",
            "Category for Sentence 1715:\n",
            "Visual Analogue Scale (VAS) Pain Level (0-10 Scale)\n",
            "Category for Sentence 1716:\n",
            "Peak plasma concentration (Cmax) of nebulized amikacin/fosfomycin following delivery of 30/12 mg, 60/24 mg, and 90/36 mg amikacin/fosfomycin via the PARI LC Sprint Nebulizer\n",
            "Category for Sentence 1717:\n",
            "Best Overall Response Rate\n",
            "Category for Sentence 1718:\n",
            "Low Density Lipoprotein particle size\n",
            "Category for Sentence 1719:\n",
            "The femoral head blood-supply artery angiographies and the areas of femoral head necrosis\n",
            "Category for Sentence 1720:\n",
            "3-year Progression-free Survival Rate\n",
            "Category for Sentence 1721:\n",
            "Postoperative pain - Clinically Aligned Pain Assessment Tool (CAPA) - Change in Pain - Getting Worse - Third postoperative day\n",
            "Category for Sentence 1722:\n",
            "New ischemic stroke or Transient Ischemic Attack:\n",
            "Category for Sentence 1723:\n",
            "Incidence of treatment-emergent clinical adverse events (AE) following single intravenous (IV) administration of BGB149 or matched placebo\n",
            "Category for Sentence 1724:\n",
            "EQ-5D-5L Self-Evaluation Questionnaire for Implant Performance\n",
            "Category for Sentence 1725:\n",
            "Symptomatic intracranial hemorrhage defined as SITS-MOST\n",
            "Category for Sentence 1726:\n",
            "Body Mass Index of patients in the control group\n",
            "Category for Sentence 1727:\n",
            "Abnormal liver funcion tests (elevated liver enzymes)\n",
            "Category for Sentence 1728:\n",
            "Dose Escalation: Pharmacokinetics (PK) parameter: AUC0-24h at at Day 15 of Cycle 1\n",
            "Category for Sentence 1729:\n",
            "Bilirubin\n",
            "Category for Sentence 1730:\n",
            "4. Longitudinal evaluation of TCR and BCR repertoire development in COVID-19 patients before and after BTK inhibition.\n",
            "Category for Sentence 1731:\n",
            "Event-Free Survival (EFS) According to HMRA in TP53 WT Population\n",
            "Category for Sentence 1732:\n",
            "Rate (%) of 30-day post-discharge hospitalization and ED visits (same-hospital), stratified by whether patient has three or more high risk medications (anticoagulants, antiplatelets, insulin, oral hypoglycemics) prior to admission\n",
            "Category for Sentence 1733:\n",
            "Autograft mid-term survivorship at 3 years postoperative\n",
            "Category for Sentence 1734:\n",
            "Duration of the treatment\n",
            "Category for Sentence 1735:\n",
            "QoL via EQ-5D-5L questionnaire in genetically defined cohorts in gastrointestinal cancer patients\n",
            "Category for Sentence 1736:\n",
            "Detectable replication competent lentivirus (RCL)\n",
            "Category for Sentence 1737:\n",
            "AE/SAE\n",
            "Category for Sentence 1738:\n",
            "Low-Density Lipoprotein Cholesterol (LDLc)\n",
            "Category for Sentence 1739:\n",
            "Change in weight at 6 months\n",
            "Category for Sentence 1740:\n",
            "Ex vivo Response/resistance\n",
            "Category for Sentence 1741:\n",
            "Semi-structured focus group interviews about Patients' Perception of Exercise\n",
            "Category for Sentence 1742:\n",
            "Index of microvascular resistance (IMR)\n",
            "Category for Sentence 1743:\n",
            "Fatigue: Changes in fatigue\n",
            "Category for Sentence 1744:\n",
            "Percentage of Participants Who Had a Response in the Hemoglobin Lineage\n",
            "Category for Sentence 1745:\n",
            "Percentage of Participants Who Discontinue Study Treatment Due to an AE\n",
            "Category for Sentence 1746:\n",
            "Speech understanding in noise\n",
            "Category for Sentence 1747:\n",
            "Disease Free Survival (DFS)\n",
            "Category for Sentence 1748:\n",
            "Life Quality\n",
            "Category for Sentence 1749:\n",
            "Patient stratification according to predefined genetic signatures\n",
            "Category for Sentence 1750:\n",
            "Hemoglobin levels (g/L)\n",
            "Category for Sentence 1751:\n",
            "Progression free survival\n",
            "Category for Sentence 1752:\n",
            "Change in brain function\n",
            "Category for Sentence 1753:\n",
            "postoperative Zonulin\n",
            "Category for Sentence 1754:\n",
            "Oral PK of MK-7762 (TBD09) following a single dose and multiple doses\n",
            "Category for Sentence 1755:\n",
            "comfort assessment\n",
            "Category for Sentence 1756:\n",
            "Change of Arm motor Fugl-Mayer scale\n",
            "Category for Sentence 1757:\n",
            "Mean Change in CD4 Cell Count by Visit\n",
            "Category for Sentence 1758:\n",
            "Cardiac toxicity rate of this combination using MUGA or 2D ECHO\n",
            "Category for Sentence 1759:\n",
            "Extracranial ORR\n",
            "Category for Sentence 1760:\n",
            "Reproducibility Coefficient (RDC) Between the Two Imaging Modalities in Liver Tumor Tissues\n",
            "Category for Sentence 1761:\n",
            "Frequency of serious adverse drug events\n",
            "Category for Sentence 1762:\n",
            "Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-VIP Level\n",
            "Category for Sentence 1763:\n",
            "Steady State Volume of Distribution (Vss/F) After Extravascular Administration for Dolutegravir\n",
            "Category for Sentence 1764:\n",
            "Tobacco use cessation among teachers\n",
            "Category for Sentence 1765:\n",
            "Safety and tolerability assessed by C-SSRS\n",
            "Category for Sentence 1766:\n",
            "Change in NEO-Five-Factor Inventory (NEO-FFI)\n",
            "Category for Sentence 1767:\n",
            "Observed Accumulation Ratio (Rac)\n",
            "Category for Sentence 1768:\n",
            "Length of hospital stay\n",
            "Category for Sentence 1769:\n",
            "Involvement in the Breast Reconstruction (BR) decision-making process scale\n",
            "Category for Sentence 1770:\n",
            "Number of subjects with overall survival\n",
            "Category for Sentence 1771:\n",
            "Number of participants with treatment-related adverse events as assessed by CTCAE v5.0\n",
            "Category for Sentence 1772:\n",
            "Questionnaire using the experience sampling method, administered by the mobile phone application.\n",
            "Category for Sentence 1773:\n",
            "Phase 2: Percentage of subjects who remain alive and progression-free at 6 months\n",
            "Category for Sentence 1774:\n",
            "physical activity\n",
            "Category for Sentence 1775:\n",
            "Change from baseline in reaching time at 4weeks\n",
            "Category for Sentence 1776:\n",
            "Proportion of measurement points with target Hb level from Week 46 to Week 52\n",
            "Category for Sentence 1777:\n",
            "Concentration of the neuropathy marker VEGFA, as measured by multiplex cytokine bead analysis or ELISA (enzyme-linked immunosorbent assay)\n",
            "Category for Sentence 1778:\n",
            "histological remission\n",
            "Category for Sentence 1779:\n",
            "Bilirubin\n",
            "Category for Sentence 1780:\n",
            "Change in tDCS headgear location\n",
            "Category for Sentence 1781:\n",
            "Quality of Life Assessment, Including Clinical Benefit Response: Overall Health\n",
            "Category for Sentence 1782:\n",
            "Number of Participants Who Discontinue Study Treatment Due to an AE\n",
            "Category for Sentence 1783:\n",
            "Spirometry - FEV1 change from 8 weeks to 16 weeks\n",
            "Category for Sentence 1784:\n",
            "Groups 1 to 4: Percentage of Participants With Adverse Events (AEs)\n",
            "Category for Sentence 1785:\n",
            "Change in verbal memory\n",
            "Category for Sentence 1786:\n",
            "Compare pregnancy outcome to low/high PIF levels in maternal blood\n",
            "Category for Sentence 1787:\n",
            "For Sum Dabigatran: Amount of the Analyte Excreted in Urine at Steady State Over the Time Interval 0-74 Hours (Ae0-74,ss ) on Day 4 and Day 11\n",
            "Category for Sentence 1788:\n",
            "Size of vessels measured by OCT\n",
            "Category for Sentence 1789:\n",
            "PD: Maximum Glucose Increase (Gmax) of Part A\n",
            "Category for Sentence 1790:\n",
            "Phase II - Best overall response rate\n",
            "Category for Sentence 1791:\n",
            "Knee Society Score\n",
            "Category for Sentence 1792:\n",
            "efficacy of multi-beam IMRT\n",
            "Category for Sentence 1793:\n",
            "Metabolomic Profile\n",
            "Category for Sentence 1794:\n",
            "Overall survival (OS) (Phase 2)\n",
            "Category for Sentence 1795:\n",
            "Number and Quality of Blastocysts\n",
            "Category for Sentence 1796:\n",
            "Change in lactate levels\n",
            "Category for Sentence 1797:\n",
            "Diastolic blood pressure\n",
            "Category for Sentence 1798:\n",
            "On-scene-time in relation to patients vomiting\n",
            "Category for Sentence 1799:\n",
            "overall survival\n",
            "Category for Sentence 1800:\n",
            "AUC (0-t) of GSK2646264 for Part A\n",
            "Category for Sentence 1801:\n",
            "Frequency of use of the Asthma Control (AC) questionnaire\n",
            "Category for Sentence 1802:\n",
            "AUC0-t of Venlafaxine.\n",
            "Category for Sentence 1803:\n",
            "Height\n",
            "Category for Sentence 1804:\n",
            "Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6\n",
            "Category for Sentence 1805:\n",
            "Amount of solution used for submucosal injection to lift the polyp\n",
            "Category for Sentence 1806:\n",
            "Currently taking PrEP\n",
            "Category for Sentence 1807:\n",
            "Tolerability\n",
            "Category for Sentence 1808:\n",
            "Pathological response rate (pRR)\n",
            "Category for Sentence 1809:\n",
            "Probing pocket depth\n",
            "Category for Sentence 1810:\n",
            "Single nucleotide polymorphisms (SNP)\n",
            "Category for Sentence 1811:\n",
            "To assess the safety\n",
            "Category for Sentence 1812:\n",
            "Evaluation of the effectiveness of the ELMO system using physiological parameters\n",
            "Category for Sentence 1813:\n",
            "Total healthcare costs (broken down by bed, laboratory, and pharmacy costs).\n",
            "Category for Sentence 1814:\n",
            "Mean Absolute Change From Baseline to Week 16 in Body Weight - Evaluable Population\n",
            "Category for Sentence 1815:\n",
            "Fasting Glucose (mg/dL)\n",
            "Category for Sentence 1816:\n",
            "Area Under the Curve (AUC) for the Total Number of Plaque Bacteria in the Mouth Post Implant Surgery\n",
            "Category for Sentence 1817:\n",
            "Phase 1 To determine the maximum tolerated dose of E7449 and in combination with carboplatin and paclitaxel\n",
            "Category for Sentence 1818:\n",
            "Part 2: Disease Control Rate (DCR)\n",
            "Category for Sentence 1819:\n",
            "Pharmacokinetics/dynamics\n",
            "Category for Sentence 1820:\n",
            "Timeline Followback (TLFB) heavy drinking days\n",
            "Category for Sentence 1821:\n",
            "Maximum observed XTMAB-16 concentration (Cmax)\n",
            "Category for Sentence 1822:\n",
            "Number of Health Risk Behaviors\n",
            "Category for Sentence 1823:\n",
            "demographic and clinical characteristics of patients\n",
            "Category for Sentence 1824:\n",
            "Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 104 Weeks\n",
            "Category for Sentence 1825:\n",
            "Total Procedure Time\n",
            "Category for Sentence 1826:\n",
            "The proportion of subjects with stable hematologic recovery (improvement documented in 2 consecutive available readings) without recent blood product transfusion support (in the past 48-72 hours)\n",
            "Category for Sentence 1827:\n",
            "Incidence of surgical complications\n",
            "Category for Sentence 1828:\n",
            "The change in number of best-corrected visual acuity (BCVA) letters from baseline to Week 26 (Cohort A) measured using electronic visual acuity (EVA).\n",
            "Category for Sentence 1829:\n",
            "Feasibility of DC vaccine administration (administration of 1st vaccine)\n",
            "Category for Sentence 1830:\n",
            "PSA recurrence rate stratified according to EGFR and HER2/neu overexpression levels.\n",
            "Category for Sentence 1831:\n",
            "Change in dyspnea\n",
            "Category for Sentence 1832:\n",
            "The primary objective is to compare & evaluate between the treatment groups the changes in WBC white blood cell counts at Week 52\n",
            "Category for Sentence 1833:\n",
            "Reduction of EBOV viral load titers by nucleic acid testing prior to hospital discharge.\n",
            "Category for Sentence 1834:\n",
            "Cognitive reserve\n",
            "Category for Sentence 1835:\n",
            "diseases-free survival\n",
            "Category for Sentence 1836:\n",
            "Clinical benefit rate (CBR) (Phase I and Phase II)\n",
            "Category for Sentence 1837:\n",
            "Serum osmolality\n",
            "Category for Sentence 1838:\n",
            "plasma kynurenine concentrations\n",
            "Category for Sentence 1839:\n",
            "Number of courses of antibiotics for wheeze between 19-24 months\n",
            "Category for Sentence 1840:\n",
            "Determine the acetaldehyde exposure to the oral cavity by comparing saliva levels before and after alcohol dose\n",
            "Category for Sentence 1841:\n",
            "Mean Hb levels at 8 weeks after using roxadustat\n",
            "Category for Sentence 1842:\n",
            "Percentage of Participants With Mucosal Healing at Weeks 6 and 14\n",
            "Category for Sentence 1843:\n",
            "Frequency of pregnancies during use of COPD medication\n",
            "Category for Sentence 1844:\n",
            "Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing\n",
            "Category for Sentence 1845:\n",
            "Changes in Calcium absorption\n",
            "Category for Sentence 1846:\n",
            "Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]\n",
            "Category for Sentence 1847:\n",
            "Part 1: Change From Baseline in Clinical Chemistry Parameters: Total Bilirubin and Creatinine- Substance P Only at Challenge Visit 1 (Day 1)\n",
            "Category for Sentence 1848:\n",
            "vIGA-AD of 'clear' or 'almost clear' at Week 1\n",
            "Category for Sentence 1849:\n",
            "Patients with two doses of CP tended to have faster PCR negative conversion time than those with one dose of CP\n",
            "Category for Sentence 1850:\n",
            "Part1:OS rate\n",
            "Category for Sentence 1851:\n",
            "Short-form 12 (SF-12) Health Related Quality of Life Questionnaire\n",
            "Category for Sentence 1852:\n",
            "Compliance with dental treatments in CKD patients\n",
            "Category for Sentence 1853:\n",
            "Provider Perceptions of ISS - Appropriateness\n",
            "Category for Sentence 1854:\n",
            "Correlation of Genomics with Vaccine/Antigen Immune Response Phenotype\n",
            "Category for Sentence 1855:\n",
            "Percentage of viable tumour cells at resection\n",
            "Category for Sentence 1856:\n",
            "AUC(TAU) for DRV, RTV, and ETR\n",
            "Category for Sentence 1857:\n",
            "Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)\n",
            "Category for Sentence 1858:\n",
            "Neck disability index\n",
            "Category for Sentence 1859:\n",
            "Safety measurments of the C-Scan System regarding SUSAR\n",
            "Category for Sentence 1860:\n",
            "Changes to a patient's usual medical treatment for fibromyalgia\n",
            "Category for Sentence 1861:\n",
            "Hepcidin\n",
            "Category for Sentence 1862:\n",
            "changes in upper mid-arm circumference\n",
            "Category for Sentence 1863:\n",
            "Vitreous Haze\n",
            "Category for Sentence 1864:\n",
            "Total cholesterol (Total-C)\n",
            "Category for Sentence 1865:\n",
            "The rate of imaging tests prescribed related with a low back pain complaint\n",
            "Category for Sentence 1866:\n",
            "number of viral particles - SARS-CoV-2 - Children-168\n",
            "Category for Sentence 1867:\n",
            "Change in BP in eGFR strata\n",
            "Category for Sentence 1868:\n",
            "Thoracic kyphosis orientation\n",
            "Category for Sentence 1869:\n",
            "Number of TV003 recipients infected with vaccine virus DENV-1, DENV-2, DENV-3, and DENV-4\n",
            "Category for Sentence 1870:\n",
            "Occurrence of injuries in relation to workouts\n",
            "Category for Sentence 1871:\n",
            "Assessing children's pain with Wong-Baker-FACES\n",
            "Category for Sentence 1872:\n",
            "Difference in Overactive Bladder Symptom Score (OABSS)\n",
            "Category for Sentence 1873:\n",
            "FT\n",
            "Category for Sentence 1874:\n",
            "Annualized rate of medical facility VOEs (AVR)\n",
            "Category for Sentence 1875:\n",
            "SOFA score measurement\n",
            "Category for Sentence 1876:\n",
            "Change in Mindfulness from Baseline\n",
            "Category for Sentence 1877:\n",
            "Long-term clinical benefit measured by disease-free survival assessed at 1, 3 and 5 years\n",
            "Category for Sentence 1878:\n",
            "Physical functioning\n",
            "Category for Sentence 1879:\n",
            "Patient's Experience with Normal Saline Instillation and Tracheostomy Tube Suctioning Questionnaire.\n",
            "Category for Sentence 1880:\n",
            "The Number of Seropositive Participants Within Each Treatment Arm Who Achieved a A/H1N1 Strain-specific HAI Antibody Titer ≥ 32 Post Dose.\n",
            "Category for Sentence 1881:\n",
            "Blood pressure Vital Signs\n",
            "Category for Sentence 1882:\n",
            "change in total of the Healthy Lifestyle Behaviours Scale points\n",
            "Category for Sentence 1883:\n",
            "Childhood Asthma Quality of Life change from 8 weeks to 16 weeks\n",
            "Category for Sentence 1884:\n",
            "Blood Pressure\n",
            "Category for Sentence 1885:\n",
            "Pain Score\n",
            "Category for Sentence 1886:\n",
            "Breast Level Specificity of CMRM for Non-malignant Breasts by Reader\n",
            "Category for Sentence 1887:\n",
            "Change in Very Low-density Lipoproteins (VLDL) (mg/dL) - Ratio to Baseline\n",
            "Category for Sentence 1888:\n",
            "Sedentary behaviour using the accelerometer using amount of minutes in the sedentary category (<1,8 METS)\n",
            "Category for Sentence 1889:\n",
            "Pediatric Quality of Life Inventory (PedQL) - Multidimensional Fatigue Scale\n",
            "Category for Sentence 1890:\n",
            "The incidence of allergic reaction\n",
            "Category for Sentence 1891:\n",
            "infarct size measured by magnetic resonance\n",
            "Category for Sentence 1892:\n",
            "sequential organ failure assessment score increases by greater or equal to 1 point from the baseline score within 72 hours of study enrollment.\n",
            "Category for Sentence 1893:\n",
            "Tumor response\n",
            "Category for Sentence 1894:\n",
            "The Three-Factor Eating Questionnaire-18 (TFEQ-18) question 8 after three months of physical training\n",
            "Category for Sentence 1895:\n",
            "Hepatic vein pressure gradient(HVPG)\n",
            "Category for Sentence 1896:\n",
            "Health Related Quality of Life for children and parents\n",
            "Category for Sentence 1897:\n",
            "Cohort 1 and Cohort 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability\n",
            "Category for Sentence 1898:\n",
            "Tear osmolarity using TearLab device\n",
            "Category for Sentence 1899:\n",
            "Dietary intake\n",
            "Category for Sentence 1900:\n",
            "Disease Response Rate\n",
            "Category for Sentence 1901:\n",
            "4) Dietary record diary (DRD).\n",
            "Category for Sentence 1902:\n",
            "Severe sepsis\n",
            "Category for Sentence 1903:\n",
            "Anal manometry\n",
            "Category for Sentence 1904:\n",
            "Immune Overall Response Rate (iORR)\n",
            "Category for Sentence 1905:\n",
            "Changes of laboratory test indexes and vital signs\n",
            "Category for Sentence 1906:\n",
            "Results on patient´s AST\n",
            "Category for Sentence 1907:\n",
            "late endothelial progenitors\n",
            "Category for Sentence 1908:\n",
            "Transplant-related toxicity\n",
            "Category for Sentence 1909:\n",
            "Program Effectiveness\n",
            "Category for Sentence 1910:\n",
            "All intracranial hemorrhage within 90 days (+/- 10 days) after onset\n",
            "Category for Sentence 1911:\n",
            "Medical Outcomes Survey Short Form-36 (SF-36) RAND SF-36\n",
            "Category for Sentence 1912:\n",
            "Changes over time in weight z-score\n",
            "Category for Sentence 1913:\n",
            "Use of anti-psychotic medications\n",
            "Category for Sentence 1914:\n",
            "Type of treatment assessed in patients with CC\n",
            "Category for Sentence 1915:\n",
            "Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration\n",
            "Category for Sentence 1916:\n",
            "Mechanistic: Longitudinal Assessment of Viral Load by Semi-Quantitative Polymerase Chain Reaction (PCR) Over Time to Day 28\n",
            "Category for Sentence 1917:\n",
            "Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24\n",
            "Category for Sentence 1918:\n",
            "Absolute Change in Eosinophilic Count (Unit: 10^9/L) From Baseline Over Time\n",
            "Category for Sentence 1919:\n",
            "Pain processing and modulation mechanisms underlying the pain sensitivity profile of adults with HF-ASD\n",
            "Category for Sentence 1920:\n",
            "Distance Uncorrected Visual Acuity (UCVA)\n",
            "Category for Sentence 1921:\n",
            "Sensitivity and specificity of NACA Estimator grading of PACW in detecting primary angle closure suspects as classified by clinical gonioscopy.\n",
            "Category for Sentence 1922:\n",
            "Treatment antimicrobial drugs\n",
            "Category for Sentence 1923:\n",
            "Liver enzymes\n",
            "Category for Sentence 1924:\n",
            "Number of participants with a newly required renal replacement therapy post index culture\n",
            "Category for Sentence 1925:\n",
            "Canadian Occupational Performance Measure (COPM) change from baseline to 6 weeks, from baseline to 4 months and to 1 year.\n",
            "Category for Sentence 1926:\n",
            "Progression-Free Survival (PFS)\n",
            "Category for Sentence 1927:\n",
            "Spanish version of the General Health Questionnaire (Goldberg et al., 1997)\n",
            "Category for Sentence 1928:\n",
            "Duration of Post Procedure Catheterization\n",
            "Category for Sentence 1929:\n",
            "Visual Acuity (ETDRS) (Pre-CAESM)\n",
            "Category for Sentence 1930:\n",
            "metastasis free survival time\n",
            "Category for Sentence 1931:\n",
            "Numbers of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Adverse Device Effects (TEADEs); Treatment Emergent Serious Adverse Events (TESAEs), Serious Adverse Device Effects (SADEs), and Unanticipated TEAEs or ADEs\n",
            "Category for Sentence 1932:\n",
            "Preterm birth\n",
            "Category for Sentence 1933:\n",
            "Vitamin A intake\n",
            "Category for Sentence 1934:\n",
            "Transference of Topical Testosterone from Dosed Males to Female Partners As Measured by net change from Baseline of Serum Testosterone in nG/dL expressed as Maximum Serum Concentration or Cmax.\n",
            "Category for Sentence 1935:\n",
            "Coverage of the strategy in the study maternities before its implementation\n",
            "Category for Sentence 1936:\n",
            "Low back disability measured with the Oswestry Disability Questionnaire\n",
            "Category for Sentence 1937:\n",
            "Asthma control\n",
            "Category for Sentence 1938:\n",
            "Alterations in daily life according to Thy-PRO-39 questionnaire\n",
            "Category for Sentence 1939:\n",
            "BDI-II\n",
            "Category for Sentence 1940:\n",
            "Major pathological response rates\n",
            "Category for Sentence 1941:\n",
            "Biochemical Relapse Free Survival Rate\n",
            "Category for Sentence 1942:\n",
            "Self-report behavioural questionnaire\n",
            "Category for Sentence 1943:\n",
            "Xerostomia as assessed by stimulated saliva secretion rate\n",
            "Category for Sentence 1944:\n",
            "Levels of sleep-related hormones\n",
            "Category for Sentence 1945:\n",
            "Incidence of acute and chronic graft-vs.-host disease (GvHD)\n",
            "Category for Sentence 1946:\n",
            "Change in United States Department of Agriculture (USDA) Healthy Eating Index (HEI)\n",
            "Category for Sentence 1947:\n",
            "Likelihood of buying the beverage\n",
            "Category for Sentence 1948:\n",
            "Incidence of perinatal and partum complications\n",
            "Category for Sentence 1949:\n",
            "Percentage change of T cells (CD3+) by flow cytometry\n",
            "Category for Sentence 1950:\n",
            "Thermal Comfort\n",
            "Category for Sentence 1951:\n",
            "Survey\n",
            "Category for Sentence 1952:\n",
            "Cutaneous sensitivity by stinging test\n",
            "Category for Sentence 1953:\n",
            "Bone Regeneration\n",
            "Category for Sentence 1954:\n",
            "CSF phospho-PKR (pPKR) Concentration\n",
            "Category for Sentence 1955:\n",
            "Area under the Concentration-Time Curve (AUC)\n",
            "Category for Sentence 1956:\n",
            "Complete Response (CR) or Complete Response With Incomplete Blood Count Recovery (CRi) by Day\n",
            "Category for Sentence 1957:\n",
            "Change on functional connectivity of visual resting network\n",
            "Category for Sentence 1958:\n",
            "Recruitment and retention\n",
            "Category for Sentence 1959:\n",
            "pH readings from Dx-pH measurement system\n",
            "Category for Sentence 1960:\n",
            "Muscular strength (peak of torque) change from baseline\n",
            "Category for Sentence 1961:\n",
            "Stent patency time\n",
            "Category for Sentence 1962:\n",
            "Biological evaluation\n",
            "Category for Sentence 1963:\n",
            "modified Medical Research Council score\n",
            "Category for Sentence 1964:\n",
            "Observed terminal elimination half-life (T1/2)\n",
            "Category for Sentence 1965:\n",
            "End-point fundamental movement skill in running, locomotion, object control and Balance\n",
            "Category for Sentence 1966:\n",
            "Muscle drug concentration\n",
            "Category for Sentence 1967:\n",
            "Exercise Tolerance Testing\n",
            "Category for Sentence 1968:\n",
            "Construct validity measured by Validation of new score\n",
            "Category for Sentence 1969:\n",
            "Assessment of mobility, balance, walking ability, and fall risk in older adults\n",
            "Category for Sentence 1970:\n",
            "The effect of vagal nerve stimulation on autonomic parameter - mean root square difference of RR intervals\n",
            "Category for Sentence 1971:\n",
            "Comprehensive Metabolic Panel\n",
            "Category for Sentence 1972:\n",
            "Change in Subjective Sleep Related Impairment (PROMIS-Pediatric- Sleep-Related Impairment [SRI])\n",
            "Category for Sentence 1973:\n",
            "Duration of fatigue\n",
            "Category for Sentence 1974:\n",
            "Change in urinary protein-to-creatinine ratio (UPCR) from baseline to Day 540±7\n",
            "Category for Sentence 1975:\n",
            "Progression free survival (PFS) and response rate (Stratum B and C)\n",
            "Category for Sentence 1976:\n",
            "IOL tilt\n",
            "Category for Sentence 1977:\n",
            "Incidence of clinically significant changes in vital signs: Blood pressure\n",
            "Category for Sentence 1978:\n",
            "Disease Activity Score (DAS)-28\n",
            "Category for Sentence 1979:\n",
            "Interleukin 8\n",
            "Category for Sentence 1980:\n",
            "3 years overall survival rate\n",
            "Category for Sentence 1981:\n",
            "11-Deoxycorticosteron (Adrenal Steroid Hormones)\n",
            "Category for Sentence 1982:\n",
            "Time to reach maximum drug concentration [Tmax]\n",
            "Category for Sentence 1983:\n",
            "Tumor infiltrating T cell (TIL) density\n",
            "Category for Sentence 1984:\n",
            "Number of Participants With Marked Abnormalities in Hematology Laboratory Test Results\n",
            "Category for Sentence 1985:\n",
            "Pregnancy-Related Empowerment Scale (PRES)\n",
            "Category for Sentence 1986:\n",
            "Change in Quality of Life\n",
            "Category for Sentence 1987:\n",
            "Treatment Acceptability and Preferences questionnaire (TAP-Q)\n",
            "Category for Sentence 1988:\n",
            "Heart examination\n",
            "Category for Sentence 1989:\n",
            "Oswestry Disability Index\n",
            "Category for Sentence 1990:\n",
            "Number and percentage of subjects with at least one systemic reaction between 1 and 7 days after vaccination.\n",
            "Category for Sentence 1991:\n",
            "Area Under the Curve Extrapolated to Infinity (AUC0-∞) - Pharmacokinetic Assessment\n",
            "Category for Sentence 1992:\n",
            "Change in health state based on the Health Utilities questionnaire (HUI-3) after 3, 6 and 12 months\n",
            "Category for Sentence 1993:\n",
            "Effectiveness of preoperative speech rehabilitation\n",
            "Category for Sentence 1994:\n",
            "Number of participants with clinically significant abnormalities in physical examination in MAD\n",
            "Category for Sentence 1995:\n",
            "Pain intensity\n",
            "Category for Sentence 1996:\n",
            "Cylinder vector analyses\n",
            "Category for Sentence 1997:\n",
            "Safety and tolerability - Vital signs - Temperature\n",
            "Category for Sentence 1998:\n",
            "Reactive hyperemia index\n",
            "Category for Sentence 1999:\n",
            "Phase IIa:ORR\n",
            "Category for Sentence 2000:\n",
            "Patient satisfaction on the esthetic aspect of the finger\n",
            "Category for Sentence 2001:\n",
            "Olanzapine intervention primary endpoint: Days alive outside hospital\n",
            "Category for Sentence 2002:\n",
            "in days from the endpoint of Study Period II to a return to a YMRS total score greater than or equal to 20 AND/OR hospitalization due to deterioration in clinical symptoms of mania, among patients who had achieved\n",
            "Category for Sentence 2003:\n",
            "Annualized Rate of Acute Serious Bacterial Infections.\n",
            "Category for Sentence 2004:\n",
            "Time to Prostate Cancer Pain Progression\n",
            "Category for Sentence 2005:\n",
            "Change in Saccadic Eye Movements (saccadic reaction time, saccadic peak velocity and saccadic inaccuracy)\n",
            "Category for Sentence 2006:\n",
            "Diagnosis of vaginitis type\n",
            "Category for Sentence 2007:\n",
            "Compliance\n",
            "Category for Sentence 2008:\n",
            "stress levels\n",
            "Category for Sentence 2009:\n",
            "Incidence of sepsis\n",
            "Category for Sentence 2010:\n",
            "Success with venous access in first needling attempt\n",
            "Category for Sentence 2011:\n",
            "worst grade toxicity per patient\n",
            "Category for Sentence 2012:\n",
            "Handgrip strength measurement\n",
            "Category for Sentence 2013:\n",
            "Components of metabolic syndrome at week 13 - change in waist circumference (cm)\n",
            "Category for Sentence 2014:\n",
            "Levels of NK cells\n",
            "Category for Sentence 2015:\n",
            "Days until successful weaning\n",
            "Category for Sentence 2016:\n",
            "Overall Survival\n",
            "Category for Sentence 2017:\n",
            "Age (years)\n",
            "Category for Sentence 2018:\n",
            "Assess the toxicity of the treatment\n",
            "Category for Sentence 2019:\n",
            "Inventory of Depressive Symptomatology-Self Report\n",
            "Category for Sentence 2020:\n",
            "Changes Scores on Valsalva ratio. K30/15.\n",
            "Category for Sentence 2021:\n",
            "Other possible causes of mildly elevated porphyrins and recurrent pain\n",
            "Category for Sentence 2022:\n",
            "Adverse events (i.e. falls)\n",
            "Category for Sentence 2023:\n",
            "HA : Parecoxib and ketorolac prevent remifentanil postinfusion secondary hyperalgesi.\n",
            "Category for Sentence 2024:\n",
            "Administration of 18F-αvβ6-BP\n",
            "Category for Sentence 2025:\n",
            "Patient satisfaction score\n",
            "Category for Sentence 2026:\n",
            "Systolic blood pressure in mmHg (mean (±SD) difference from baseline) at the end of follow-up\n",
            "Category for Sentence 2027:\n",
            "Change in Patient-reported symptoms as measured by ESAS-r\n",
            "Category for Sentence 2028:\n",
            "Carer satisfaction with palliative care\n",
            "Category for Sentence 2029:\n",
            "Mean anxiety and depression scores\n",
            "Category for Sentence 2030:\n",
            "Speech recognition in noise\n",
            "Category for Sentence 2031:\n",
            "Describe health itineraries based on the three delays model in hospital admitted children with suspected bloodstream infection\n",
            "Category for Sentence 2032:\n",
            "6 month prostate biopsy\n",
            "Category for Sentence 2033:\n",
            "Short form of Foot and Ankle Ability Measure (QuickFAAM)\n",
            "Category for Sentence 2034:\n",
            "Anesthesia time\n",
            "Category for Sentence 2035:\n",
            "Percentage of Participants Who Achieved Weight Loss ≥5%\n",
            "Category for Sentence 2036:\n",
            "Intraoperative blood loss\n",
            "Category for Sentence 2037:\n",
            "Laboratory safety assessments - CSF (Part 2 only)\n",
            "Category for Sentence 2038:\n",
            "Change in (CD3+CD8+) CX3CR1+\n",
            "Category for Sentence 2039:\n",
            "Drug use disorders identification test\n",
            "Category for Sentence 2040:\n",
            "USP (Urinary Symptoms Profile) score\n",
            "Category for Sentence 2041:\n",
            "3-year overall survival (OS)\n",
            "Category for Sentence 2042:\n",
            "Safety Outcome (6.1 of 7)\n",
            "Category for Sentence 2043:\n",
            "Rate (%) of inappropriate prescriptions of NSAID at admission and discharge\n",
            "Category for Sentence 2044:\n",
            "The Scale for the Assessment of Negative Symptoms (SANS) - Diminished Motivation\n",
            "Category for Sentence 2045:\n",
            "Median Progression-free Survival (PFS)\n",
            "Category for Sentence 2046:\n",
            "Well-being / quality of life\n",
            "Category for Sentence 2047:\n",
            "General health\n",
            "Category for Sentence 2048:\n",
            "Echocardiography on the coronary artery lesion of Kawasaki disease\n",
            "Category for Sentence 2049:\n",
            "Job Quality\n",
            "Category for Sentence 2050:\n",
            "Maximum Observed Plasma Concentration (Cmax) of Metabolites BMT-153261 and BMT-158170\n",
            "Category for Sentence 2051:\n",
            "Toxicity Rate\n",
            "Category for Sentence 2052:\n",
            "Availability of social support\n",
            "Category for Sentence 2053:\n",
            "ROM Shoulder Abduction(right)\n",
            "Category for Sentence 2054:\n",
            "Serum urea level\n",
            "Category for Sentence 2055:\n",
            "Clinical response\n",
            "Category for Sentence 2056:\n",
            "Ratio of CSF sAPPβ and CSF sAPPα\n",
            "Category for Sentence 2057:\n",
            "Percentage of Participants With Grade 3 or Higher Adverse Events Considered At Least Possibly Related to Treatment\n",
            "Category for Sentence 2058:\n",
            "Questionnaire assessing mentall well-being: \"Warwick-Edinburgh Mental Well-Being Scale\" (SWEMWBS)\n",
            "Category for Sentence 2059:\n",
            "Change in diet: Dietary screener questionnaire\n",
            "Category for Sentence 2060:\n",
            "Apparent Terminal Half-life (T1/2) of GSK2586881-Part 1\n",
            "Category for Sentence 2061:\n",
            "Care provided\n",
            "Category for Sentence 2062:\n",
            "Color Trails Test - Change from baseline after the intervention\n",
            "Category for Sentence 2063:\n",
            "Positive and Negative Syndrome Scale Total Score\n",
            "Category for Sentence 2064:\n",
            "Percentage of Participants with Objective Response as Determined By The Independent Review Facility (IRF) According To Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Arm A)\n",
            "Category for Sentence 2065:\n",
            "Hamilton Depression Rating Scale\n",
            "Category for Sentence 2066:\n",
            "Recruitment\n",
            "Category for Sentence 2067:\n",
            "Changes in parent physical activity\n",
            "Category for Sentence 2068:\n",
            "Change in QoL, assessed by EuroQol 5 Dimensions (EQ-5D) questionnaire.\n",
            "Category for Sentence 2069:\n",
            "Long-term effect of reldesemtiv on ALSFRS-R functional outcomes and hospitalization by comparing early-start to delayed-start groups from CY 5031\n",
            "Category for Sentence 2070:\n",
            "Changes from baseline fatigue level at week 8\n",
            "Category for Sentence 2071:\n",
            "Exploratory biomarkers to evaluate inflammation\n",
            "Category for Sentence 2072:\n",
            "Percentage of Participants With Antibody Titer ≥40 at 28 Days Post Vaccination\n",
            "Category for Sentence 2073:\n",
            "Healthcare Utilization - Office Visits\n",
            "Category for Sentence 2074:\n",
            "Change in neurocognitive performance (compared to baseline): Trail making\n",
            "Category for Sentence 2075:\n",
            "Prespecified Adverse Events: atrial fibrillation\n",
            "Category for Sentence 2076:\n",
            "Comparison of the concentration ratios of inflammation marker [aqueous humor / blood] between the different types of atrophic AMD defined by autofluorescence exam (non-hyperautofluorescent or hyperautofluorescent form)\n",
            "Category for Sentence 2077:\n",
            "CT-Likelihood ratio-\n",
            "Category for Sentence 2078:\n",
            "EEG wave band activity with dark chocolate ingestion\n",
            "Category for Sentence 2079:\n",
            "Peak blood lactate levels during the postoperative period\n",
            "Category for Sentence 2080:\n",
            "change in neurocognitive function (NCF)\n",
            "Category for Sentence 2081:\n",
            "Urine spectral profile after twelve hours\n",
            "Category for Sentence 2082:\n",
            "HIV Knowledge (Young People)\n",
            "Category for Sentence 2083:\n",
            "Apparent Volume of Distribution (Vd/F)\n",
            "Category for Sentence 2084:\n",
            "Differences in postoperative anxiety numerical rating scale scores\n",
            "Category for Sentence 2085:\n",
            "MR imaging\n",
            "Category for Sentence 2086:\n",
            "Occurrence of any complication during hospitalization within 30 days of surgery\n",
            "Category for Sentence 2087:\n",
            "Number of hospitalizations\n",
            "Category for Sentence 2088:\n",
            "Multi-target hepatocellular carcinoma panel (MHP) score\n",
            "Category for Sentence 2089:\n",
            "Glucose stability from baseline to 12 weeks as measured by hemoglobin A1c (HbA1c)\n",
            "Category for Sentence 2090:\n",
            "Part 1: Maximum observed plasma concentration of GSK2336805\n",
            "Category for Sentence 2091:\n",
            "Change in blood glucose\n",
            "Category for Sentence 2092:\n",
            "Change from foot self care observation guide at baseline and sixth month\n",
            "Category for Sentence 2093:\n",
            "Number of Participants With a Change in Measurable Disease as Determined by the Prostate Cancer Working Group 3 (PCWG3)\n",
            "Category for Sentence 2094:\n",
            "Inflammatory Cytokine Response to Ablation Procedure\n",
            "Category for Sentence 2095:\n",
            "1-year overall survival\n",
            "Category for Sentence 2096:\n",
            "To evaluate SARS-CoV-2 viral load.\n",
            "Category for Sentence 2097:\n",
            "Percent Change from Baseline in Heart Rate at Day 42\n",
            "Category for Sentence 2098:\n",
            "Change in ARAT score\n",
            "Category for Sentence 2099:\n",
            "Differences in symptoms (leg effort)\n",
            "Category for Sentence 2100:\n",
            "Percentage of participants by type of coverage\n",
            "Category for Sentence 2101:\n",
            "Anxiety and depression (HAD)\n",
            "Category for Sentence 2102:\n",
            "Patient reported outcomes-anxiety\n",
            "Category for Sentence 2103:\n",
            "Level of social support\n",
            "Category for Sentence 2104:\n",
            "Difference in partner perceptions of participant's cognitive difficulties in everyday life, measured by Mc Nair CDS (range 0-156, higher score indicates greater cognitive difficulties)\n",
            "Category for Sentence 2105:\n",
            "linear measurements on the superimposed CBCTs of the buccal bone width gain at different locations\n",
            "Category for Sentence 2106:\n",
            "Lower health care costs than incremental program costs\n",
            "Category for Sentence 2107:\n",
            "Serum folate levels\n",
            "Category for Sentence 2108:\n",
            "Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 24\n",
            "Category for Sentence 2109:\n",
            "Change from Baseline Anxiety and Depression symptoms at 1 week after intervention\n",
            "Category for Sentence 2110:\n",
            "Treatment effects\n",
            "Category for Sentence 2111:\n",
            "Error of size estimation for colorectal polyps using POSEIDON versus physician optical evaluation\n",
            "Category for Sentence 2112:\n",
            "Number of Subjects With Cyclin-dependent Kinase-6 (CDK6) Copy Number Variations\n",
            "Category for Sentence 2113:\n",
            "Bullous Pemphigoid Disease Area Index (BPDAI) severity score\n",
            "Category for Sentence 2114:\n",
            "Bio-equivalence study of Dr Reddys Laboratories Cetirizine Hydrochloride Tablets 10 mg\n",
            "Category for Sentence 2115:\n",
            "The changes in proptosis responder rate over time\n",
            "Category for Sentence 2116:\n",
            "Total transcutaneous bilirubin\n",
            "Category for Sentence 2117:\n",
            "Plasma biomarkers of inflammation, lung epithelial injury,endothelial injury, markers of change in other end-organ function\n",
            "Category for Sentence 2118:\n",
            "The composite of all-cause mortality, heart failure events\n",
            "Category for Sentence 2119:\n",
            "Phase Ib: Tmax of LHRH Agonist in Combination With GDC-0810 and/or Palbociclib\n",
            "Category for Sentence 2120:\n",
            "active range of motion (AROM)\n",
            "Category for Sentence 2121:\n",
            "Number of times of self-reported drug use in vivo during the week between lab sessions.\n",
            "Category for Sentence 2122:\n",
            "Patient Health Questionnaire-9 (PHQ-9)\n",
            "Category for Sentence 2123:\n",
            "Duration of Response\n",
            "Category for Sentence 2124:\n",
            "Serum hsCRP\n",
            "Category for Sentence 2125:\n",
            "Incidence of COVID-19 reinfection\n",
            "Category for Sentence 2126:\n",
            "Change from baseline in Algometry\n",
            "Category for Sentence 2127:\n",
            "Cartilage thickness values (millimeters)\n",
            "Category for Sentence 2128:\n",
            "Postprandial Triglyceride Response to High-Fat Meal\n",
            "Category for Sentence 2129:\n",
            "Changes in Orthostatic Stress Test outcomes\n",
            "Category for Sentence 2130:\n",
            "Heart Rate (HR) variation\n",
            "Category for Sentence 2131:\n",
            "Time of inpatient stay (days).\n",
            "Category for Sentence 2132:\n",
            "Whole-body fatty acid oxidation rate\n",
            "Category for Sentence 2133:\n",
            "Short-Musculoskeletal Function Assessment - Dysfunction Index\n",
            "Category for Sentence 2134:\n",
            "Total morphine consumption\n",
            "Category for Sentence 2135:\n",
            "Cohort C: Change From Baseline in Liver Stiffness as Evaluated by FibroScan at Week 16\n",
            "Category for Sentence 2136:\n",
            "Real-world progression-free survival (rwPFS)\n",
            "Category for Sentence 2137:\n",
            "Fasted metabolism (1)\n",
            "Category for Sentence 2138:\n",
            "Change in Functional Outcomes as Measured by Patient's Global Impression of Change\n",
            "Category for Sentence 2139:\n",
            "State Hope Scale (SHS)\n",
            "Category for Sentence 2140:\n",
            "changes in blood pressure with oxytocin\n",
            "Category for Sentence 2141:\n",
            "Ultrasound evaluation\n",
            "Category for Sentence 2142:\n",
            "variation of HIL concentration between both groups\n",
            "Category for Sentence 2143:\n",
            "Mean Pre-dose FEV1 a.m. Response (Diary Data) of Last-7-days-before-week 24-visit.\n",
            "Category for Sentence 2144:\n",
            "Arrhythmia requiring medical team intervention\n",
            "Category for Sentence 2145:\n",
            "OL Period: Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values\n",
            "Category for Sentence 2146:\n",
            "Concordance between QTc intervals (in ms) measured by smartwatch combined with Cardiologs AI and that measured by manually read 12-lead ECG\n",
            "Category for Sentence 2147:\n",
            "Concurrent validity of the Adult rejection Sensitivity Questionnaire (A-RSQ) with the Positive And Negative Affect Schedule (PANAS) after the rejection situation.\n",
            "Category for Sentence 2148:\n",
            "Percentage of Participants With Maintenance of Platelet count of >=50,000/mcL to last Participant Visit\n",
            "Category for Sentence 2149:\n",
            "Mortality Rate\n",
            "Category for Sentence 2150:\n",
            "variation of Cytokine, PASI, BSA\n",
            "Category for Sentence 2151:\n",
            "Disease Control Rate (DCR): Percentage of Participants With Complete (CR) or Partial Response (PR), or Stable Disease (SD) for ≥ 16 Weeks According to RECIST Version 1.1\n",
            "Category for Sentence 2152:\n",
            "Area under the plasma concentration-time curve (AUC) of GLPG1690 (Part 2).\n",
            "Category for Sentence 2153:\n",
            "Difference in proportion of patients with a reduction from baseline of 75 % in Eczema Area and Severity Index (EASI) score\n",
            "Category for Sentence 2154:\n",
            "Self-Esteem, measured with the Rosenberg Self-Esteem Scale (RSES)\n",
            "Category for Sentence 2155:\n",
            "Positive rate of ADA in volunteers in TNM002 groups\n",
            "Category for Sentence 2156:\n",
            "Collect digital markers\n",
            "Category for Sentence 2157:\n",
            "Maximum Plasma Concentration, Cmax (ng/mL)\n",
            "Category for Sentence 2158:\n",
            "hospital data: postoperative morbidity\n",
            "Category for Sentence 2159:\n",
            "Internal Consistency of the Nocturia Impact (NI) Total Score for Each Day NI Diaries Were Completed Assessed as Cronbach's Alpha Values\n",
            "Category for Sentence 2160:\n",
            "Area under the concentration versus time curve from zero to infinity (AUC) of paclitaxel in plasma\n",
            "Category for Sentence 2161:\n",
            "Mortality\n",
            "Category for Sentence 2162:\n",
            "Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.1\n",
            "Category for Sentence 2163:\n",
            "Daily heart rate\n",
            "Category for Sentence 2164:\n",
            "Changes from baseline blood pressure at 8 weeks\n",
            "Category for Sentence 2165:\n",
            "Dose-Limiting Toxicities (DLT)\n",
            "Category for Sentence 2166:\n",
            "Number of in-patient hospital days 1 year prior to return of results\n",
            "Category for Sentence 2167:\n",
            "Pain Interference With Normal Work as Measured by the m-BPI-sf\n",
            "Category for Sentence 2168:\n",
            "assess insulin sensitivity in late breast cancer survivors\n",
            "Category for Sentence 2169:\n",
            "Feasibility of recruiting patients into a dental quitline\n",
            "Category for Sentence 2170:\n",
            "Intervention Feedback\n",
            "Category for Sentence 2171:\n",
            "Speech recognition in quiet\n",
            "Category for Sentence 2172:\n",
            "Patient experience\n",
            "Category for Sentence 2173:\n",
            "Compliance with prescription of AYMES PARIS\n",
            "Category for Sentence 2174:\n",
            "Clinical related non-major bleeding events\n",
            "Category for Sentence 2175:\n",
            "Operating room time\n",
            "Category for Sentence 2176:\n",
            "non-cholera diarrhea\n",
            "Category for Sentence 2177:\n",
            "Change in self-reported self-management, as measured by the Southampton Stroke Self-Management Questionnaire\n",
            "Category for Sentence 2178:\n",
            "Change in hand grip strength\n",
            "Category for Sentence 2179:\n",
            "Change in modified Knee Injury and Osteoarthritis Outcome Score (KOOS) score\n",
            "Category for Sentence 2180:\n",
            "Percentage of Participants who are Progression Free at Month 6, as Assessed by RANO Criteria (All Participants)\n",
            "Category for Sentence 2181:\n",
            "The evaluation of the abundance of Porphyromonas gingivalis in plaque samples\n",
            "Category for Sentence 2182:\n",
            "Quality of real-time image guidance provided the tri-60Co system, as defined by the treating radiation oncologist's ability to visualize the target lesion using the on-board MRI\n",
            "Category for Sentence 2183:\n",
            "Therapeutic Success\n",
            "Category for Sentence 2184:\n",
            "Maternal outcomes\n",
            "Category for Sentence 2185:\n",
            "Correlation between the value of the ITMES score and postoperative best-corrected visual acuity\n",
            "Category for Sentence 2186:\n",
            "Socio - demographic variables: Number of siblings, country of origin, educational level and social class, according to the proposal of the Spanish Society of Epidemiology and the Spanish Society of Family and Community Medicine.\n",
            "Category for Sentence 2187:\n",
            "Change in Oxygenation Index (OI) From Baseline to 48 Hours Following Study Drug Administration\n",
            "Category for Sentence 2188:\n",
            "Tolerability of intradermal injections of maxadilan in healthy male subjects. Assessed using the Numerical rating scale-11 for pain.\n",
            "Category for Sentence 2189:\n",
            "Impact of both treatments on body weight (in kilograms).\n",
            "Category for Sentence 2190:\n",
            "Percentage of neurosphere formation\n",
            "Category for Sentence 2191:\n",
            "Monocular Mesopic Contrast Sensitivity Without Glare (1.5, 3 Cycles/Degree)\n",
            "Category for Sentence 2192:\n",
            "Family Conflict\n",
            "Category for Sentence 2193:\n",
            "The changes of biomarkers related to Takayasu's disease at the end of 24 weeks and 56 weeks compared to the baseline, including the whole blood cell RNA transcripts, and gene epigenetics.\n",
            "Category for Sentence 2194:\n",
            "Mean Change From Baseline in Work Productivity and Activity Impairment (WPAI) under usual care at Year1\n",
            "Category for Sentence 2195:\n",
            "Clinically relevant non-major bleeding\n",
            "Category for Sentence 2196:\n",
            "Number of Participants With Adverse Events\n",
            "Category for Sentence 2197:\n",
            "ONP Intentions\n",
            "Category for Sentence 2198:\n",
            "Progression-free survival at 24 months (PFS24)\n",
            "Category for Sentence 2199:\n",
            "Dementia Knowledge Assessment Scale (DKAS)\n",
            "Category for Sentence 2200:\n",
            "Duration of recurrent diarrhea episodes\n",
            "Category for Sentence 2201:\n",
            "To evaluate change in the Clinical Global Impression - Improvement scale (CGI-I).\n",
            "Category for Sentence 2202:\n",
            "Neurobehavioral outcome Of the Preterm Very low birth weight babies\n",
            "Category for Sentence 2203:\n",
            "IGF-1/IGFBP-3 molar ratio\n",
            "Category for Sentence 2204:\n",
            "Food preference (ratings) task\n",
            "Category for Sentence 2205:\n",
            "To observe the change in cross sectional area of the Rectus Femoris (RFcsa, measured in cm2) during critical illness and recovery.\n",
            "Category for Sentence 2206:\n",
            "Change in Body Dissatisfaction Scale\n",
            "Category for Sentence 2207:\n",
            "PTSD Symptom Scale - Interview for DSM-5 (PSS-I-5)\n",
            "Category for Sentence 2208:\n",
            "Volume of Distribution (Vss) after single dose for all periods\n",
            "Category for Sentence 2209:\n",
            "Number of Newborns With Intraventricular Hemorrhage\n",
            "Category for Sentence 2210:\n",
            "Capability Wellbeing\n",
            "Category for Sentence 2211:\n",
            "Progression-Free Survival (PFS)\n",
            "Category for Sentence 2212:\n",
            "Nasolacrimal duct permeability\n",
            "Category for Sentence 2213:\n",
            "change in BMD hip\n",
            "Category for Sentence 2214:\n",
            "shoulder pain and disability index for shoulder pain\n",
            "Category for Sentence 2215:\n",
            "Estradiol and progesterone levels in breast tissue and plasma assessed by liquid chromatography/tandem mass spectrometry\n",
            "Category for Sentence 2216:\n",
            "λz\n",
            "Category for Sentence 2217:\n",
            "Total length of stay in ED\n",
            "Category for Sentence 2218:\n",
            "Evaluation of operative times\n",
            "Category for Sentence 2219:\n",
            "For single dose if data permit: oral clearance (CL/F)\n",
            "Category for Sentence 2220:\n",
            "questionnaire: BAI (2nd)\n",
            "Category for Sentence 2221:\n",
            "Area under the plasma concentration-time curve (AUC)\n",
            "Category for Sentence 2222:\n",
            "Need for re-operation of target wound site\n",
            "Category for Sentence 2223:\n",
            "death\n",
            "Category for Sentence 2224:\n",
            "Change in Percent Sleep Efficiency (total sleep time divided by time in bed) measured by actigraphy\n",
            "Category for Sentence 2225:\n",
            "Change from baseline in vital signs.\n",
            "Category for Sentence 2226:\n",
            "Maximum Measured Concentration (Cmax) of the Analytes in Plasma After Single Administration of T80/A5/H12.5 mg FDC Tablet\n",
            "Category for Sentence 2227:\n",
            "Proportion of patients reporting none, a little bit, somewhat, quite a bit or very mouth interference with daily activity as a result of their mouth sores as measured by PRO-CTCAE on Day 14\n",
            "Category for Sentence 2228:\n",
            "Safety and tolerability of IMP after single and multiple oral administration\n",
            "Category for Sentence 2229:\n",
            "Ketone level\n",
            "Category for Sentence 2230:\n",
            "conformity to TIDieR checklist in each center and for each case manager interviewed\n",
            "Category for Sentence 2231:\n",
            "Comparison of changes in insulin sensitivity and glucose tolerance\n",
            "Category for Sentence 2232:\n",
            "The change in the Visual Analogue Scale (VAS) of painfulness\n",
            "Category for Sentence 2233:\n",
            "Change in waist circumference from baseline\n",
            "Category for Sentence 2234:\n",
            "Overall OLT-free Survival\n",
            "Category for Sentence 2235:\n",
            "Plasmatic levels of Vascular Endothelial Growth Factor (VEGF) at 6 months of age\n",
            "Category for Sentence 2236:\n",
            "Estimated Glomerular Filtration Rate (eGFR) (creatinine)\n",
            "Category for Sentence 2237:\n",
            "Occurrence of all serious adverse events (SAE).\n",
            "Category for Sentence 2238:\n",
            "Implantation Characteristics\n",
            "Category for Sentence 2239:\n",
            "Number of participants with abnormal findings in phosphate\n",
            "Category for Sentence 2240:\n",
            "Forced Expiratory Volume in the first second (FEV1) for patients with Chronic Obstructive Pulmonary Disease（COPD） or asthma\n",
            "Category for Sentence 2241:\n",
            "The primary objective measures will consist of fasting blood glucose, insulin and HA1C.\n",
            "Category for Sentence 2242:\n",
            "Patient global satisfaction numerical rating scale\n",
            "Category for Sentence 2243:\n",
            "HDL-cholesterol\n",
            "Category for Sentence 2244:\n",
            "Remission rate of depression\n",
            "Category for Sentence 2245:\n",
            "Mean Duration of Morning Stiffness\n",
            "Category for Sentence 2246:\n",
            "Major bleeding\n",
            "Category for Sentence 2247:\n",
            "Neonates' mobile and immobile time in 24 hours\n",
            "Category for Sentence 2248:\n",
            "Change in Transcranial Magnetic Stimulation (TMS) Responses Associated With Training Session 2\n",
            "Category for Sentence 2249:\n",
            "Number of Participants With Target Lesion Failure (TLF) (Cardiac Death,(Target Vessel Myocardial Infarction(TV-MI), ID-TLR)\n",
            "Category for Sentence 2250:\n",
            "acute kidney injury\n",
            "Category for Sentence 2251:\n",
            "Safety of the combination of SU011248 and paclitaxel\n",
            "Category for Sentence 2252:\n",
            "Change on axial diffusivity (AD) of the posterior visual pathway.\n",
            "Category for Sentence 2253:\n",
            "Change from baseline lean body mass at 12-week.\n",
            "Category for Sentence 2254:\n",
            "Determine the number of Covid-19 patients who were unable to complete SCE Therapy\n",
            "Category for Sentence 2255:\n",
            "Determine whether quality of life, fatigue and xerostomia differ as a function of treatment assignment at 3, 12, and 24 months after completing radiotherapy.\n",
            "Category for Sentence 2256:\n",
            "Early complications and adverse events\n",
            "Category for Sentence 2257:\n",
            "left ventricular systolic function recovery by ejection fraction\n",
            "Category for Sentence 2258:\n",
            "Hyaluronic acid area ratio\n",
            "Category for Sentence 2259:\n",
            "Number of Participants with Adverse Events as a Measure of Safety and Tolerability\n",
            "Category for Sentence 2260:\n",
            "Quantify whether the changes in inattentive symptoms in groups B (Neurofeedback training) correlate with changes in specific EEG parameter, namely the P300 wave.\n",
            "Category for Sentence 2261:\n",
            "Rate of residual axillary lymph node metastasis on axillary surgery\n",
            "Category for Sentence 2262:\n",
            "Tmax of midazolam, when administered with PF-07817883, in PART-5:DDI\n",
            "Category for Sentence 2263:\n",
            "Nottingham Health Profile (NHP)\n",
            "Category for Sentence 2264:\n",
            "Prevalence of peripartum cardiomyopathy (PPCM) in Nigeria\n",
            "Category for Sentence 2265:\n",
            "Time to First Hospitalization Due to Respiratory Related Serious Adverse Events (SAEs) in Extension Study\n",
            "Category for Sentence 2266:\n",
            "Subacromial space\n",
            "Category for Sentence 2267:\n",
            "Number of adverse events (AEs), including serious adverse events (SAEs)\n",
            "Category for Sentence 2268:\n",
            "Number of Patients Who Reported Continued Pain Continued Post-traumatic Pain at 6 Months Post Admission\n",
            "Category for Sentence 2269:\n",
            "To define the PK profile of PRTH-101 together with pembrolizumab\n",
            "Category for Sentence 2270:\n",
            "Complications\n",
            "Category for Sentence 2271:\n",
            "Relative performance of DBT and MBI within subgroups categorized by breast cancer risk\n",
            "Category for Sentence 2272:\n",
            "Change in Multidimensional Scale of Perceived Social Support (MSPSS) - Friends\n",
            "Category for Sentence 2273:\n",
            "Time to hospital discharge\n",
            "Category for Sentence 2274:\n",
            "Area under the curve from time zero to end of dosing interval (AUC0-tau) of ISB 1342 (Part 1 and Part 2)\n",
            "Category for Sentence 2275:\n",
            "Changes in physical activity after three-months intervention\n",
            "Category for Sentence 2276:\n",
            "Presence of alcohol abuse evaluated at the first clinical consultation according to the AUDIT(Alcohol Use Disorders Identification Test) questionnaire.\n",
            "Category for Sentence 2277:\n",
            "Decision Making\n",
            "Category for Sentence 2278:\n",
            "the remission rate (MADRS scale ≤ 8 )\n",
            "Category for Sentence 2279:\n",
            "Change in substance use.\n",
            "Category for Sentence 2280:\n",
            "Days of phototherapy\n",
            "Category for Sentence 2281:\n",
            "Change in exhaled Nitric Oxide concentration after Long acting Beta 2 Agonist assumption\n",
            "Category for Sentence 2282:\n",
            "Change in Self-Reported Physical Activity assessed by the Godin Leisure Time Exercise Questionnaire\n",
            "Category for Sentence 2283:\n",
            "Percent Change From Baseline in Daily Oral Corticosteroid (OCS) Dose During Weeks 16-20 and Weeks 32-36\n",
            "Category for Sentence 2284:\n",
            "Hospital stay\n",
            "Category for Sentence 2285:\n",
            "Change in Percentage of Collagen Density in Wound Area as Assessed by Light Microscopy of Masson's Trichrome-stained Biopsy Sections\n",
            "Category for Sentence 2286:\n",
            "Proportion of patients with migraine\n",
            "Category for Sentence 2287:\n",
            "Comparing FSH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))\n",
            "Category for Sentence 2288:\n",
            "To compare segment stenosis score (SSS) at 10-years between CT and ICA group\n",
            "Category for Sentence 2289:\n",
            "To assess the correlation between hemoperfusion and positive short-term outcome\n",
            "Category for Sentence 2290:\n",
            "The occurrence of defects, failures, and fractures of the inPROBE probe during the diagnostic procedure leading to AE/ SAE.\n",
            "Category for Sentence 2291:\n",
            "The Urinary Excretion of PD Marker\n",
            "Category for Sentence 2292:\n",
            "Ability to Eat\n",
            "Category for Sentence 2293:\n",
            "Clinical signs of VVA\n",
            "Category for Sentence 2294:\n",
            "CGM-Measured Percent Time in Range 70-180 mg/dL Improvement From Baseline to 16 Weeks ≥10%\n",
            "Category for Sentence 2295:\n",
            "AUC-0-last\n",
            "Category for Sentence 2296:\n",
            "Number of Participants With Improved, No Change, or Worsened World Health Organisation Functional Class From Baseline to Week 16\n",
            "Category for Sentence 2297:\n",
            "Number of participants with post-intervention Falls.\n",
            "Category for Sentence 2298:\n",
            "Protection Indexes of One Vaccine Dose For Symptomatic COVID-19\n",
            "Category for Sentence 2299:\n",
            "To establish the efficacy of the ELECTRODUCER SLEEVE device\n",
            "Category for Sentence 2300:\n",
            "Quality of Life will be measured using the Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ)\n",
            "Category for Sentence 2301:\n",
            "Abortion rate\n",
            "Category for Sentence 2302:\n",
            "Joint structure US\n",
            "Category for Sentence 2303:\n",
            "Average Change Rate of Fecal Residual Zinc from Baseline at 6 and 12 weeks\n",
            "Category for Sentence 2304:\n",
            "Occular hypertension\n",
            "Category for Sentence 2305:\n",
            "Percentage of Participants Progression-free at 6 Months\n",
            "Category for Sentence 2306:\n",
            "Oxygen consumption index after the participants are taken into the operating room\n",
            "Category for Sentence 2307:\n",
            "symptom burden negative urine culture\n",
            "Category for Sentence 2308:\n",
            "Opioid consumption dose after operation\n",
            "Category for Sentence 2309:\n",
            "Progression-free survival\n",
            "Category for Sentence 2310:\n",
            "Imaging surveillance\n",
            "Category for Sentence 2311:\n",
            "Likeability of the Parenting Young Children Check-up Program\n",
            "Category for Sentence 2312:\n",
            "true diffusion\n",
            "Category for Sentence 2313:\n",
            "Apnea-hypopnea index (AHI), defined as the average rate of apneas and hypopneas per hour of sleep\n",
            "Category for Sentence 2314:\n",
            "Return to work: Number of days passed from the day of the injury to the day where the patient resume his work.\n",
            "Category for Sentence 2315:\n",
            "the rate of local recurrence\n",
            "Category for Sentence 2316:\n",
            "Overall survival\n",
            "Category for Sentence 2317:\n",
            "Perceived Stress Scale (PSS)\n",
            "Category for Sentence 2318:\n",
            "Prevalence of congenital heart disease\n",
            "Category for Sentence 2319:\n",
            "Change in proportion of patients with BCVA Snellen equivalent of 20/40 or better\n",
            "Category for Sentence 2320:\n",
            "Long-term disease and death risk after extremely early puberty\n",
            "Category for Sentence 2321:\n",
            "Change in Walking Speed\n",
            "Category for Sentence 2322:\n",
            "Acceptability - Educational Tool\n",
            "Category for Sentence 2323:\n",
            "Manual Muscle Testing 8 (MMT8)\n",
            "Category for Sentence 2324:\n",
            "28 days treatment with AFQ056 on behavior (communication, socialization, daily living, repetitive behaviors, anxiety/avoidance, clinical global improvement)\n",
            "Category for Sentence 2325:\n",
            "Change in MyotonPRO\n",
            "Category for Sentence 2326:\n",
            "experience prior to film insertion\n",
            "Category for Sentence 2327:\n",
            "Calculation of the rates of breast conservation therapy in the two arms with regard to the initially planned surgery.\n",
            "Category for Sentence 2328:\n",
            "Evaluation of forced expiratory flow rate between 25% and 75% of FVC which has been exhaled (FEF25-75%)\n",
            "Category for Sentence 2329:\n",
            "Incidence of adverse events (AEs)\n",
            "Category for Sentence 2330:\n",
            "protein expression levels of LNK\n",
            "Category for Sentence 2331:\n",
            "Number of Participants With Diabetes Treatments\n",
            "Category for Sentence 2332:\n",
            "Comparison of golimumab serum sample through venous puncture and dried blood spot analysis\n",
            "Category for Sentence 2333:\n",
            "Incidence of falls\n",
            "Category for Sentence 2334:\n",
            "AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-243\n",
            "Category for Sentence 2335:\n",
            "Accuracy of nail position\n",
            "Category for Sentence 2336:\n",
            "Parkinsonian disability using UPDRS (blinded investigator-rated\n",
            "Category for Sentence 2337:\n",
            "Opioid Consumption (Number of Pills Taken)\n",
            "Category for Sentence 2338:\n",
            "The difference of middle cerebral artery blood flow velocity between different positions.\n",
            "Category for Sentence 2339:\n",
            "Estimated blood loss\n",
            "Category for Sentence 2340:\n",
            "Platelet reactivity\n",
            "Category for Sentence 2341:\n",
            "Percent slow wave sleep (Stages 3&4 combined)\n",
            "Category for Sentence 2342:\n",
            "Acute toxicity of SABR\n",
            "Category for Sentence 2343:\n",
            "Radiologic examination\n",
            "Category for Sentence 2344:\n",
            "Number of participants with treatment-related adverse events as classified by MedDRA\n",
            "Category for Sentence 2345:\n",
            "Part 2 (Disease Progression): Change From Baseline in Functioning as Measured by the Personal and Social Performance (PSP) Total Score\n",
            "Category for Sentence 2346:\n",
            "kidney function (S-creatinine, S-BUN)\n",
            "Category for Sentence 2347:\n",
            "Body composition: Android-gynoid ratio\n",
            "Category for Sentence 2348:\n",
            "The patients' adherence to treatment measured by the percentage of missed doses in each arm of the trials\n",
            "Category for Sentence 2349:\n",
            "Change From Baseline in Bilirubin, Creatinine, and Urate at Week 52\n",
            "Category for Sentence 2350:\n",
            "Gastrointestinal Symptom Rating Scale\n",
            "Category for Sentence 2351:\n",
            "Changes in serum phosphorous levels from baseline values at each time point.\n",
            "Category for Sentence 2352:\n",
            "Change in body esteem\n",
            "Category for Sentence 2353:\n",
            "CRP and Procalcitonin Levels\n",
            "Category for Sentence 2354:\n",
            "Rate of normalization of spermogram\n",
            "Category for Sentence 2355:\n",
            "The percentage of patients who are able to achieve a bladder volume within +/- 30% of planning volume, on all treatment CBCT (cone beam computed tomography) scans\n",
            "Category for Sentence 2356:\n",
            "Long-term RV function\n",
            "Category for Sentence 2357:\n",
            "Peripheral blood\n",
            "Category for Sentence 2358:\n",
            "Secondary validity analysis\n",
            "Category for Sentence 2359:\n",
            "Part 1: Number of Participants Who Died Due to All Causes at Day 60\n",
            "Category for Sentence 2360:\n",
            "Part A: Maximum concentration (Cmax) for single and multiple dose of ARV-110\n",
            "Category for Sentence 2361:\n",
            "Time to Biochemical Failure Cumulative Incidence Percentile\n",
            "Category for Sentence 2362:\n",
            "Change from baseline and placebo-corrected change from baseline in ECG parameter - QRS interval\n",
            "Category for Sentence 2363:\n",
            "Drug effect characteristics\n",
            "Category for Sentence 2364:\n",
            "The eradication rates of intraluminal therapy\n",
            "Category for Sentence 2365:\n",
            "Pharmacokinetic profile\n",
            "Category for Sentence 2366:\n",
            "To compare effectiveness of the ATOMS and AUS devices in patients using results from the 24-hour pad test.\n",
            "Category for Sentence 2367:\n",
            "long-term radial artery occlusion\n",
            "Category for Sentence 2368:\n",
            "% of patients with radiological improvement\n",
            "Category for Sentence 2369:\n",
            "Pocket Depth\n",
            "Category for Sentence 2370:\n",
            "Change in Systolic / Diastolic BP (mmHg)\n",
            "Category for Sentence 2371:\n",
            "Change in Shoulder Flexion\n",
            "Category for Sentence 2372:\n",
            "University of Washington- Quality of Life (UW-QOL)\n",
            "Category for Sentence 2373:\n",
            "Recurrent disease\n",
            "Category for Sentence 2374:\n",
            "Stabilometry variable center of pressure speed displacement of the latero-lateral(lat-lat) direction open eyes before progressive pressure release\n",
            "Category for Sentence 2375:\n",
            "The secondary outcome measure is rate of respiratory depression\n",
            "Category for Sentence 2376:\n",
            "Maximum tolerated dose (MTD)\n",
            "Category for Sentence 2377:\n",
            "Number of Participants With Abnormal Physical Examinations Findings\n",
            "Category for Sentence 2378:\n",
            "Within-person change in Medication Adherence.\n",
            "Category for Sentence 2379:\n",
            "Blood flow through a. carotis interna\n",
            "Category for Sentence 2380:\n",
            "Laboratory HbA1c\n",
            "Category for Sentence 2381:\n",
            "Change in skin score assessment: scaling\n",
            "Category for Sentence 2382:\n",
            "Ratings of subjective drug effects\n",
            "Category for Sentence 2383:\n",
            "Number of participants with adverse events\n",
            "Category for Sentence 2384:\n",
            "the change in mean lipid arc\n",
            "Category for Sentence 2385:\n",
            "Changes in quality of life\n",
            "Category for Sentence 2386:\n",
            "Identification of peripheral alpha-synuclein via histology of skin biopsies\n",
            "Category for Sentence 2387:\n",
            "Use of the SFE to detect QRH and KSP via contrast\n",
            "Category for Sentence 2388:\n",
            "PK: t½ of Necitumumab After Multiple Doses\n",
            "Category for Sentence 2389:\n",
            "Tenofovir safety for infants measured by incidence of serious adverse events (SAEs)\n",
            "Category for Sentence 2390:\n",
            "Drainproduction in milliliters\n",
            "Category for Sentence 2391:\n",
            "Alabama Parenting Questionnaire\n",
            "Category for Sentence 2392:\n",
            "Observation of Mother-Child Interaction (OMCI)\n",
            "Category for Sentence 2393:\n",
            "Phase 2 portion: Specific Th2 cell-mediated immunity (CMI) response\n",
            "Category for Sentence 2394:\n",
            "Evaluation of the antitumor activity of the combination in terms of progression free survival (PFS)\n",
            "Category for Sentence 2395:\n",
            "Gestational age of the onset of flu-like signs and symptoms\n",
            "Category for Sentence 2396:\n",
            "Duration of ICU stay (days)\n",
            "Category for Sentence 2397:\n",
            "Liver function\n",
            "Category for Sentence 2398:\n",
            "cost-saving\n",
            "Category for Sentence 2399:\n",
            "Increased Fluorodeoxyglucose (FDG) PET Standardized Uptake Value (SUV) After rTSH Specificity\n",
            "Category for Sentence 2400:\n",
            "Subjective symptoms in the morning after a night of active dreaming\n",
            "Category for Sentence 2401:\n",
            "Duration of Drug-Free Interval Prior to Treatment Cycle 6\n",
            "Category for Sentence 2402:\n",
            "number of correct femoral tunnel position\n",
            "Category for Sentence 2403:\n",
            "Changes in breath alcohol concentration\n",
            "Category for Sentence 2404:\n",
            "Progression-free survival (PFS)\n",
            "Category for Sentence 2405:\n",
            "Lumbar Fusion rate\n",
            "Category for Sentence 2406:\n",
            "Amount of analyte that was eliminated in urine at steady state over an uniform dosing interval τ (Aeτ,ss)\n",
            "Category for Sentence 2407:\n",
            "Comparison of central aortic blood pressure differences among treatment groups\n",
            "Category for Sentence 2408:\n",
            "Comparison of HP 13C 2HG/aKG ratio with surgical results (Cohort 2)\n",
            "Category for Sentence 2409:\n",
            "Antibody against Spike protein measurement by ELISA test\n",
            "Category for Sentence 2410:\n",
            "AUCGLA 0-30h\n",
            "Category for Sentence 2411:\n",
            "Lexicon access assessment\n",
            "Category for Sentence 2412:\n",
            "2-item warmth perception measure at the hands at t1, t2 and t3\n",
            "Category for Sentence 2413:\n",
            "Number of participants with wound dehiscence(complete)\n",
            "Category for Sentence 2414:\n",
            "5-hydroxy Saxagliptin T1/2\n",
            "Category for Sentence 2415:\n",
            "Acceptability (perceived usefulness and ease of use)\n",
            "Category for Sentence 2416:\n",
            "Adverse events severity and frequency\n",
            "Category for Sentence 2417:\n",
            "Pulmonary function\n",
            "Category for Sentence 2418:\n",
            "Cohort B: Change from Baseline in PSSI Score at Week 16\n",
            "Category for Sentence 2419:\n",
            "Changes in the VAS Score From Baseline.\n",
            "Category for Sentence 2420:\n",
            "Assess disease-free intervals (DFIs) between surgical resection of disease for at least 5 years\n",
            "Category for Sentence 2421:\n",
            "PK of ADC, TAb, MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 28 (AUC0-28d) at Cycle 1 Day 1\n",
            "Category for Sentence 2422:\n",
            "the timing of achieving the target level of LDL-C at months 1, 3, 6, 7, 9, 12 of study therapy\n",
            "Category for Sentence 2423:\n",
            "the all-cause one-year mortality according to the group\n",
            "Category for Sentence 2424:\n",
            "Healing parameter\n",
            "Category for Sentence 2425:\n",
            "Patient satisfaction\n",
            "Category for Sentence 2426:\n",
            "Area Under the Concentration-Versus-Time Curve (AUC) of LY3454738\n",
            "Category for Sentence 2427:\n",
            "Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration at Time \"t\" (AUC0-t) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291\n",
            "Category for Sentence 2428:\n",
            "Number of participants with Treatment Emergent Adverse Event (TEAEs) in multiple ascending doses\n",
            "Category for Sentence 2429:\n",
            "Skin Conductance Level - Electrodermal Activity\n",
            "Category for Sentence 2430:\n",
            "Death or disabling stroke\n",
            "Category for Sentence 2431:\n",
            "Zarit Burden Interview-Short Form\n",
            "Category for Sentence 2432:\n",
            "Number of Subjects With a First Episode Reported of Invasive Pneumococcal Disease (IPD) Due to Pneumococcal Serotypes Other Than Streptococcus (S. pn.) Vaccine and Cross-reactive Serotypes.\n",
            "Category for Sentence 2433:\n",
            "Duration in the post-anaesthesia care unit\n",
            "Category for Sentence 2434:\n",
            "Percentage of patients with undetectable viral load\n",
            "Category for Sentence 2435:\n",
            "Total Weight Change From Baseline at 12 Weeks in kg\n",
            "Category for Sentence 2436:\n",
            "Mean percentage change from baseline at week 12 (or the last assessment) on serum triglyceride (TG) level.\n",
            "Category for Sentence 2437:\n",
            "Serum PSA at randomization, one month, four months\n",
            "Category for Sentence 2438:\n",
            "Fatigue severity\n",
            "Category for Sentence 2439:\n",
            "3D185 Plasma concentration\n",
            "Category for Sentence 2440:\n",
            "Number of Subjects Who Reported Solicited Local and Systemic Reactions (Day 1 to Day 7 Postvaccination), After Any Vaccination\n",
            "Category for Sentence 2441:\n",
            "Proportion of subjects with adverse events of special interest\n",
            "Category for Sentence 2442:\n",
            "Whole Blood White Blood Cells\n",
            "Category for Sentence 2443:\n",
            "Time to Radiological Bone Progression\n",
            "Category for Sentence 2444:\n",
            "Median Number of Days in Administrative Segregation\n",
            "Category for Sentence 2445:\n",
            "Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability\n",
            "Category for Sentence 2446:\n",
            "Mean Change From Baseline in AST Value\n",
            "Category for Sentence 2447:\n",
            "Peptide-YY\n",
            "Category for Sentence 2448:\n",
            "Hand Grip Strength\n",
            "Category for Sentence 2449:\n",
            "Pain\n",
            "Category for Sentence 2450:\n",
            "Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)\n",
            "Category for Sentence 2451:\n",
            "Maintenance Study - Number of Participants With Individual Mayo Subscore (Stool Frequency) up to Week 44\n",
            "Category for Sentence 2452:\n",
            "Mean Change from Baseline in Consumption of High Calorie Foods/Drinks at 1-month Follow-up\n",
            "Category for Sentence 2453:\n",
            "Three dimensional analysis with Digital Image Correlation\n",
            "Category for Sentence 2454:\n",
            "Lawton Brody Index\n",
            "Category for Sentence 2455:\n",
            "Infant IgE\n",
            "Category for Sentence 2456:\n",
            "Overall survival\n",
            "Category for Sentence 2457:\n",
            "Body Composition. The changes are being evaluated.\n",
            "Category for Sentence 2458:\n",
            "Change in Hip circumference (cm)\n",
            "Category for Sentence 2459:\n",
            "The difference between LUS Scores at T5 in patients ventilated with VCV and PCV\n",
            "Category for Sentence 2460:\n",
            "Patient satisfaction scale (CSQ-8)\n",
            "Category for Sentence 2461:\n",
            "Change of reading scores 6 months post hyperopia spectacle correction\n",
            "Category for Sentence 2462:\n",
            "Homogentisic Acid Excretion\n",
            "Category for Sentence 2463:\n",
            "Percent change and absolute change from baseline in non-HDL-C\n",
            "Category for Sentence 2464:\n",
            "Incidence of clinically significant abnormal vital signs\n",
            "Category for Sentence 2465:\n",
            "Blood pressure\n",
            "Category for Sentence 2466:\n",
            "occurrence of resistant mutants in partial responders (detectable RNA) or after the occurrence of virological breakthrough and long term evolution of these mutations (on serum bank)\n",
            "Category for Sentence 2467:\n",
            "Comparison of the incidence of allergic reaction during and after oral food challenge with cow's milk protein between children previously fed with extensively - hydrolyzed formulas and amino acid formulas\n",
            "Category for Sentence 2468:\n",
            "Brunnstrom stage hand\n",
            "Category for Sentence 2469:\n",
            "Parasitological cure rates\n",
            "Category for Sentence 2470:\n",
            "Overall survival (OS)\n",
            "Category for Sentence 2471:\n",
            "The proportion of oncologists who agree to participate in the study\n",
            "Category for Sentence 2472:\n",
            "Eyes irritability\n",
            "Category for Sentence 2473:\n",
            "Quality of life (QLQ-MY20 questionnaires)\n",
            "Category for Sentence 2474:\n",
            "Change in SGRQ Score: Impact\n",
            "Category for Sentence 2475:\n",
            "Family Member-reported Quality of End of Life Communication (QOC) Received From Study Surgeon\n",
            "Category for Sentence 2476:\n",
            "Percent of patients with any adverse experience\n",
            "Category for Sentence 2477:\n",
            "Changes in bone specific alkaline phosphatase (bAP)\n",
            "Category for Sentence 2478:\n",
            "Type of Correlation of Upper Limb Konectom DOAs Versus Revised Upper Limb Module (RULM) in PwSMA\n",
            "Category for Sentence 2479:\n",
            "Change in microbial composition on skin following application of Micrococcus luteus Q24 in balm from Day 0 (baseline) to 11 days\n",
            "Category for Sentence 2480:\n",
            "10-point Numerical Pain Rating Scale\n",
            "Category for Sentence 2481:\n",
            "C reactive protein as prognostic factors\n",
            "Category for Sentence 2482:\n",
            "number and severity of Adverse Events\n",
            "Category for Sentence 2483:\n",
            "Resolution of high-grade AIN at 3 and 6 months after randomization, on a per-lesion basis\n",
            "Category for Sentence 2484:\n",
            "Tmax,ss\n",
            "Category for Sentence 2485:\n",
            "Late toxicity\n",
            "Category for Sentence 2486:\n",
            "Manual measurement\n",
            "Category for Sentence 2487:\n",
            "Mortality\n",
            "Category for Sentence 2488:\n",
            "Gestational incidents\n",
            "Category for Sentence 2489:\n",
            "Glycemic Control (HbA1c)\n",
            "Category for Sentence 2490:\n",
            "Total symptom score\n",
            "Category for Sentence 2491:\n",
            "Cumulative duration of opioid use in ARCR augmented with REGENETEN versus ARCR alone\n",
            "Category for Sentence 2492:\n",
            "Overall response rate (ORR) per 2003 IWG criteria\n",
            "Category for Sentence 2493:\n",
            "Compliance to therapy\n",
            "Category for Sentence 2494:\n",
            "Patient-Reported Outcomes Measurement Information System Physical Function Computer Adaptive Test (directly after visit)\n",
            "Category for Sentence 2495:\n",
            "Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 ancestral strain\n",
            "Category for Sentence 2496:\n",
            "Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 6\n",
            "Category for Sentence 2497:\n",
            "Phenotype-genotype correlation\n",
            "Category for Sentence 2498:\n",
            "Baseline submaximal fitness test performance\n",
            "Category for Sentence 2499:\n",
            "Locoregional tumour control\n",
            "Category for Sentence 2500:\n",
            "Depressive symptoms assessed on the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) at 1 month\n",
            "Category for Sentence 2501:\n",
            "Treatment Emergent Adverse Events of NCI CTCAE ≥Grade 3\n",
            "Category for Sentence 2502:\n",
            "The event rate will be calculated for:\n",
            "Category for Sentence 2503:\n",
            "Phenylalanine Metabolites: e.g.phenylethylamine, tyramine, phenylpyruvate, others\n",
            "Category for Sentence 2504:\n",
            "Change from baseline 3D computed tomography data at 12th~16th week\n",
            "Category for Sentence 2505:\n",
            "CL/F of Free Platinum, Total Platinum, and 5-FU\n",
            "Category for Sentence 2506:\n",
            "Major adverse cardiac events (MACE)\n",
            "Category for Sentence 2507:\n",
            "Ankle arm index\n",
            "Category for Sentence 2508:\n",
            "PFS\n",
            "Category for Sentence 2509:\n",
            "change oral glucose tolerance\n",
            "Category for Sentence 2510:\n",
            "Area Under the Plasma Concentration Versus Time Data Pairs at Steady State (AUCss)\n",
            "Category for Sentence 2511:\n",
            "Improvement in L-dopa 'onset' time and L-dopa 'on-time' duration following H.pylori eradication\n",
            "Category for Sentence 2512:\n",
            "Change From Baseline in the Mean Spasticity 100 mm Visual Analogue Scale Score at Week 18\n",
            "Category for Sentence 2513:\n",
            "Skeletal muscle power (Watts)\n",
            "Category for Sentence 2514:\n",
            "Change in Dietary practice\n",
            "Category for Sentence 2515:\n",
            "Apgars at 5 and 10 minutes\n",
            "Category for Sentence 2516:\n",
            "Maternal visceral fat\n",
            "Category for Sentence 2517:\n",
            "Overall Survival (OS)\n",
            "Category for Sentence 2518:\n",
            "Change in Thrombocytes\n",
            "Category for Sentence 2519:\n",
            "fasting HDL cholesterol\n",
            "Category for Sentence 2520:\n",
            "methods of treatment with Remdesivir and the main outcomes\n",
            "Category for Sentence 2521:\n",
            "High Level Mobility Assessment Tool (HiMAT)\n",
            "Category for Sentence 2522:\n",
            "Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA)\n",
            "Category for Sentence 2523:\n",
            "Pulmonary Function Tests\n",
            "Category for Sentence 2524:\n",
            "Child Survey\n",
            "Category for Sentence 2525:\n",
            "proportion of days participants walked the recommended number of steps\n",
            "Category for Sentence 2526:\n",
            "Maximum Concentration (Cmax)\n",
            "Category for Sentence 2527:\n",
            "Tolerability: Dose Interruptions by Participant - Number of Cycles\n",
            "Category for Sentence 2528:\n",
            "Ventilator-free Days\n",
            "Category for Sentence 2529:\n",
            "Platelet count\n",
            "Category for Sentence 2530:\n",
            "Complications\n",
            "Category for Sentence 2531:\n",
            "Minimum Observed Plasma Concentration Over the Dose Interval (Cmin) Analysis of INCB054329\n",
            "Category for Sentence 2532:\n",
            "1 Repetition Maximum leg press\n",
            "Category for Sentence 2533:\n",
            "Feasability of assisted nerve blocks\n",
            "Category for Sentence 2534:\n",
            "Number of severity criteria most commonly encountered in emergencies.\n",
            "Category for Sentence 2535:\n",
            "Primary Patency\n",
            "Category for Sentence 2536:\n",
            "Plasma PAGN AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants\n",
            "Category for Sentence 2537:\n",
            "Northwick Park neck pain questionnaire (for physical function)\n",
            "Category for Sentence 2538:\n",
            "Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose\n",
            "Category for Sentence 2539:\n",
            "Ease of intubation (VAS)\n",
            "Category for Sentence 2540:\n",
            "PROMIS-10 Questionnaire\n",
            "Category for Sentence 2541:\n",
            "Phase angle\n",
            "Category for Sentence 2542:\n",
            "Proportion of patients who develop a specific acute toxicity (dermatitis)\n",
            "Category for Sentence 2543:\n",
            "The Number of Patients in Which the T-DOC® NXT Catheters Are Safe in Measuring Urodynamic Pressure in Adults.\n",
            "Category for Sentence 2544:\n",
            "Change of Creatinine clearance from baseline\n",
            "Category for Sentence 2545:\n",
            "Vasoactive agents required\n",
            "Category for Sentence 2546:\n",
            "Optimal timing of delivery in PAS for best maternal outcome\n",
            "Category for Sentence 2547:\n",
            "Evidence of disease progression in hospitalised patients (moderate and severe cases)\n",
            "Category for Sentence 2548:\n",
            "pain intensity\n",
            "Category for Sentence 2549:\n",
            "Optimal on-time adherence\n",
            "Category for Sentence 2550:\n",
            "Change From Baseline in National Cancer Comprehensive Network Head and Neck Symptom Index-22 Item Scores (NCCN FHNSI-22) at CRT Phase and Maintenance Phase\n",
            "Category for Sentence 2551:\n",
            "Hospital re-admission\n",
            "Category for Sentence 2552:\n",
            "Validity\n",
            "Category for Sentence 2553:\n",
            "Gastrointestinal Health measured by the gastrointestinal symptom rating scale at 5 months\n",
            "Category for Sentence 2554:\n",
            "Infant feeding practices\n",
            "Category for Sentence 2555:\n",
            "pharmacotherapy adherence\n",
            "Category for Sentence 2556:\n",
            "Parkinsons disease quality of life questionnaire-39 (PDQ-39) change from baseline, 6 months, 12 months, 18 months and 24 months.\n",
            "Category for Sentence 2557:\n",
            "Co-Primary Efficacy: Improvement in Tinnitus Functional Index (TFI) Total Score From Baseline to FUV3\n",
            "Category for Sentence 2558:\n",
            "Changes in perceived support for physical activity from friends and family members\n",
            "Category for Sentence 2559:\n",
            "Serum samples will be collected and analyzed for measurement of total IgE\n",
            "Category for Sentence 2560:\n",
            "Factors associated with the development and progression of Parkinson's related spinal disorders\n",
            "Category for Sentence 2561:\n",
            "Duration of response (DoR)\n",
            "Category for Sentence 2562:\n",
            "Change in Physical Function\n",
            "Category for Sentence 2563:\n",
            "Difference in average steps-per-day between groups\n",
            "Category for Sentence 2564:\n",
            "Generalized Anxiety Disorder-7\n",
            "Category for Sentence 2565:\n",
            "Duration of Composite Complete Remission in FLT3-ITD (-) Participants Who Achieved CRc Based on All On-Treatment Data\n",
            "Category for Sentence 2566:\n",
            "Progression-free survival (PFS)\n",
            "Category for Sentence 2567:\n",
            "Response rate\n",
            "Category for Sentence 2568:\n",
            "Examine the construct validity, internal consistency, item-response performance, and short-term stability of a health-related needs assessment self-report instrument for adult childhood cancer survivors.\n",
            "Category for Sentence 2569:\n",
            "Changes in the pericardial physiology\n",
            "Category for Sentence 2570:\n",
            "Depression- Baseline\n",
            "Category for Sentence 2571:\n",
            "Acceptability Questionnaire\n",
            "Category for Sentence 2572:\n",
            "Incidence of postoperative vertigo\n",
            "Category for Sentence 2573:\n",
            "Change from Baseline in Circulating Hemoglobin A1c Levels at Week 4 and Differences Between Groups at Baseline and Week 4\n",
            "Category for Sentence 2574:\n",
            "Changes in serum markers of inflammation and free fatty acids.\n",
            "Category for Sentence 2575:\n",
            "EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI)\n",
            "Category for Sentence 2576:\n",
            "Side effects or adverse events from the study device using a multiple choice side effect questionare\n",
            "Category for Sentence 2577:\n",
            "Days to first 3 consecutive days of drinking\n",
            "Category for Sentence 2578:\n",
            "Incidence of treatment-emergent adverse events (Safety and Tolerability)\n",
            "Category for Sentence 2579:\n",
            "frequency and characterization of AEs and SAEs\n",
            "Category for Sentence 2580:\n",
            "Visual gait analysis\n",
            "Category for Sentence 2581:\n",
            "Inconvenience rates\n",
            "Category for Sentence 2582:\n",
            "Axillary temperature < 36.0 degrees Celsius\n",
            "Category for Sentence 2583:\n",
            "Overall survival\n",
            "Category for Sentence 2584:\n",
            "Time of blind intubation measure in seconds\n",
            "Category for Sentence 2585:\n",
            "Direct and Indirect Costs\n",
            "Category for Sentence 2586:\n",
            "Maximum Tolerated Dose (MTD)\n",
            "Category for Sentence 2587:\n",
            "Sleep\n",
            "Category for Sentence 2588:\n",
            "Concentrations of total radiolabelled 14C-content in blood, plasma, urine, and feces.\n",
            "Category for Sentence 2589:\n",
            "Cost-utility analysis that will compare the 2 groups at 1 year from the community's perspective.\n",
            "Category for Sentence 2590:\n",
            "Target Lesion Failure (TLF)\n",
            "Category for Sentence 2591:\n",
            "Heart function - Tricuspid annular plane systolic excursion\n",
            "Category for Sentence 2592:\n",
            "Change in Subjective Effects for LIKE of METH Challenge Doses\n",
            "Category for Sentence 2593:\n",
            "Summary of Encapsulated Asparaginase (U/L) Over Time\n",
            "Category for Sentence 2594:\n",
            "Documentation of adverse event, physical examination, clinical laboratory safety, vital signs and ECG recording at prespecified time-points.\n",
            "Category for Sentence 2595:\n",
            "CD4 cell count\n",
            "Category for Sentence 2596:\n",
            "Change from baseline in Functional Assessment of Cancer Therapy - Bone Marrow Transplantation (FACT-BMT) score\n",
            "Category for Sentence 2597:\n",
            "Cardiovascular analysis for heart rate\n",
            "Category for Sentence 2598:\n",
            "Comparison of the clinical and biological profiles of patients presenting chilblains according to their SARS-CoV-2 virological status (in case of over-representation of SARS-CoV-2 positive patients, the results will be given without comparison).\n",
            "Category for Sentence 2599:\n",
            "Clinical Global Improvement\n",
            "Category for Sentence 2600:\n",
            "Measure and Report Abiraterone Drug Targets' SNP Genotypes which are effectiveness-associated, and which are risk-associated.\n",
            "Category for Sentence 2601:\n",
            "Subject Satisfaction\n",
            "Category for Sentence 2602:\n",
            "Safety of Carbamazepine\n",
            "Category for Sentence 2603:\n",
            "Pharmacodynamic (PD) Profile - Change from baseline in average glucose by CGM\n",
            "Category for Sentence 2604:\n",
            "Recovery Assessment Scale score\n",
            "Category for Sentence 2605:\n",
            "Percent Change From Baseline Range of Motion After the Last Injection\n",
            "Category for Sentence 2606:\n",
            "Parts 1, 2 and 3: Time to Response\n",
            "Category for Sentence 2607:\n",
            "Change From Baseline in 2-hr Post-Meal Glucose (PMG) at Week 18\n",
            "Category for Sentence 2608:\n",
            "Blood oxygen pressure\n",
            "Category for Sentence 2609:\n",
            "Time to maximum plasma concentration (Tmax) of lenzilumab\n",
            "Category for Sentence 2610:\n",
            "Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry test\n",
            "Category for Sentence 2611:\n",
            "Amount of hairline stabilization\n",
            "Category for Sentence 2612:\n",
            "Number of participants that had any difficulty using the REDCap interface.\n",
            "Category for Sentence 2613:\n",
            "Systolic Blood Pressure\n",
            "Category for Sentence 2614:\n",
            "Implant stability\n",
            "Category for Sentence 2615:\n",
            "Clinical Diagnosis of Unilateral Primary Aldosteronism\n",
            "Category for Sentence 2616:\n",
            "Muscle will be examined for histological appearance\n",
            "Category for Sentence 2617:\n",
            "Clinical symptoms\n",
            "Category for Sentence 2618:\n",
            "Difficulties in emotion regulation as measured by the DERS-SF\n",
            "Category for Sentence 2619:\n",
            "Safety assessment on the incidence and severity of adverse events using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\n",
            "Category for Sentence 2620:\n",
            "Visual-attention task accuracy\n",
            "Category for Sentence 2621:\n",
            "State Trait Anxiety Inventory Y-1\n",
            "Category for Sentence 2622:\n",
            "Hospital Anxiety and Depression Scale (HAD)\n",
            "Category for Sentence 2623:\n",
            "Anterior chamber depth (ACD)\n",
            "Category for Sentence 2624:\n",
            "Opioid use\n",
            "Category for Sentence 2625:\n",
            "Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate\n",
            "Category for Sentence 2626:\n",
            "Change in Self-management behavior\n",
            "Category for Sentence 2627:\n",
            "Duration of Response (DOR)\n",
            "Category for Sentence 2628:\n",
            "Insomnia\n",
            "Category for Sentence 2629:\n",
            "Target lesion failure（TLF）\n",
            "Category for Sentence 2630:\n",
            "Effect of Androgel Treatment on Relative Nuclear Factor kB Activity Compared to Placebo\n",
            "Category for Sentence 2631:\n",
            "RSA outcome, functional recovery and metabolic treatment response\n",
            "Category for Sentence 2632:\n",
            "Return to continence\n",
            "Category for Sentence 2633:\n",
            "Hospital length of stay\n",
            "Category for Sentence 2634:\n",
            "Medical adverse events\n",
            "Category for Sentence 2635:\n",
            "Pharmacokinetic parameters derived from plasma concentrations of NBMI: AUC%Extrap,obs\n",
            "Category for Sentence 2636:\n",
            "Anterior Cingulate Cortex - Choline\n",
            "Category for Sentence 2637:\n",
            "Change from Baseline in High Density Lipoprotein cholesterol\n",
            "Category for Sentence 2638:\n",
            "Effect of stent on ureteral peristalsis in stented ureter\n",
            "Category for Sentence 2639:\n",
            "Impact of Music on EMG (M. Zygomaticus, M. Corrugator)\n",
            "Category for Sentence 2640:\n",
            "Addiction Severity Index (ASI) gambling severity scores\n",
            "Category for Sentence 2641:\n",
            "Tolerability and Efficacy of Compound GW506U78 in relapsed/refractory T-ALL/NHL\n",
            "Category for Sentence 2642:\n",
            "Median progression-free survival\n",
            "Category for Sentence 2643:\n",
            "Change in Anxiety\n",
            "Category for Sentence 2644:\n",
            "Changes in creatine kinase\n",
            "Category for Sentence 2645:\n",
            "Summary for Change From Baseline Neutrophil Cell Counts in Blood\n",
            "Category for Sentence 2646:\n",
            "30-day mortality\n",
            "Category for Sentence 2647:\n",
            "Reachable Work Space (RWS)\n",
            "Category for Sentence 2648:\n",
            "HPV viral load\n",
            "Category for Sentence 2649:\n",
            "Self-reported questionnaire(2)\n",
            "Category for Sentence 2650:\n",
            "Endoleak\n",
            "Category for Sentence 2651:\n",
            "Plasma urea and creatinine post-supplementation\n",
            "Category for Sentence 2652:\n",
            "prediction of postoperative fecal incontinence by the score of Stadelmaier and Matzel (Score =18.230 - 0.94x anastomotic level - 0.18 x resting pressure + 3.72 x radiochemotherapy (done 1, not done 0)\n",
            "Category for Sentence 2653:\n",
            "Effects of robotic system (SWalker + VR) use in gait rehabilitation - Autonomy/independence. Quality of life.\n",
            "Category for Sentence 2654:\n",
            "Phase 2: Specificity of dogs detecting COVID-19 on worn clothing samples.\n",
            "Category for Sentence 2655:\n",
            "Improvement in AM, pre-dose, instantaneous total nasal symptom scores after 2 weeks of treatment, overall evaluation of response to therapy after 2 weeks of treatment for subjects ages 6 to <12 years.\n",
            "Category for Sentence 2656:\n",
            "Healthy dietary intake\n",
            "Category for Sentence 2657:\n",
            "2- Rate of decline of the serum creatinine level.\n",
            "Category for Sentence 2658:\n",
            "Changes in Anxiety\n",
            "Category for Sentence 2659:\n",
            "Change in upper limb functions as assessed by the ABILHAND\n",
            "Category for Sentence 2660:\n",
            "Salivary antibody response\n",
            "Category for Sentence 2661:\n",
            "Physical Performance\n",
            "Category for Sentence 2662:\n",
            "Anti-tumor effect (PR, CR, SD and PD) of BKM120 in combination with fulvestrant\n",
            "Category for Sentence 2663:\n",
            "Cancer-specific Survival\n",
            "Category for Sentence 2664:\n",
            "Number of Individuals Screened and Eligible Per Collection Site.\n",
            "Category for Sentence 2665:\n",
            "Preparation for Discharge from Neonatal Intensive Care Unit and Home Care Scale\n",
            "Category for Sentence 2666:\n",
            "Change from baseline in the alkaline phosphatase after 20 days of treatment\n",
            "Category for Sentence 2667:\n",
            "Relationship between daily behaviors in school-aged children with Pompe disease and development, as assessed by Child Behavior Checklist.\n",
            "Category for Sentence 2668:\n",
            "Comparison between saliva and blood\n",
            "Category for Sentence 2669:\n",
            "To study baseline antioxidant capacity (ORAC), selected biomarkers of nutritional status and nutritional risk of patients beginning therapy for head and neck cancers.\n",
            "Category for Sentence 2670:\n",
            "Change in Human Papilloma Virus (HPV) vaccine rate with provider education in medicine/pediatric resident clinic\n",
            "Category for Sentence 2671:\n",
            "Health related quality of life including urinary, bowel and sexual function as measured by the EPIC questionnaire\n",
            "Category for Sentence 2672:\n",
            "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole\n",
            "Category for Sentence 2673:\n",
            "Percentage (%) of Participants Achieving 4-Component Clinical Remission\n",
            "Category for Sentence 2674:\n",
            "Mortality\n",
            "Category for Sentence 2675:\n",
            "Effectiveness of the pressure\n",
            "Category for Sentence 2676:\n",
            "Observation of in-Vivo Pro-social Behavior\n",
            "Category for Sentence 2677:\n",
            "implant success\n",
            "Category for Sentence 2678:\n",
            "Concentration of inflammation biomarker interferon gamma (IFN-gamma)\n",
            "Category for Sentence 2679:\n",
            "Time to Maximum Plasma Concentration (Tmax) for Tivantinib and its major metabolites, HPM4, HPM5, HPM6, and HPM8\n",
            "Category for Sentence 2680:\n",
            "Patient Feedback Survey\n",
            "Category for Sentence 2681:\n",
            "Change in exercise capacity as measured by Six Minute Walk Test (6MWT)\n",
            "Category for Sentence 2682:\n",
            "Local-regional Failure (Percentage of Participants With Local-regional Failure)\n",
            "Category for Sentence 2683:\n",
            "The client adopted a modern contraceptive method (LARC or SARC)\n",
            "Category for Sentence 2684:\n",
            "Effect of Tiotropium Bromide Combined With Odaterol on bronchial airway wall area change\n",
            "Category for Sentence 2685:\n",
            "Median Clinical Response to Single Agent Talazoparib\n",
            "Category for Sentence 2686:\n",
            "Fasting glucose\n",
            "Category for Sentence 2687:\n",
            "Duration of hospitalisation\n",
            "Category for Sentence 2688:\n",
            "Compartmental model complexity\n",
            "Category for Sentence 2689:\n",
            "3 year recurrence free survival\n",
            "Category for Sentence 2690:\n",
            "University of Rotterdam Hospital Xerostomia Questionnaire - \"Do you have a sore or painful mouth?\"\n",
            "Category for Sentence 2691:\n",
            "Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03\n",
            "Category for Sentence 2692:\n",
            "Urinary metabolic ratio (UMR) tramadol/M1 in urine collection\n",
            "Category for Sentence 2693:\n",
            "Gametocyte carriage\n",
            "Category for Sentence 2694:\n",
            "Heart Rate\n",
            "Category for Sentence 2695:\n",
            "Difference of cardiac output\n",
            "Category for Sentence 2696:\n",
            "Progression-free survival\n",
            "Category for Sentence 2697:\n",
            "Distant disease-free survival\n",
            "Category for Sentence 2698:\n",
            "ST-segment resolution 90 minute ECG TIMI-flow post PCI indirect infarct size by enzyme release individual clinical endpoints\n",
            "Category for Sentence 2699:\n",
            "Corrected (with pinhole contact lens) Near Vision Acuity\n",
            "Category for Sentence 2700:\n",
            "Systemic Inflammation - Serum/Plasma Cytokines\n",
            "Category for Sentence 2701:\n",
            "To Evaluate PK interaction of amlodipine and valsartan\n",
            "Category for Sentence 2702:\n",
            "Percent Improvement of Individually Measured Signs of the Disease\n",
            "Category for Sentence 2703:\n",
            "Correlation of increased abdominal pressure with renal dysfunction assessed by creatinine.\n",
            "Category for Sentence 2704:\n",
            "LDL Cholesterol\n",
            "Category for Sentence 2705:\n",
            "The evaluation of sleeping status\n",
            "Category for Sentence 2706:\n",
            "Range of immune responses\n",
            "Category for Sentence 2707:\n",
            "System workflow impact, 28 day revisit\n",
            "Category for Sentence 2708:\n",
            "ICOS count\n",
            "Category for Sentence 2709:\n",
            "Falls Efficacy Scale International\n",
            "Category for Sentence 2710:\n",
            "Schirmer's test\n",
            "Category for Sentence 2711:\n",
            "Visual Acuities\n",
            "Category for Sentence 2712:\n",
            "Maintenance of Executive Function (DD) following intervention.\n",
            "Category for Sentence 2713:\n",
            "Number of Participants with myocardial infarction\n",
            "Category for Sentence 2714:\n",
            "Duration of hospital stay\n",
            "Category for Sentence 2715:\n",
            "treatment response measured by ADAS-cog\n",
            "Category for Sentence 2716:\n",
            "Change in Emotional Wellbeing\n",
            "Category for Sentence 2717:\n",
            "ventilatory stability by frequency of central apnea\n",
            "Category for Sentence 2718:\n",
            "the duration of sensory blocks\n",
            "Category for Sentence 2719:\n",
            "Kansas Parental Satisfaction Scale\n",
            "Category for Sentence 2720:\n",
            "Fever (Cº)\n",
            "Category for Sentence 2721:\n",
            "Mean Maximum Concentration (Cmax) of Ertapenem in Hemodialysis Patients\n",
            "Category for Sentence 2722:\n",
            "McGill Questionnaire\n",
            "Category for Sentence 2723:\n",
            "Back pain beliefs\n",
            "Category for Sentence 2724:\n",
            "Relapse\n",
            "Category for Sentence 2725:\n",
            "Patient satisfaction\n",
            "Category for Sentence 2726:\n",
            "Number of Subjects With Adverse Reactions.\n",
            "Category for Sentence 2727:\n",
            "Difference in the iAUC for glucagon after food ingestion between high-protein and standard diet groups\n",
            "Category for Sentence 2728:\n",
            "Change in PDQ8 compared to baseline\n",
            "Category for Sentence 2729:\n",
            "To assess the safety of patients or their partners performance of unsupervised Somatuline Autogel injections.\n",
            "Category for Sentence 2730:\n",
            "Apparent Volume of Distribution (Vdz/F) of Macitentan\n",
            "Category for Sentence 2731:\n",
            "Cervical Rotation Range of Motion (CROM)\n",
            "Category for Sentence 2732:\n",
            "Mean Percentage Change in MIRCERA and Darbepoetin Alpha Dose Over Time\n",
            "Category for Sentence 2733:\n",
            "Severity of visual symptoms of Visual Snow Syndrome on a 0-10 VAS\n",
            "Category for Sentence 2734:\n",
            "Percentage of patients that have not progressed\n",
            "Category for Sentence 2735:\n",
            "Evaluate the number of adverse events per subject, including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 811\n",
            "Category for Sentence 2736:\n",
            "Age\n",
            "Category for Sentence 2737:\n",
            "Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'\n",
            "Category for Sentence 2738:\n",
            "Modified Rankin Scale (mRS) 0-1 at 3 months\n",
            "Category for Sentence 2739:\n",
            "Pain Reduction\n",
            "Category for Sentence 2740:\n",
            "Composite complete remission rate\n",
            "Category for Sentence 2741:\n",
            "Functional MRI highlighting a specific modulation of the structures involved in the cognitive control circuit\n",
            "Category for Sentence 2742:\n",
            "HISTOLOGY RESULTS\n",
            "Category for Sentence 2743:\n",
            "Number of adverse events related to safety of the nerve block\n",
            "Category for Sentence 2744:\n",
            "Complications\n",
            "Category for Sentence 2745:\n",
            "Percentage of participants with recurrence\n",
            "Category for Sentence 2746:\n",
            "Quality-of-life evaluation (SF-36 questionnaire)\n",
            "Category for Sentence 2747:\n",
            "Fluid resuscitation requirements\n",
            "Category for Sentence 2748:\n",
            "Number of Participants With Composite Efficacy Outcome\n",
            "Category for Sentence 2749:\n",
            "Change from baseline at each time point of measurement in hematocrit\n",
            "Category for Sentence 2750:\n",
            "Percentage of Participants with Recovery Success Measured by modified Rankin Scale (mRS) score of 0-1 on the final mRS assessment.\n",
            "Category for Sentence 2751:\n",
            "change from baseline in smoking craving on Visual Analog Scale of Cigarette Craving at week 4\n",
            "Category for Sentence 2752:\n",
            "Assessment of the quality of life\n",
            "Category for Sentence 2753:\n",
            "Stroke volume index\n",
            "Category for Sentence 2754:\n",
            "Anxiety and Depression\n",
            "Category for Sentence 2755:\n",
            "Binocular photopic uncorrected visual acuity\n",
            "Category for Sentence 2756:\n",
            "Changes From Baseline in Pulse Rate at Final Assessment\n",
            "Category for Sentence 2757:\n",
            "Overall survival (OS)\n",
            "Category for Sentence 2758:\n",
            "Live birth rate\n",
            "Category for Sentence 2759:\n",
            "Gnaq mutation status\n",
            "Category for Sentence 2760:\n",
            "ICD-10-Symptom-Rating (ISR) - Change from Baseline at 6 months\n",
            "Category for Sentence 2761:\n",
            "Median Overall Survival After Treatment With Doxil, Carboplatin and Bevacizumab in Patients With ER, PR, HER2neu Negative\n",
            "Category for Sentence 2762:\n",
            "Blinding feasibility of outcome assessors, measured by the Bang blinding index.\n",
            "Category for Sentence 2763:\n",
            "Trajectories of Parenting Young Children (See Reference Section for citing of title)\n",
            "Category for Sentence 2764:\n",
            "Concentric muscle strength\n",
            "Category for Sentence 2765:\n",
            "BDI at 8-Week Follow-Up\n",
            "Category for Sentence 2766:\n",
            "Number of Participants With TCZ Dose Change According to the Reason for Change\n",
            "Category for Sentence 2767:\n",
            "tAUC and iAUC analyses for insulin\n",
            "Category for Sentence 2768:\n",
            "Response blast-free hypoplastic or aplastic bone marrow from time of transplant to one day following the second treatment\n",
            "Category for Sentence 2769:\n",
            "mortality rate\n",
            "Category for Sentence 2770:\n",
            "Sleep and Health Questionnaire Result\n",
            "Category for Sentence 2771:\n",
            "Change in GHSQ Emotional Item 4\n",
            "Category for Sentence 2772:\n",
            "Change in unintended pregnancy\n",
            "Category for Sentence 2773:\n",
            "occurrence of adverse events\n",
            "Category for Sentence 2774:\n",
            "HIV and PrEP knowledge\n",
            "Category for Sentence 2775:\n",
            "Number of blood component transfusions used during perioperative period for surgery\n",
            "Category for Sentence 2776:\n",
            "Change from Quality of life (self-reported questionnaire)\n",
            "Category for Sentence 2777:\n",
            "Clinical Global Impression - Improvement\n",
            "Category for Sentence 2778:\n",
            "Evaluating the superioty of pain reduction with the combined mode compared to the low frequency reference mode.\n",
            "Category for Sentence 2779:\n",
            "Preoperative fitness based on [oxygen uptake (VO2) at the ventilatory anaerobic threshold (VAT) <11 mL/kg/min]\n",
            "Category for Sentence 2780:\n",
            "Maximum Observed Serum Concentration (Cmax) For SHR-1210\n",
            "Category for Sentence 2781:\n",
            "height\n",
            "Category for Sentence 2782:\n",
            "Maximum ticagrelor and AR-C124900XX concentration\n",
            "Category for Sentence 2783:\n",
            "The severity of urine leakage\n",
            "Category for Sentence 2784:\n",
            "Change in quality of life as measured by the Parkinson's Disease Questionnaire- Short Form (PDQ-8)\n",
            "Category for Sentence 2785:\n",
            "Change in fasting plasma glucose\n",
            "Category for Sentence 2786:\n",
            "Kilocalories delivered by enteral and/or parenteral route and Energy balance\n",
            "Category for Sentence 2787:\n",
            "Primary Efficacy - MRI-measured healing rate in the rotator cuff tear\n",
            "Category for Sentence 2788:\n",
            "Change in HOMA-R\n",
            "Category for Sentence 2789:\n",
            "Adverse events post-enrollment\n",
            "Category for Sentence 2790:\n",
            "Change From Baseline of Surgical Site Pain Level (NRS) at Rest [Percentage of Baseline Pain]\n",
            "Category for Sentence 2791:\n",
            "4 Hours, Continuous Overall Net Glycemic Action (CONGA) for Sensor Glucose Data During Periods of CGM Wear, Masked Versus Unmasked Phase\n",
            "Category for Sentence 2792:\n",
            "Evolution of the fasting blood concentrations of non-HDL cholesterol\n",
            "Category for Sentence 2793:\n",
            "Sensibility and specificity of CT-Scan.\n",
            "Category for Sentence 2794:\n",
            "To assess the effectiveness of Fasenra (benralizumab) in adult patients of severe asthma with eosinophilic phenotype over a period of 24 weeks\n",
            "Category for Sentence 2795:\n",
            "Savings\n",
            "Category for Sentence 2796:\n",
            "The time of delivery\n",
            "Category for Sentence 2797:\n",
            "Terminal elimination rate constant (λz)\n",
            "Category for Sentence 2798:\n",
            "Infarction incidence demonstrated by computerized tomography (CT).\n",
            "Category for Sentence 2799:\n",
            "Peripheral artery disease symptoms: muscle pain after physical effort, aches, cooling sensation, and paresthesia.\n",
            "Category for Sentence 2800:\n",
            "Body Mass Index - BMI\n",
            "Category for Sentence 2801:\n",
            "Change in fasting plasma insulin\n",
            "Category for Sentence 2802:\n",
            "Resilience\n",
            "Category for Sentence 2803:\n",
            "Compare the overall survival (OS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo\n",
            "Category for Sentence 2804:\n",
            "Glycaemic control\n",
            "Category for Sentence 2805:\n",
            "Degree of satisfaction of the researcher\n",
            "Category for Sentence 2806:\n",
            "Change in Scores on Aphasia Communication Outcome Measure from Pre- to Post- Treatment\n",
            "Category for Sentence 2807:\n",
            "Re-intervention Rates for Surgical Complications\n",
            "Category for Sentence 2808:\n",
            "\"C-PROM\" questionnaire to measure Personal Recovery\n",
            "Category for Sentence 2809:\n",
            "Outcome Expectations for Exercise Scale\n",
            "Category for Sentence 2810:\n",
            "Sleep Status: Total Sleep Time\n",
            "Category for Sentence 2811:\n",
            "Change in WHO Quality of Life From 6 Months to 12 Months\n",
            "Category for Sentence 2812:\n",
            "Head Circumference Growth Velocity\n",
            "Category for Sentence 2813:\n",
            "To determine the effect of resB® Lung Support on biomarkers of inflammation\n",
            "Category for Sentence 2814:\n",
            "Bleeding on probing\n",
            "Category for Sentence 2815:\n",
            "Delphi Round 2\n",
            "Category for Sentence 2816:\n",
            "Incidence of Adverse reactions\n",
            "Category for Sentence 2817:\n",
            "Trastuzumab - AUC\n",
            "Category for Sentence 2818:\n",
            "Pregnancy rates (per stimulation cycle and embryo transfer)\n",
            "Category for Sentence 2819:\n",
            "Change in SBP in Subjects From Baseline at Week 24\n",
            "Category for Sentence 2820:\n",
            "Drug Abuse Screening Test-10 Total Scores\n",
            "Category for Sentence 2821:\n",
            "Adverse Events\n",
            "Category for Sentence 2822:\n",
            "BSQ-8C\n",
            "Category for Sentence 2823:\n",
            "Mortality\n",
            "Category for Sentence 2824:\n",
            "T1/2\n",
            "Category for Sentence 2825:\n",
            "Bilateral blindness in people aged 60 years and older, defined as pinhole visual acuity worse than Snellen 20/400 (Metric Snellen worse than 6/120; logMAR worse than 1.3) in the better-seeing eye\n",
            "Category for Sentence 2826:\n",
            "Education status\n",
            "Category for Sentence 2827:\n",
            "Fatigue score\n",
            "Category for Sentence 2828:\n",
            "For safety: NCI-CTCAE scale version 3.0\n",
            "Category for Sentence 2829:\n",
            "Viral load drop from baseline through Week 12\n",
            "Category for Sentence 2830:\n",
            "Half-life\n",
            "Category for Sentence 2831:\n",
            "Level of optical density of the macula lutea\n",
            "Category for Sentence 2832:\n",
            "Progress free survival (PFS) per RECIST v1.1\n",
            "Category for Sentence 2833:\n",
            "Progression Free Survival\n",
            "Category for Sentence 2834:\n",
            "Plasma Ribavirin Levels\n",
            "Category for Sentence 2835:\n",
            "Subgroup analyses of micro-randomized notifications by notification type\n",
            "Category for Sentence 2836:\n",
            "Number of High Amplitude Propagating Contractions (HAPCs) during HRM\n",
            "Category for Sentence 2837:\n",
            "Response rate differences\n",
            "Category for Sentence 2838:\n",
            "Time to reach the MSSBP target (based on the BP measurements during office visits)\n",
            "Category for Sentence 2839:\n",
            "Safety\n",
            "Category for Sentence 2840:\n",
            "Change from 1 month estradiol at 6 months\n",
            "Category for Sentence 2841:\n",
            "Improvement in oral-related quality of life.\n",
            "Category for Sentence 2842:\n",
            "change from baseline expiratory time to complete recovery after exercise\n",
            "Category for Sentence 2843:\n",
            "Waveform Data Completeness\n",
            "Category for Sentence 2844:\n",
            "the objective response rate (ORR）\n",
            "Category for Sentence 2845:\n",
            "Ulcer size\n",
            "Category for Sentence 2846:\n",
            "Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 2\n",
            "Category for Sentence 2847:\n",
            "Patient satisfaction\n",
            "Category for Sentence 2848:\n",
            "AUC (the area under the curve) [Pharmacokinetics]\n",
            "Category for Sentence 2849:\n",
            "Dropout rates\n",
            "Category for Sentence 2850:\n",
            "Living Kidney Donor Evaluation Started\n",
            "Category for Sentence 2851:\n",
            "Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.\n",
            "Category for Sentence 2852:\n",
            "Overall safety profile in terms of changes in measurements of systolic and diastolic blood pressure following administration of OPTISON.\n",
            "Category for Sentence 2853:\n",
            "Among Smokers: Cigarette consumption\n",
            "Category for Sentence 2854:\n",
            "Duration of Solicited Local AEs in Subjects Aged 3-17 Years.\n",
            "Category for Sentence 2855:\n",
            "toxicity\n",
            "Category for Sentence 2856:\n",
            "Change in Systolic/Diastolic blood pressure from screening to end of study\n",
            "Category for Sentence 2857:\n",
            "Percent change from baseline to Week 24 in untrimmed distal airway resistance corrected for lung volume ([s]iRaw) at TLC\n",
            "Category for Sentence 2858:\n",
            "Perimetry\n",
            "Category for Sentence 2859:\n",
            "Repeated recurrent incidence of suicide attempts\n",
            "Category for Sentence 2860:\n",
            "Cost of Hospital admissions (including ICU) per year overall and by ICD-10 (ICD-9)/OPCS/HRG\n",
            "Category for Sentence 2861:\n",
            "Tssmax after multiple dosing\n",
            "Category for Sentence 2862:\n",
            "Distress associated with IV insertion\n",
            "Category for Sentence 2863:\n",
            "Femoral subcutaneous adipose tissue biopsy\n",
            "Category for Sentence 2864:\n",
            "Phase II: Overall survival (OS)\n",
            "Category for Sentence 2865:\n",
            "Primary objective: Salivary Cortisol Slopes\n",
            "Category for Sentence 2866:\n",
            "Changes in systolic blood pressure during the study\n",
            "Category for Sentence 2867:\n",
            "Endothelial function\n",
            "Category for Sentence 2868:\n",
            "Qualitative Measure: Observed emotions\n",
            "Category for Sentence 2869:\n",
            "Numeric Rating scale for pain assesment during the first postoperative 12 hours\n",
            "Category for Sentence 2870:\n",
            "Tegner activity level score\n",
            "Category for Sentence 2871:\n",
            "C. Percentage frequency of single nucleotide polymorphisms among patients in the Suicide group.\n",
            "Category for Sentence 2872:\n",
            "TMT Test\n",
            "Category for Sentence 2873:\n",
            "Objective Tumoral Response defined by RECISt criteria performed by MRI\n",
            "Category for Sentence 2874:\n",
            "Multiple Sclerosis Functional Composite (MSFC)-functional ability\n",
            "Category for Sentence 2875:\n",
            "Absolute Change in High Sensitivity C-Reactive Protein (hsCRP)\n",
            "Category for Sentence 2876:\n",
            "Duration of Response when NT219 is used in combination with ERBITUX®\n",
            "Category for Sentence 2877:\n",
            "Change in Barnes Global Clinical Assessment of Akathisia Score During Extension Phase\n",
            "Category for Sentence 2878:\n",
            "neurodevelopment biomarker\n",
            "Category for Sentence 2879:\n",
            "Incidence, frequency and severity of adverse events (AEs)\n",
            "Category for Sentence 2880:\n",
            "The predictive ability of change in Plethysmographic Variability Index after Tidal volume challenge to predict fluid responsiveness\n",
            "Category for Sentence 2881:\n",
            "Seroconversion\n",
            "Category for Sentence 2882:\n",
            "CLDEQ-8 scores at 8 weeks\n",
            "Category for Sentence 2883:\n",
            "Changes in defecation time\n",
            "Category for Sentence 2884:\n",
            "- the pain felt by the patients, during and after the radiofrequency\n",
            "Category for Sentence 2885:\n",
            "delta in the value of zonulin\n",
            "Category for Sentence 2886:\n",
            "Nursing impact\n",
            "Category for Sentence 2887:\n",
            "Number of Participants that Maintain Mask Seal Integrity\n",
            "Category for Sentence 2888:\n",
            "Depression\n",
            "Category for Sentence 2889:\n",
            "Lambda z of DTG and 3TC in in the Fed State: Part 1\n",
            "Category for Sentence 2890:\n",
            "Immunohistochemical analysis of CA-IX expression, (p)VHL status, HIF1-a, VEGF and PDGF expression, apoptosis and necrosis of surgical specimen\n",
            "Category for Sentence 2891:\n",
            "Percentage of adolescents with chronic conditions showing good adherence to treatment as measured by Medication Adherence Report Scale (MARS)\n",
            "Category for Sentence 2892:\n",
            "Adverse events related to exercise rehabilitation\n",
            "Category for Sentence 2893:\n",
            "Care staff's satisfaction\n",
            "Category for Sentence 2894:\n",
            "Seated blood pressure\n",
            "Category for Sentence 2895:\n",
            "Acceptability\n",
            "Category for Sentence 2896:\n",
            "Change in Small LDL Particles\n",
            "Category for Sentence 2897:\n",
            "Change from baseline in Beck Depression Inventory (BDI)\n",
            "Category for Sentence 2898:\n",
            "Rates of major adverse cardiac and cerebrovascular events at 6-month assessment\n",
            "Category for Sentence 2899:\n",
            "Change in haemodynamic parameters in the substudy \"Energy\"\n",
            "Category for Sentence 2900:\n",
            "Dose Limiting Toxicity (DLT)\n",
            "Category for Sentence 2901:\n",
            "Mass spectrometry-based measurement of abundance of metabolites in blood\n",
            "Category for Sentence 2902:\n",
            "Quality of Life (QOL) as measured by EORTC QOL before and after study treatment, every 6 months for 2 years, and then annually\n",
            "Category for Sentence 2903:\n",
            "Rate of Dependency between MRI parameters and clinical scores/questionnaires\n",
            "Category for Sentence 2904:\n",
            "Kinesthetic and Visual Imagery Ouestionnaire\n",
            "Category for Sentence 2905:\n",
            "Progression-free Survival(PFS)\n",
            "Category for Sentence 2906:\n",
            "The satisfaction of the staffs as for the implementation and the realization of the experiment\n",
            "Category for Sentence 2907:\n",
            "Response inhibition\n",
            "Category for Sentence 2908:\n",
            "Side-effects attributable to analgesia\n",
            "Category for Sentence 2909:\n",
            "US - Grey level co-occurrence matrices (GLCM)\n",
            "Category for Sentence 2910:\n",
            "Phase I: AUC0-T\n",
            "Category for Sentence 2911:\n",
            "Number of Participants With Clinically Meaningful Changes in Vital Signs\n",
            "Category for Sentence 2912:\n",
            "Percentage of Participants With Adverse Events (AEs)\n",
            "Category for Sentence 2913:\n",
            "The incidence of adverse events, including neurotoxicity, as determined using the National Cancer Institute (NCI) Common Toxicity Criteria version 3.0 (CTCAE v3.0)\n",
            "Category for Sentence 2914:\n",
            "Determine the pharmacokinetics of plerixafor on azacitidine\n",
            "Category for Sentence 2915:\n",
            "incidence of AEs and laboratory abnormalities\n",
            "Category for Sentence 2916:\n",
            "Period 1: AUC0-inf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-935 After Oral Administration\n",
            "Category for Sentence 2917:\n",
            "Change from baseline in Visual Analog Scale score\n",
            "Category for Sentence 2918:\n",
            "Mean Amplitude of Glycemic Excursions (MAGE)\n",
            "Category for Sentence 2919:\n",
            "Quality of life of patients as assessed by QOLIE-10 questionnaire\n",
            "Category for Sentence 2920:\n",
            "Change in Action Arm Research Test (ARAT)\n",
            "Category for Sentence 2921:\n",
            "Percentage of Participants With Clear LDI at Week 24\n",
            "Category for Sentence 2922:\n",
            "3-year Overall Survival (OS)\n",
            "Category for Sentence 2923:\n",
            "percentage of immune cells in peripheral blood\n",
            "Category for Sentence 2924:\n",
            "Efficacy: Percent change in SBP from baseline at each time point\n",
            "Category for Sentence 2925:\n",
            "Safety and tolerability of darapladib when co-administered with Rosuvastatin assessed by vital signs\n",
            "Category for Sentence 2926:\n",
            "Signal-to-noise ratio (SNR) of hyperpolarized lactate\n",
            "Category for Sentence 2927:\n",
            "Change in Lipoprotein A1\n",
            "Category for Sentence 2928:\n",
            "Incidence and frequency of hypoglycemia (BS <54 mg/dl) episodes\n",
            "Category for Sentence 2929:\n",
            "Change in Risk/protective factors Assessed by Questionnaires\n",
            "Category for Sentence 2930:\n",
            "Overall survival of MGUS patients\n",
            "Category for Sentence 2931:\n",
            "Pharmacokinetics parameters of SHR3824 and Metformin after multiple dose: AUCss\n",
            "Category for Sentence 2932:\n",
            "Incidence of MACE. (MACE is defined as the composite of cardiac death, Q-wave myocardial infarction (MI), and unscheduled, ischemia driven revascularization of the target lesion.)\n",
            "Category for Sentence 2933:\n",
            "Effect of physiotherapy on distance obtained with six-minute walk test as a measurement of functional capacity in patients with chronic kidney disease.\n",
            "Category for Sentence 2934:\n",
            "Incidence of severe infection of grade 4 and above according to Common Terminology Criteria for Adverse Events (CTCAE)\n",
            "Category for Sentence 2935:\n",
            "Arm Vascular Function in Response to Exercise (Handgrip Exercise Test)\n",
            "Category for Sentence 2936:\n",
            "Number of participants having achievement of a vIGA-AD response (score 0 or 1 and ≥ 2 points improvement) at Week 12 (Day 84)\n",
            "Category for Sentence 2937:\n",
            "overall survival\n",
            "Category for Sentence 2938:\n",
            "Change From Baseline in FEV1/FVC After 12 Weeks of Treatment\n",
            "Category for Sentence 2939:\n",
            "Safety Assessment\n",
            "Category for Sentence 2940:\n",
            "Mean Clinical Global Impression-Improvement (CGI-I) Score\n",
            "Category for Sentence 2941:\n",
            "Assessment of efficacy by patient on a 4-point scale\n",
            "Category for Sentence 2942:\n",
            "Time to Improvement of 100 mL in FEV1 Over Time - ITT Population\n",
            "Category for Sentence 2943:\n",
            "Features of Cushing's Syndrome\n",
            "Category for Sentence 2944:\n",
            "Rate of postoperation Surgical wound infection\n",
            "Category for Sentence 2945:\n",
            "left ventricular mass\n",
            "Category for Sentence 2946:\n",
            "Trough plasma concentration (Ctrough) for ACT-333679\n",
            "Category for Sentence 2947:\n",
            "Changes of inflammatory indicators after surgery\n",
            "Category for Sentence 2948:\n",
            "Sarcopenia/ muscle mass\n",
            "Category for Sentence 2949:\n",
            "Quality of Memory and Attention based on results using CDR System\n",
            "Category for Sentence 2950:\n",
            "Part 1: Maximum Observed Plasma Concentration (Cmax) of RO7020531 and Its Metabolites Including RO7011785, RO7018822 and RO7033805: SAD and MAD\n",
            "Category for Sentence 2951:\n",
            "Inflammatory Markers,TNF-α\n",
            "Category for Sentence 2952:\n",
            "Total number of blood transfusions because of access-site or access-related bleeding\n",
            "Category for Sentence 2953:\n",
            "Hepcidin level\n",
            "Category for Sentence 2954:\n",
            "Pretreatment Heart Rate (HR) in Tiotropium and Placebo Groups\n",
            "Category for Sentence 2955:\n",
            "AUC24 of Gilteritinib in Co-administration With Voriconazole\n",
            "Category for Sentence 2956:\n",
            "Percent Change From Baseline to Week 24 in Total Body Fat\n",
            "Category for Sentence 2957:\n",
            "Proportion of patients requiring a cystectomy, either immediately after TURBT#2 or as salvage after surveillance or CRT\n",
            "Category for Sentence 2958:\n",
            "Complete Cure at 12 months in the Target Toes\n",
            "Category for Sentence 2959:\n",
            "The Children's Depression Inventory-2 (CDI-2) Score\n",
            "Category for Sentence 2960:\n",
            "Hospital stay\n",
            "Category for Sentence 2961:\n",
            "molecular screening(collected of blood,tumor tissue Malignant ascites, pleural effusions, or pericardial effusions will be analyzed)\n",
            "Category for Sentence 2962:\n",
            "Cost-effectiveness of topiramate versus naltrexone, as measured by Disability-Adjusted Life Years (DALYs)\n",
            "Category for Sentence 2963:\n",
            "Comparison of pleural fluid/plasma protein ratio and inflammatory mediators\n",
            "Category for Sentence 2964:\n",
            "Shedding of Polio virus in stool samples\n",
            "Category for Sentence 2965:\n",
            "Changes from baseline in total protein of Laboratory Examination.\n",
            "Category for Sentence 2966:\n",
            "Difference in proportion with controlled BP at 24 months\n",
            "Category for Sentence 2967:\n",
            "Number of hyperkalemia (≥5.6 mmol/L) and severe hyperkalemia (>6 mmol/L) events\n",
            "Category for Sentence 2968:\n",
            "Percentage of participants reporting Adverse Events (AEs) within 1 month after vaccination\n",
            "Category for Sentence 2969:\n",
            "Incidence Rate of Major Bleeding During the Follow-up Period: Secondary Prevention (Balanced) Cohorts\n",
            "Category for Sentence 2970:\n",
            "Exposure to inhaled anesthetics\n",
            "Category for Sentence 2971:\n",
            "Number of Participants With Grade 3-4 Serum Chemistry Abnormalities in Creatinine, Potassium, Sodium and Phosphorous\n",
            "Category for Sentence 2972:\n",
            "Anxiety level\n",
            "Category for Sentence 2973:\n",
            "Iop and Bleb height,extent and vascularity\n",
            "Category for Sentence 2974:\n",
            "Means score for body image (BIS).\n",
            "Category for Sentence 2975:\n",
            "metabolomic parameters\n",
            "Category for Sentence 2976:\n",
            "Proportion of subjects with a baseline platelet count <20 Gi/L and an increase to >20 Gi/L and by at least 2x baseline; or a baseline platelet count between >=20-<30 Gi/L and an absolute platelet count increase to >=50 Gi/L at any time during treatment.\n",
            "Category for Sentence 2977:\n",
            "Fall frequency\n",
            "Category for Sentence 2978:\n",
            "Diastolic arterial pressure (DAP), measured before and after anesthesia induction was assessed to determine of post-induction hypotension in patients undergoing general anesthesia induction with TCI (target controlled infusion) or manual\n",
            "Category for Sentence 2979:\n",
            "Pharmacokinetics - T1/2\n",
            "Category for Sentence 2980:\n",
            "The Change of SF-36 From Baseline at 1 Day, 3 Months, and 6 Months\n",
            "Category for Sentence 2981:\n",
            "Time-to-progress (TTP)\n",
            "Category for Sentence 2982:\n",
            "Change From Baseline in Erythrocyte Sedimentation Rate (ESR)\n",
            "Category for Sentence 2983:\n",
            "Patient Assessment of Need for Retreatment at Week 4\n",
            "Category for Sentence 2984:\n",
            "Quality of life as measured by the Quality of Life in Epilepsy questionnaire score\n",
            "Category for Sentence 2985:\n",
            "Number and percent of responders\n",
            "Category for Sentence 2986:\n",
            "Change in VAS\n",
            "Category for Sentence 2987:\n",
            "Percentage of complete resection R0 after endoscopic treatment\n",
            "Category for Sentence 2988:\n",
            "Raltegravir Cmax in 1 Dosing Interval\n",
            "Category for Sentence 2989:\n",
            "Severity at 3-month follow up visit after surgery of non-motor symptoms as assessed by the Non-motor Symptoms Scale (NMSS)\n",
            "Category for Sentence 2990:\n",
            "Group Kids and Group Teens: Change in high density lipoprotein (HDL)\n",
            "Category for Sentence 2991:\n",
            "Change in the Canadian Occupational Performance Measure between baseline, Post Day 1 and Post Day 30\n",
            "Category for Sentence 2992:\n",
            "Transcutaneous Bilirubin Levels\n",
            "Category for Sentence 2993:\n",
            "Progression free survival\n",
            "Category for Sentence 2994:\n",
            "Variability in Daily FEV1, Estimated by Half Range (i.e., Half the Difference Between Maximum and Minimum Values)\n",
            "Category for Sentence 2995:\n",
            "Change in stool redox potential (faecal)\n",
            "Category for Sentence 2996:\n",
            "Rating of perceived exertion (only young group)\n",
            "Category for Sentence 2997:\n",
            "Summary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and Post-baseline (PBL)\n",
            "Category for Sentence 2998:\n",
            "The Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 18, 54, and 78 Weeks of Treatment\n",
            "Category for Sentence 2999:\n",
            "Duration of oxytocin use\n",
            "Category for Sentence 3000:\n",
            "Duration of response (DOR)\n",
            "Category for Sentence 3001:\n",
            "Change from baseline in clinical chemistry parameter: Total bilirubin (Micromoles per liter)\n",
            "Category for Sentence 3002:\n",
            "Overall Health-related Quality of Life (SF-36)\n",
            "Category for Sentence 3003:\n",
            "HSV infectivity\n",
            "Category for Sentence 3004:\n",
            "Knowledge of the Gluten Free Diet\n",
            "Category for Sentence 3005:\n",
            "VAS Score\n",
            "Category for Sentence 3006:\n",
            "Symptomatic Pulmonary Embolism (PE) at 36 Months\n",
            "Category for Sentence 3007:\n",
            "Perceived quality of care (PACIC): Patient Assessment of Chronic Illness Care\n",
            "Category for Sentence 3008:\n",
            "Change from baseline to Week 52 in body weight percentiles\n",
            "Category for Sentence 3009:\n",
            "Urine Pregnancy Test\n",
            "Category for Sentence 3010:\n",
            "Association of Marker WNT4 rs3820282 with Changes of Collagen Fibers\n",
            "Category for Sentence 3011:\n",
            "Self-reported physical activity\n",
            "Category for Sentence 3012:\n",
            "pregnancy rate\n",
            "Category for Sentence 3013:\n",
            "Change in self-efficacy scores\n",
            "Category for Sentence 3014:\n",
            "Progression of myopia defined as change in axial length 18 months after start of intervention\n",
            "Category for Sentence 3015:\n",
            "impact of neuropschychological function on psychological pain\n",
            "Category for Sentence 3016:\n",
            "Incidence of unstable angina\n",
            "Category for Sentence 3017:\n",
            "Cmax of Aprepitant Following Administration of 10 mg Dose Equivalent in 6 to <12 Year Age Group\n",
            "Category for Sentence 3018:\n",
            "Relation between hypotension index and acute kidney injury\n",
            "Category for Sentence 3019:\n",
            "Cognitive function evaluation (MoCA)\n",
            "Category for Sentence 3020:\n",
            "Percentage of subjects with complete closure of defect\n",
            "Category for Sentence 3021:\n",
            "Infertility Stress\n",
            "Category for Sentence 3022:\n",
            "Gender difference in post-transplant primary disease recurrence\n",
            "Category for Sentence 3023:\n",
            "Nutrient intake\n",
            "Category for Sentence 3024:\n",
            "composite outcome\n",
            "Category for Sentence 3025:\n",
            "Overall survival (OS)\n",
            "Category for Sentence 3026:\n",
            "Objective response rate\n",
            "Category for Sentence 3027:\n",
            "Measure of Health-related quality of life (HRQL) at six months\n",
            "Category for Sentence 3028:\n",
            "Mean Inspiratory and Expiratory Pressure (MIP/MEP)\n",
            "Category for Sentence 3029:\n",
            "P-selectin concentration\n",
            "Category for Sentence 3030:\n",
            "Progression-free Survival\n",
            "Category for Sentence 3031:\n",
            "Objective Response Rate (ORR)\n",
            "Category for Sentence 3032:\n",
            "Description of the aspect of the saliva collected: mucous or fluid\n",
            "Category for Sentence 3033:\n",
            "Whole Body Lean Mass\n",
            "Category for Sentence 3034:\n",
            "Control rate of hypertension evaluated by office blood pressure at 2 weeks\n",
            "Category for Sentence 3035:\n",
            "Compensatory step initiation time\n",
            "Category for Sentence 3036:\n",
            "QoR-40 score\n",
            "Category for Sentence 3037:\n",
            "To compare the incidence and the score of pain between the patients with ropivacaine and the patients without ropivacaine delivered by inter pleural road\n",
            "Category for Sentence 3038:\n",
            "Sociodemographic Questionnaire - Socioeconomic Status\n",
            "Category for Sentence 3039:\n",
            "Time at which maximum concentration is reached\n",
            "Category for Sentence 3040:\n",
            "cumulative fluid balance over 7 days\n",
            "Category for Sentence 3041:\n",
            "Infant Social Emotional Development\n",
            "Category for Sentence 3042:\n",
            "Time to Failure to Maintain Response in Y-MRS Total Score\n",
            "Category for Sentence 3043:\n",
            "Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 6 and Month 9\n",
            "Category for Sentence 3044:\n",
            "Change From Baseline in Plasma Concentration of Sex Hormone-Binding Globulin (SHBG)\n",
            "Category for Sentence 3045:\n",
            "Identification of molecular and functional abnormalities associated with known or novel forms of PID (repository study).\n",
            "Category for Sentence 3046:\n",
            "Satisfaction Survey\n",
            "Category for Sentence 3047:\n",
            "Number of unsolicited positive versus negative comments from participants, families, and Palliative Care Unit staff\n",
            "Category for Sentence 3048:\n",
            "Postprandial plasma amino acid concentration, absolute change from baseline to 60 minutes\n",
            "Category for Sentence 3049:\n",
            "SUVmax of primary tumor or nodal metastasis of baseline FDG PET/CT with PD-L1 expression (positive vs. negative)\n",
            "Category for Sentence 3050:\n",
            "OAB drug treatment satisfaction\n",
            "Category for Sentence 3051:\n",
            "Change in the latency of SSEP compared to baseline.\n",
            "Category for Sentence 3052:\n",
            "MR elastography\n",
            "Category for Sentence 3053:\n",
            "Proliferation and apoptosis analysis of FNA samples\n",
            "Category for Sentence 3054:\n",
            "Death\n",
            "Category for Sentence 3055:\n",
            "The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE\n",
            "Category for Sentence 3056:\n",
            "Aortic distensibility\n",
            "Category for Sentence 3057:\n",
            "Muscle Strength (Handgrip Test)\n",
            "Category for Sentence 3058:\n",
            "Generic quality of life\n",
            "Category for Sentence 3059:\n",
            "Incidence of EBV-associated lymphoproliferative disorder\n",
            "Category for Sentence 3060:\n",
            "Evaluate safety and tolerability of ASN008 topical gel to define a maximum tolerated dose (Part A and B)\n",
            "Category for Sentence 3061:\n",
            "Chair Stand Test\n",
            "Category for Sentence 3062:\n",
            "Feasibility: Adherence rates\n",
            "Category for Sentence 3063:\n",
            "Evaluate the incidence of adverse events including laboratory abnormalities after a single booster does of sipuleucel-T\n",
            "Category for Sentence 3064:\n",
            "translational research\n",
            "Category for Sentence 3065:\n",
            "Probing Depth\n",
            "Category for Sentence 3066:\n",
            "Complete ablation rate of main lesions at 6 months\n",
            "Category for Sentence 3067:\n",
            "Reduction of the intensity of pain\n",
            "Category for Sentence 3068:\n",
            "Morphine Equivalents\n",
            "Category for Sentence 3069:\n",
            "Fatigue\n",
            "Category for Sentence 3070:\n",
            "Blood pressure\n",
            "Category for Sentence 3071:\n",
            "Change in Inflammatory Biomarker Levels: Interleukin (IL)-1b\n",
            "Category for Sentence 3072:\n",
            "Cohort B: Terminal half life (t1/2)(Day 14)\n",
            "Category for Sentence 3073:\n",
            "The Drug-Taking Confidence Questionnaire (DTCQ).\n",
            "Category for Sentence 3074:\n",
            "the adverse event and discomfort\n",
            "Category for Sentence 3075:\n",
            "Monitoring of DBP\n",
            "Category for Sentence 3076:\n",
            "Change in waist circumference.\n",
            "Category for Sentence 3077:\n",
            "Visual Analogue Scale (VAS) Pain Score\n",
            "Category for Sentence 3078:\n",
            "Functional Assessment of Cancer Therapy-Breast (FACT-B) Questionnaire\n",
            "Category for Sentence 3079:\n",
            "Body mass index\n",
            "Category for Sentence 3080:\n",
            "Female Genital Self-Image Scale - 7 (FGSIS-7)\n",
            "Category for Sentence 3081:\n",
            "Number of Heavy Drinking Days Per Two Week Segment\n",
            "Category for Sentence 3082:\n",
            "Controls objective\n",
            "Category for Sentence 3083:\n",
            "Percentage of Initial Responders to ARC-520 Therapy Achieving a 1-log Reduction in HBsAg at Week 36 Compared to Baseline\n",
            "Category for Sentence 3084:\n",
            "Arrhythmia occurrence between groups\n",
            "Category for Sentence 3085:\n",
            "Disc Height Index\n",
            "Category for Sentence 3086:\n",
            "Mechanism study: Mitochondrial function measured in adipose tissue biopsies\n",
            "Category for Sentence 3087:\n",
            "Number of Participants Categorized by Worst Value for AST (SGOT) During the Study\n",
            "Category for Sentence 3088:\n",
            "Functional Outcome\n",
            "Category for Sentence 3089:\n",
            "iAUC glucose\n",
            "Category for Sentence 3090:\n",
            "Maximum Plasma Concentration (Cmax) of L-glutamine at 0.1 g/kg twice daily, 0.3 g/kg twice daily, and 0.6 g/kg once daily in SCD patients\n",
            "Category for Sentence 3091:\n",
            "Overall survival\n",
            "Category for Sentence 3092:\n",
            "Head circumference compared to normal pediatric growth curves.\n",
            "Category for Sentence 3093:\n",
            "Change From Baseline in Respiration Rate: Part A\n",
            "Category for Sentence 3094:\n",
            "Resting Energy Expenditure in Type 2 Diabetes with metformin\n",
            "Category for Sentence 3095:\n",
            "Sleep Efficiency (SE)\n",
            "Category for Sentence 3096:\n",
            "Improvement in Number connection tests\n",
            "Category for Sentence 3097:\n",
            "Examine possible predictors of treatment-related amenorrhea including age, smoking history, race, and treatment variables\n",
            "Category for Sentence 3098:\n",
            "Phase II: best objective response rate (BORR)\n",
            "Category for Sentence 3099:\n",
            "Physical activity level (sedentary, light, moderate-to-vigorous) assessed by Actigraph GT3x\n",
            "Category for Sentence 3100:\n",
            "Sex differences in the effect of abstinence on sensitivity of the P3 response to alcohol.\n",
            "Category for Sentence 3101:\n",
            "Opioid consumption\n",
            "Category for Sentence 3102:\n",
            "Night eating\n",
            "Category for Sentence 3103:\n",
            "Subjective Opiate Withdrawal Scales (SOWS) Total Scores During the Double-Blind Treatment Period\n",
            "Category for Sentence 3104:\n",
            "Number of physiotherapist visits\n",
            "Category for Sentence 3105:\n",
            "hemodynamic conditions\n",
            "Category for Sentence 3106:\n",
            "Pharmacodynamic analyses: blood cytokines\n",
            "Category for Sentence 3107:\n",
            "Change from baseline in cancer related fatigue, anxiety, depression, and health related quality of life\n",
            "Category for Sentence 3108:\n",
            "- Heart rate and cardiac output\n",
            "Category for Sentence 3109:\n",
            "Percentage of Participants Who Experienced a Solicited AE up to Day 182\n",
            "Category for Sentence 3110:\n",
            "Clinical_Symbol Digit Modalities Test\n",
            "Category for Sentence 3111:\n",
            "QoL measured by WHO-QoL Bref\n",
            "Category for Sentence 3112:\n",
            "St. George's Respiratory Questionnaire (SGRQ)\n",
            "Category for Sentence 3113:\n",
            "Opioid utilization (48 hour post-operative)\n",
            "Category for Sentence 3114:\n",
            "Red Blood Cell folate status\n",
            "Category for Sentence 3115:\n",
            "3yOSR\n",
            "Category for Sentence 3116:\n",
            "Functional scale: Shoulder Pain and Disability Index (SPADI)\n",
            "Category for Sentence 3117:\n",
            "Total body clearance (CL) of components of BMS-986263 for injection\n",
            "Category for Sentence 3118:\n",
            "INCAT Sensory Sum score (ISS)\n",
            "Category for Sentence 3119:\n",
            "AUC0-t of Losartan (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)\n",
            "Category for Sentence 3120:\n",
            "Mattis Scale\n",
            "Category for Sentence 3121:\n",
            "Overall Response Rate (ORR) - Cohort 4\n",
            "Category for Sentence 3122:\n",
            "Maternal demographics\n",
            "Category for Sentence 3123:\n",
            "7- and 30-day all-cause mortality from arrival\n",
            "Category for Sentence 3124:\n",
            "Duration of Response Rate per RECIST 1.1\n",
            "Category for Sentence 3125:\n",
            "AE\n",
            "Category for Sentence 3126:\n",
            "Area Under the Concentration Versus Time Curve From Time Zero to Last Measurable Plasma Concentration (AUClast) of Oseltamivir and Oseltamivir Carboxylate on Day 1\n",
            "Category for Sentence 3127:\n",
            "Change in HOME subscore of parent responsivity\n",
            "Category for Sentence 3128:\n",
            "SOFA Score,\n",
            "Category for Sentence 3129:\n",
            "PD AUC for TRFC at 12 MHz fundamental\n",
            "Category for Sentence 3130:\n",
            "Sleepiness at 12 months after hospital discharge\n",
            "Category for Sentence 3131:\n",
            "Number of Participants With Clinically Significant Laboratory Abnormalities - Liver\n",
            "Category for Sentence 3132:\n",
            "Covariate 10\n",
            "Category for Sentence 3133:\n",
            "Serum adiponectin and leptin levels\n",
            "Category for Sentence 3134:\n",
            "Change in Cardiac Self-Efficacy (CSE)\n",
            "Category for Sentence 3135:\n",
            "blood pressure, change from baseline\n",
            "Category for Sentence 3136:\n",
            "4x10 meter fast-paced walk test (40m-FWT)\n",
            "Category for Sentence 3137:\n",
            "Self-reported maximum walking distance\n",
            "Category for Sentence 3138:\n",
            "Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 18)\n",
            "Category for Sentence 3139:\n",
            "Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12\n",
            "Category for Sentence 3140:\n",
            "OPY utilization\n",
            "Category for Sentence 3141:\n",
            "Phase 2: Percentage of Participants Achieving Culture Conversion\n",
            "Category for Sentence 3142:\n",
            "Change from Baseline Total corneal refractive power at 3 months\n",
            "Category for Sentence 3143:\n",
            "Number of Participants With Adverse Events Assessed by Vital Signs, Clinical Laboratory and Physical Exam\n",
            "Category for Sentence 3144:\n",
            "Nomadism indicator (potential risk factor)\n",
            "Category for Sentence 3145:\n",
            "Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)\n",
            "Category for Sentence 3146:\n",
            "Evidence of success of decision aid to providers and patients, which leads to improved knowledge, reduced decisional conflict and enhanced satisfaction with the decision, and enhanced adherence to medication.\n",
            "Category for Sentence 3147:\n",
            "Interleukin-10/Interleukin-6（IL-10/IL-6）\n",
            "Category for Sentence 3148:\n",
            "Part 1: Percentage of MAD Participants With Abnormalities in ECG Parameters\n",
            "Category for Sentence 3149:\n",
            "Serum renin concentrations correlate with Pmsa in postoperative cardiac surgical patients\n",
            "Category for Sentence 3150:\n",
            "PK: Area under the concentration-time curve during a dosing interval (tau) at steady state (AUCtau) of Selpercatinib (Day 10 of Period 2)\n",
            "Category for Sentence 3151:\n",
            "Estimated difference in driving performance across driving features over the glycemic trajectory after glucose vs. aspartame intake\n",
            "Category for Sentence 3152:\n",
            "Time to Reach the Maximum Plasma or CSF concentration (Tmax)\n",
            "Category for Sentence 3153:\n",
            "Improvement of photoprotective function of the skin\n",
            "Category for Sentence 3154:\n",
            "Percentage of Participants With pCR by Proliferation of Ki67\n",
            "Category for Sentence 3155:\n",
            "The secondary outcome was change in body mass index (BMI).\n",
            "Category for Sentence 3156:\n",
            "Biomarkers: tryptophan\n",
            "Category for Sentence 3157:\n",
            "Comparison of Mortality Rates.\n",
            "Category for Sentence 3158:\n",
            "Polysomnographic Sleep measures\n",
            "Category for Sentence 3159:\n",
            "Patient Compliance in Type 2 Diabetes Mellitus Treatment Scale\n",
            "Category for Sentence 3160:\n",
            "Number and proportion of patients with decline (patients who didn't have any clinical signs of aspiration at the first timepoint of interest and gained it at the next timepoint of interest)\n",
            "Category for Sentence 3161:\n",
            "Non-violent delinquent behavior frequency\n",
            "Category for Sentence 3162:\n",
            "Maternal-infant attachment\n",
            "Category for Sentence 3163:\n",
            "SF-12\n",
            "Category for Sentence 3164:\n",
            "Duration of vasopressor support\n",
            "Category for Sentence 3165:\n",
            "Pharmacokinetic :Area Under the Concentration Curve (0 to 24 Hour), AZD6765 MAD Day 6 Dose of AZD8108\n",
            "Category for Sentence 3166:\n",
            "Complete remission (CR)\n",
            "Category for Sentence 3167:\n",
            "Change from 6 weeks in recurrence at 26 and 52 weeks.\n",
            "Category for Sentence 3168:\n",
            "Hemoglobin drop\n",
            "Category for Sentence 3169:\n",
            "objective response rate (ORR)\n",
            "Category for Sentence 3170:\n",
            "Number of Participants with Infusion Related Reactions (IRRs) by Severity\n",
            "Category for Sentence 3171:\n",
            "postoperative atrial fibrillation (POAF)\n",
            "Category for Sentence 3172:\n",
            "Improvement in respiratory function as assessed by spirometry, and impulse oscillometry vs. serum concentration of montelukast.\n",
            "Category for Sentence 3173:\n",
            "Changes in neck pain intensity with visual analogue scale (VAS)\n",
            "Category for Sentence 3174:\n",
            "Change in D-dimer From Week 2 to Week 26\n",
            "Category for Sentence 3175:\n",
            "Time to neurologic progression\n",
            "Category for Sentence 3176:\n",
            "Changes in measured biochemical markers\n",
            "Category for Sentence 3177:\n",
            "Repeated detection of dominant strictures, as determined by two independent assessors, that were not treated by ERC\n",
            "Category for Sentence 3178:\n",
            "Change in the percentage of patients with HBV viral suppression (Effectiveness of antiviral therapy in HBV-infected patients)\n",
            "Category for Sentence 3179:\n",
            "Number of Participants Requiring Dose Reductions\n",
            "Category for Sentence 3180:\n",
            "Static Physician Global Assessment score (sPGA)\n",
            "Category for Sentence 3181:\n",
            "Occurrence of bleeding event\n",
            "Category for Sentence 3182:\n",
            "Variation of FCV between both groups\n",
            "Category for Sentence 3183:\n",
            "Cerebral Blood Flow\n",
            "Category for Sentence 3184:\n",
            "Maximum tolerated dose (MTD)\n",
            "Category for Sentence 3185:\n",
            "Processing Speed composite\n",
            "Category for Sentence 3186:\n",
            "the diagnosis efficiency of the computer-assist diagnosis tool\n",
            "Category for Sentence 3187:\n",
            "Corneal and conjunctival staining and conjunctival redness\n",
            "Category for Sentence 3188:\n",
            "Genomic findings\n",
            "Category for Sentence 3189:\n",
            "Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate\n",
            "Category for Sentence 3190:\n",
            "Frequency of side effects of opioids\n",
            "Category for Sentence 3191:\n",
            "Diagnostic Yield of EUS-FNB and EUS-FNA\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "categorized_sentences = []\n",
        "\n",
        "for category, values in categories.items():\n",
        "    for value in values:\n",
        "        index, threshold, similarity = value\n",
        "        categorized_sentences.append({\n",
        "              'Sentence_category': df['measure'][category],\n",
        "              'Sentence_index': df['measure'][index],\n",
        "              'Similarity': similarity,\n",
        "              'Threshold': threshold\n",
        "         })\n",
        "\n",
        "categorized_df = pd.DataFrame(categorized_sentences)\n",
        "categorized_df\n"
      ],
      "metadata": {
        "id": "bV63JRF8W9uK",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 423
        },
        "outputId": "989dfd7c-1b83-48e7-b66f-3962fe7f94b8"
      },
      "execution_count": 21,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                          Sentence_category  \\\n",
              "0         Change from baseline in Adult Sickle Cell Qual...   \n",
              "1         Change from baseline in Adult Sickle Cell Qual...   \n",
              "2         Change from baseline in Adult Sickle Cell Qual...   \n",
              "3         Change from baseline in Adult Sickle Cell Qual...   \n",
              "4         Change from baseline in Adult Sickle Cell Qual...   \n",
              "...                                                     ...   \n",
              "15959530               Frequency of side effects of opioids   \n",
              "15959531               Frequency of side effects of opioids   \n",
              "15959532            Diagnostic Yield of EUS-FNB and EUS-FNA   \n",
              "15959533            Diagnostic Yield of EUS-FNB and EUS-FNA   \n",
              "15959534            Diagnostic Yield of EUS-FNB and EUS-FNA   \n",
              "\n",
              "                                             Sentence_index  Similarity  \\\n",
              "0         Safety and tolerability of the microdialysis t...    0.863903   \n",
              "1         Area Under the Curve Calculated From 0 to 4 Ho...    0.853759   \n",
              "2                Baseline oral healthcare-related knowledge    0.747487   \n",
              "3                              Tmax Following Single Dosing    0.842666   \n",
              "4                  Patient-centered Outcomes - Satisfaction    0.828900   \n",
              "...                                                     ...         ...   \n",
              "15959530            Diagnostic Yield of EUS-FNB and EUS-FNA    0.715669   \n",
              "15959531  ARI with microbiologically confirmed influenza...    0.732320   \n",
              "15959532  ARI with microbiologically confirmed influenza...    0.729068   \n",
              "15959533  ARI with microbiologically confirmed influenza...    0.729068   \n",
              "15959534  ARI with microbiologically confirmed influenza...    0.729068   \n",
              "\n",
              "          Threshold  \n",
              "0               0.5  \n",
              "1               0.5  \n",
              "2               0.5  \n",
              "3               0.5  \n",
              "4               0.5  \n",
              "...             ...  \n",
              "15959530        0.7  \n",
              "15959531        0.7  \n",
              "15959532        0.5  \n",
              "15959533        0.6  \n",
              "15959534        0.7  \n",
              "\n",
              "[15959535 rows x 4 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-0c61a98f-1f86-453b-a875-560094f6696b\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Sentence_category</th>\n",
              "      <th>Sentence_index</th>\n",
              "      <th>Similarity</th>\n",
              "      <th>Threshold</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Change from baseline in Adult Sickle Cell Qual...</td>\n",
              "      <td>Safety and tolerability of the microdialysis t...</td>\n",
              "      <td>0.863903</td>\n",
              "      <td>0.5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Change from baseline in Adult Sickle Cell Qual...</td>\n",
              "      <td>Area Under the Curve Calculated From 0 to 4 Ho...</td>\n",
              "      <td>0.853759</td>\n",
              "      <td>0.5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Change from baseline in Adult Sickle Cell Qual...</td>\n",
              "      <td>Baseline oral healthcare-related knowledge</td>\n",
              "      <td>0.747487</td>\n",
              "      <td>0.5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Change from baseline in Adult Sickle Cell Qual...</td>\n",
              "      <td>Tmax Following Single Dosing</td>\n",
              "      <td>0.842666</td>\n",
              "      <td>0.5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Change from baseline in Adult Sickle Cell Qual...</td>\n",
              "      <td>Patient-centered Outcomes - Satisfaction</td>\n",
              "      <td>0.828900</td>\n",
              "      <td>0.5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15959530</th>\n",
              "      <td>Frequency of side effects of opioids</td>\n",
              "      <td>Diagnostic Yield of EUS-FNB and EUS-FNA</td>\n",
              "      <td>0.715669</td>\n",
              "      <td>0.7</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15959531</th>\n",
              "      <td>Frequency of side effects of opioids</td>\n",
              "      <td>ARI with microbiologically confirmed influenza...</td>\n",
              "      <td>0.732320</td>\n",
              "      <td>0.7</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15959532</th>\n",
              "      <td>Diagnostic Yield of EUS-FNB and EUS-FNA</td>\n",
              "      <td>ARI with microbiologically confirmed influenza...</td>\n",
              "      <td>0.729068</td>\n",
              "      <td>0.5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15959533</th>\n",
              "      <td>Diagnostic Yield of EUS-FNB and EUS-FNA</td>\n",
              "      <td>ARI with microbiologically confirmed influenza...</td>\n",
              "      <td>0.729068</td>\n",
              "      <td>0.6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15959534</th>\n",
              "      <td>Diagnostic Yield of EUS-FNB and EUS-FNA</td>\n",
              "      <td>ARI with microbiologically confirmed influenza...</td>\n",
              "      <td>0.729068</td>\n",
              "      <td>0.7</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>15959535 rows × 4 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-0c61a98f-1f86-453b-a875-560094f6696b')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-0c61a98f-1f86-453b-a875-560094f6696b button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-0c61a98f-1f86-453b-a875-560094f6696b');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-5aafd908-9079-4aad-9f26-ed80637e4d16\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-5aafd908-9079-4aad-9f26-ed80637e4d16')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-5aafd908-9079-4aad-9f26-ed80637e4d16 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "categorized_df"
            }
          },
          "metadata": {},
          "execution_count": 21
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "categorized_df.sort_values(\"Similarity\", inplace=True, ascending=False)\n",
        "categorized_df"
      ],
      "metadata": {
        "id": "dhUlUe6SQkCm",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 423
        },
        "outputId": "571b1a5c-3723-47c7-d281-30ba07ad0683"
      },
      "execution_count": 22,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                  Sentence_category  \\\n",
              "14993750  number of correct femoral tunnel position   \n",
              "11966758                         Skin melanin index   \n",
              "11970499                         Skin melanin index   \n",
              "14992634  number of correct femoral tunnel position   \n",
              "11970501                         Skin melanin index   \n",
              "...                                             ...   \n",
              "7570656                  Lower body muscle strength   \n",
              "2440585                     Cmax of free dabigatran   \n",
              "5636422                    Incident prostate cancer   \n",
              "7570768                  Lower body muscle strength   \n",
              "9299292            Content of coaching interactions   \n",
              "\n",
              "                                             Sentence_index  Similarity  \\\n",
              "14993750                                            Relapse    1.000000   \n",
              "11966758          number of correct femoral tunnel position    1.000000   \n",
              "11970499                                            Relapse    1.000000   \n",
              "14992634                                            Relapse    1.000000   \n",
              "11970501          number of correct femoral tunnel position    1.000000   \n",
              "...                                                     ...         ...   \n",
              "7570656                 Immune Overall Response Rate (iORR)    0.500183   \n",
              "2440585             treatment response measured by ADAS-cog    0.500176   \n",
              "5636422                               Myocardial infarction    0.500166   \n",
              "7570768                                         Age (years)    0.500105   \n",
              "9299292   Absolute Change in Eosinophilic Count (Unit: 1...    0.500052   \n",
              "\n",
              "          Threshold  \n",
              "14993750        0.9  \n",
              "11966758        0.5  \n",
              "11970499        0.9  \n",
              "14992634        0.6  \n",
              "11970501        1.0  \n",
              "...             ...  \n",
              "7570656         0.5  \n",
              "2440585         0.5  \n",
              "5636422         0.5  \n",
              "7570768         0.5  \n",
              "9299292         0.5  \n",
              "\n",
              "[15959535 rows x 4 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-4dfab967-5cba-4dc3-9c55-aa73fc6a0741\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Sentence_category</th>\n",
              "      <th>Sentence_index</th>\n",
              "      <th>Similarity</th>\n",
              "      <th>Threshold</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>14993750</th>\n",
              "      <td>number of correct femoral tunnel position</td>\n",
              "      <td>Relapse</td>\n",
              "      <td>1.000000</td>\n",
              "      <td>0.9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11966758</th>\n",
              "      <td>Skin melanin index</td>\n",
              "      <td>number of correct femoral tunnel position</td>\n",
              "      <td>1.000000</td>\n",
              "      <td>0.5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11970499</th>\n",
              "      <td>Skin melanin index</td>\n",
              "      <td>Relapse</td>\n",
              "      <td>1.000000</td>\n",
              "      <td>0.9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14992634</th>\n",
              "      <td>number of correct femoral tunnel position</td>\n",
              "      <td>Relapse</td>\n",
              "      <td>1.000000</td>\n",
              "      <td>0.6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11970501</th>\n",
              "      <td>Skin melanin index</td>\n",
              "      <td>number of correct femoral tunnel position</td>\n",
              "      <td>1.000000</td>\n",
              "      <td>1.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7570656</th>\n",
              "      <td>Lower body muscle strength</td>\n",
              "      <td>Immune Overall Response Rate (iORR)</td>\n",
              "      <td>0.500183</td>\n",
              "      <td>0.5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2440585</th>\n",
              "      <td>Cmax of free dabigatran</td>\n",
              "      <td>treatment response measured by ADAS-cog</td>\n",
              "      <td>0.500176</td>\n",
              "      <td>0.5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5636422</th>\n",
              "      <td>Incident prostate cancer</td>\n",
              "      <td>Myocardial infarction</td>\n",
              "      <td>0.500166</td>\n",
              "      <td>0.5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7570768</th>\n",
              "      <td>Lower body muscle strength</td>\n",
              "      <td>Age (years)</td>\n",
              "      <td>0.500105</td>\n",
              "      <td>0.5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9299292</th>\n",
              "      <td>Content of coaching interactions</td>\n",
              "      <td>Absolute Change in Eosinophilic Count (Unit: 1...</td>\n",
              "      <td>0.500052</td>\n",
              "      <td>0.5</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>15959535 rows × 4 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-4dfab967-5cba-4dc3-9c55-aa73fc6a0741')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-4dfab967-5cba-4dc3-9c55-aa73fc6a0741 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-4dfab967-5cba-4dc3-9c55-aa73fc6a0741');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-184c04a7-5cb7-4d57-9990-743108b6bf47\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-184c04a7-5cb7-4d57-9990-743108b6bf47')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-184c04a7-5cb7-4d57-9990-743108b6bf47 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "categorized_df"
            }
          },
          "metadata": {},
          "execution_count": 22
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "categorized_df.groupby(\"Sentence_category\")[[\"Sentence_index\", \"Similarity\"]].first().reset_index()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 423
        },
        "id": "xfd3NDg5-77c",
        "outputId": "0e31ef79-3605-405d-9cf5-d0b96a129ce3"
      },
      "execution_count": 23,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                      Sentence_category  \\\n",
              "0     \"C-PROM\" questionnaire to measure Personal Rec...   \n",
              "1           % of patients with radiological improvement   \n",
              "2     % of patients with treatment failure defined a...   \n",
              "3     (Phase 3) Change From Baseline in the Function...   \n",
              "4                       - Heart rate and cardiac output   \n",
              "...                                                 ...   \n",
              "3120  ventilatory stability by frequency of central ...   \n",
              "3121                   worst grade toxicity per patient   \n",
              "3122                                                 λz   \n",
              "3123                      • Fall in Faecal Calprotectin   \n",
              "3124  • Percentage of patients with severe asthma wh...   \n",
              "\n",
              "                                         Sentence_index  Similarity  \n",
              "0     Time to reach the MSSBP target (based on the B...    0.877558  \n",
              "1     Assessment of Area Under the Plasma Concentrat...    0.918555  \n",
              "2                                                Survey    0.910103  \n",
              "3      Symptomatic Pulmonary Embolism (PE) at 36 Months    0.944611  \n",
              "4            Nomadism indicator (potential risk factor)    0.910598  \n",
              "...                                                 ...         ...  \n",
              "3120       Progress free survival (PFS) per RECIST v1.1    0.921258  \n",
              "3121  Change in Functional Outcomes as Measured by P...    0.900503  \n",
              "3122                             Anxiety and Depression    0.901621  \n",
              "3123  Need for facilitated dental treatment and foll...    0.888675  \n",
              "3124                      Effectiveness of the pressure    0.923048  \n",
              "\n",
              "[3125 rows x 3 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-81929adf-3822-480e-ac0a-d272f94d2779\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Sentence_category</th>\n",
              "      <th>Sentence_index</th>\n",
              "      <th>Similarity</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>\"C-PROM\" questionnaire to measure Personal Rec...</td>\n",
              "      <td>Time to reach the MSSBP target (based on the B...</td>\n",
              "      <td>0.877558</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>% of patients with radiological improvement</td>\n",
              "      <td>Assessment of Area Under the Plasma Concentrat...</td>\n",
              "      <td>0.918555</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>% of patients with treatment failure defined a...</td>\n",
              "      <td>Survey</td>\n",
              "      <td>0.910103</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>(Phase 3) Change From Baseline in the Function...</td>\n",
              "      <td>Symptomatic Pulmonary Embolism (PE) at 36 Months</td>\n",
              "      <td>0.944611</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>- Heart rate and cardiac output</td>\n",
              "      <td>Nomadism indicator (potential risk factor)</td>\n",
              "      <td>0.910598</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3120</th>\n",
              "      <td>ventilatory stability by frequency of central ...</td>\n",
              "      <td>Progress free survival (PFS) per RECIST v1.1</td>\n",
              "      <td>0.921258</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3121</th>\n",
              "      <td>worst grade toxicity per patient</td>\n",
              "      <td>Change in Functional Outcomes as Measured by P...</td>\n",
              "      <td>0.900503</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3122</th>\n",
              "      <td>λz</td>\n",
              "      <td>Anxiety and Depression</td>\n",
              "      <td>0.901621</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3123</th>\n",
              "      <td>• Fall in Faecal Calprotectin</td>\n",
              "      <td>Need for facilitated dental treatment and foll...</td>\n",
              "      <td>0.888675</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3124</th>\n",
              "      <td>• Percentage of patients with severe asthma wh...</td>\n",
              "      <td>Effectiveness of the pressure</td>\n",
              "      <td>0.923048</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>3125 rows × 3 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-81929adf-3822-480e-ac0a-d272f94d2779')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-81929adf-3822-480e-ac0a-d272f94d2779 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-81929adf-3822-480e-ac0a-d272f94d2779');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-2805492f-dfeb-4de8-9d08-d11e68fa24a9\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-2805492f-dfeb-4de8-9d08-d11e68fa24a9')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-2805492f-dfeb-4de8-9d08-d11e68fa24a9 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"categorized_df\",\n  \"rows\": 3125,\n  \"fields\": [\n    {\n      \"column\": \"Sentence_category\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 3125,\n        \"samples\": [\n          \"Correlation of BMPR2 Expression with right ventricular function\",\n          \"Performance analysis of TEG6S kaolin parameters for the diagnosis of coagulation disorders in PPH.\",\n          \"Change From Baseline in Peak Forced Vital Capacity (at Week 8)\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sentence_index\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1378,\n        \"samples\": [\n          \"Changes in creatine kinase\",\n          \"Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 ancestral strain\",\n          \"Seated blood pressure\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Similarity\",\n      \"properties\": {\n        \"dtype\": \"float32\",\n        \"num_unique_values\": 3015,\n        \"samples\": [\n          0.8552623987197876,\n          0.9037147760391235,\n          0.9188365340232849\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 23
        }
      ]
    }
  ]
}